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Breast cancer is one of the deadliest malignancies worldwide and also in the United States.  
Patients with triple negative breast cancer (TNBC), where the cancer cells do not express nuclear 
hormone receptors and human epidermal growth factor receptor 2 (HER2), have worse survival 
rate compared to the patients with luminal subtypes of cancer. Here, we have shown that 
Cysteine-rich 61-Connective Tissue Growth Factor-nephroblastoma-overexpressed 5 (CCN5) 
induces growth arrest of TNBC cells in-vitro and in xenograft tumors.  Our studies show that 
after being secreted into the extracellular matrix, CCN5 binds to the α6β1 integrins of the cells 
leading to inhibition of the PI3K-AKT signaling pathway. This leads to stabilization and nuclear 
localization of FOXO3A resulting in transcriptional activation of the cyclin-dependent kinase 
inhibitor P27KIP1.  Also, we found that the CCN5-induced PI3K-AKT inactivation leads to 
stabilization and nuclear accumulation of P27KIP1 resulting in cell cycle arrest of TNBC cells. 
Next, we have shown that CCN5 protein can induce expression of estrogen receptor-α (ER-α) in 
mammary epithelial cells. We found that mammary epithelium-specific overexpression of CCN5 
in transgenic mice leads to an increase in ER-α expression and that this impact of CCN5 is not 
restricted to the normal cells. CCN5 treatment leads to an expression of functional ER-α in the 
TNBC cells, both in-vitro and in xenograft models, and sensitizes these cells to tamoxifen, 
commonly used for endocrine therapies. Mechanistically, transcriptional activation of ER-α by 
CCN5 is also mediated by FOXO3A stabilization via PI3K-AKT inhibition. Lack of ER-α 
expression in TNBC cells or loss of ER-α activation after endocrine treatment of luminal cancers 
makes these breast cancer cells resistant to tamoxifen and other endocrine therapies.  Evidently, 
CCN5-mediated restoration of ER-α and its downstream signaling cascades renders the TNBC 
cells sensitive to tamoxifen.  As these tumors mostly lack CCN5 expression, we anticipate that 
restoration of CCN5 expression might be able to provide breakthroughs in the treatment of these 
tumors. Finally, we discuss the effects of CCN5 expression on yet another aggressive breast 
cancer subtype, characterized by HER2 overexpression. Mammary-specific expression of CCN5 
in HER2 overexpressing mice delays tumor progression significantly and reduces the tumor 
burden. Initial observations indicate that CCN5 induces expression of P16INK4A and P19ARF, 
resulting in cell cycle arrest of the tumor cells. Collectively, these studies suggest that CCN5 
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CHAPTER I: General Introduction 
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ARCHITECTURE OF HUMAN BREAST: AN OVERVIEW  
A healthy adult female breast, like most other organs in the human body, consists of both 
epithelial and stromal elements.  However, unlike most of the other organs, the female breast is 
subject to significant changes in its composition and architecture depending on the pubertal stage 
and lactation status.  
Human female breasts have a comprehensive ductal network that connects the functional 
units of the breast, the milk-producing lobular acini, to the exterior via the nipple. The lumen of 
the branching ducts and the lobules are lined by columnar and cuboidal epithelial cells, which are 
the epithelial element of the human mammary gland (Figure I.1).  The stromal component 
makes up most of the breast volume in the non-lactational state and is composed of adipose and 
fibrous connective tissues, the ratio of which varies from individual to individual (Figure I.2).  
At the prepubertal age, beneath the nipple lies a small number of branching ducts, the 
epithelial component, which are rudimentary at that stage and does not further develop in males. 
The proliferative growth and branching of the ductal epithelium are slow at this stage.  At 
puberty, the growth and branching of the ducts, as well as mass of stromal components, increase 
significantly in the female breast.  At the post-pubertal stage, the cells at the terminal ends of the 
ducts proliferate and give rise to bud-like structures each of which develops into secretory glands 
during pregnancy. 
An adult human female breast, irrespective of the age and body weight, is composed of 
15-20 large lactiferous ducts running from individual lobes, named a tubulo-acinar gland. Each 
of these lactiferous ducts drains-out to the exterior through different openings in the nipple 
(Figure I.1).  Within the mammary lobes, the lactiferous ducts branch and sub-branch into 
segmental and sub-segmental ducts which finally branch into terminal ducts. Each of these 
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terminal ducts further branches and form a cluster of acinar (glandular) structures which together 
forms a single lobule.  These lobules have loose fibrous connective tissue interspersed within, 
which is distinctly different from the denser extralobular stroma. Each lobe in an adult breast has 
20-40 such lobules (Figure I.2).  As a terminal duct forms acinus and a cluster of these acini 
form a lobule, the entire lobule along with both the parts of the terminal duct inside and outside 
of the lobule is known as a Terminal Ductal Lobular Unit (TDLU)(Hayes, 2000) (Figure I.1).  
In a resting non-pregnant non-lactating adult breast, larger ducts which are lined with 
columnar epithelium and stratified cuboidal epithelium are more prominent compared to the 
acini which are lined with cuboidal epithelium (Figure I.1).  At the onset of pregnancy and 
during lactation, the number of acini increases drastically as the epithelial cells at the terminal 
ends of the ductal tree start to proliferate under hormonal influence.  
Both in the ductal and lobular parts, the epithelial lining is composed of two layers of 
epithelial cells, namely the luminal epithelial cells (immediate lining of the lumen) and the 
myoepithelial cells, which are contractile and lies in between the luminal epithelial layer and the 
basement membrane (Figure I.1).  At the post-menopausal stage, involution of the epithelial 
ductal and lobular network leads to a significant change in the breast tissue architecture leaving 
the fibrous connective tissue to occupy most of the tissue mass. 
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BREAST CANCER: A GLOBAL DISEASE 
Breast cancer remains as one of the deadliest malignant disease affecting almost every family 
either directly or indirectly throughout the world.  A very similar situation also exists in the 
Western countries including the United States.  Approximately 12.4% of US women or one in 
every eight US women have a lifetime risk of developing invasive breast cancer.  By the end of 
the current year, approximately 250,000 new cases of breast cancer are anticipated to get 
reported (R. L. Siegel, Miller, & Jemal, 2017). Despite all the research and treatment advances, 
40,000 women are predicted to succumb to this deadly disease (R. L. Siegel et al., 2017).  
However, the 5-year survival rate for breast cancer is close to 90 percent at present, and the 
number of deaths due to breast cancer has been steadily decreasing (National Cancer Institute; R. 
L. Siegel et al., 2017). Timely screenings and tests for this deadly disease have enabled the 
physicians across the USA and the world to diagnose breast cancer at earlier stages leading to an 
improvement in the 5-year survival rate of the disease. Regular mammograms for screening 
every woman after her 40 years of age and breast MRIs for screening in the population with 
genetic susceptibility to breast cancer owing to a familial history of BRCA gene mutations have 
led to a gradual decrease of breast cancer mortality (National Cancer Institute).  
BREAST CANCER: ORIGIN AND STAGES OF PROGRESSION  
Breast cancer, in most of the cases, arises from the ductal and alveolar epithelial cells of 
mammary gland epithelium. The epithelial cells lining the ductal and alveolar lumen undergoes 
cycles of proliferation depending on the changing hormonal influences in the human body. These 
include menstrual cycles, pregnancy, and lactation status. This process renders the proliferating 
epithelial cells susceptible to mutations which might lead to unrestricted proliferation and 
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eventual transformation to neoplastic cells leading to invasion followed by metastatic growth in 
the distant organs such lungs, liver, brain, and bones.  
Based on morphological and pathobiological progression, breast cancer is classified into pre-
neoplastic and neoplastic lesions.  These include- 
• HYPERPLASIA:  The initial pre-malignant stage is known as hyperplasia where only 
hyperproliferation of ductal and lobular epithelial cells can be noticed.   
• ATYPICAL HYPERPLASIA: The next stage in the sequence of the progression of breast 
cancer is atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) where 
the proliferating cells under pathologic examination appear to be different from the 
typical epithelial cells usually with hyperchromatic nuclei.  
• CARCINOMA IN SITU: The ductal carcinoma in-situ (DCIS) or lobular carcinoma in-
situ (LCIS), as the nomenclature suggests, refer to the stage where the abnormally 
proliferating ductal epithelial cells and lobular epithelial cells have not encroached into 
the surrounding stroma. At this stage, the cells are limited within the confines of ductal 
boundaries of myoepithelial cells and basement membrane.  The DCIS stage is 
considered as a non-malignant stage (Stage 0).  Whether patients with DCIS should be 
treated has been a matter of debate among the clinicians as only a fraction of DCIS 
patients eventually develop invasive breast cancer and had a morbidity rate of 1-2% 
(Burstein, Polyak, Wong, Lester, & Kaelin, 2004; Ceilley et al., 2004).  Depending on the 
architectural patterns, clinicians classify DCIS into solid, comedo, cribriform, papillary 
and micropapillary patterns.  A significant fraction of DCIS lesions shows similar intra-
lesion heterogeneity as invasive carcinomas (Allred et al., 2008). 
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• INVASION: Eventually, the neoplastic cells invade the surrounding stroma, disrupting 
the myoepithelial cell lining and the basement membrane matrix surrounding the ducts. 
At this point, it is classified as invasive ductal carcinoma.  As the disease progresses, a 
population of the cancer cells which have invaded into the stroma might intravasate into 
the lymphatic vessels and blood vessels, gaining access to distant organs to form 
metastatic secondary tumors (Figure I.3).  
BREAST CANCER STAGING: Breast cancer is most commonly staged by the clinicians per 
‘TNM’ system staging. It follows the criteria of - tumor size (T), lymph node positivity (N) and 
metastasis status (M). Lymph node positivity (N) signifies the extent of spread of cancer cells to 
the lymph nodes and metastasis status (M) signifies if the tumor cells have spread or 
metastasized to distant organs.  Breast cancers are broadly staged into Stage 0 to Stage IV 
depending on the TNM scores. Stage 0 signifies the DCIS stage (TisN0M0) while stage IV 
represents metastatic tumor (TanyNanyM1 - as once evidence for metastasis is confirmed, the tumor 
size and lymph node positivity do not bear significance clinically). 
BREAST CANCER: SUBTYPES AND HETEROGENEITY  
The clinicians have classically subdivided breast cancers into three very broad subtypes per 
expression status of nuclear hormone receptors [estrogen receptor-α (ER-α and progesterone 
receptor (PR)] and receptor tyrosine kinase HER2 (or ERBB2).  The subtypes are - endocrine 
receptor-positive type (expressing ER-α, PR or both), HER2 positive type (HER2 expression) 
and triple negative type (TNBC), which expresses none of the receptors (ER, PR or HER2).  This 
classical subtyping has been popular with the clinicians mainly as each of the subtypes of tumors 
required three broadly different approaches to treatment (Figure I.4, upper panel). 
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Insights from molecular subtyping of breast cancer 
Recent advances in molecular and genetic profiling of breast cancer have provided many insights 
about the breast cancer types and have led to the emergence of sub-classes of breast cancer  
(Perou, 2011; Perou et al., 2000; Prat & Perou, 2011; Sorlie et al., 2001). The characteristics of 
these subtypes might be indicative of different cell types of origin (Perou et al., 2000).  
One key example is sub-classification of the ER-α positive subtype into two distinct 
groups, which has been widely accepted by the clinicians. Microarray studies of multiple breast 
tumor samples revealed that ER-α positive tumors mostly are characterized by the relatively high 
expression of many genes expressed by breast luminal cells which are further corroborated by 
the expression of luminal cell keratins 8/18 (Perou et al., 2000).  The gene expression analyses 
have shown that the tumor cells of luminal cluster are characterized by high expression of 
transcription factors ER- α, GATA binding protein 3 (GATA-3), X-box Binding Protein 1 
(XBP1), and Forkhead Box A1 (FOXA1) (as well as luminal cytokeratin 8 and 18) (Perou et al., 
2000).  Subsequent studies from the same group established that Luminal type of breast tumors 
can at least be sub-classified into Luminal A and Luminal B subtypes (Sorlie et al., 2001).  The 
Luminal A tumors are usually positive for ER-α and PR and negative for HER2.  These tumors 
are generally of lower pathological grade, and the cells are mostly highly differentiated.  The 
Luminal B tumors are ER-α positive with or without PR and HER2 expression.  Luminal B 
tumors express the same luminal cell gene signature at a lower level and show higher expression 
of proliferation genes (e.g., Ki67) than luminal A tumors (Hoadley Katherine A., 2014). 
The other two major subtypes are (i) basal-like subtype and (ii)HER2 overexpressing 
subtype. Basal-like tumors mostly lack the expression of HER2 or the endocrine receptors and 
largely overlap with the classical triple negative group of breast tumors.  However, gene 
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expression profiling demonstrated not all TNBC are basal-type, and not all basal-like tumors are 
triple negative.  Thus, it indicates that molecular stratification of clinically identified triple 
negative tumors might be highly useful (Prat et al., 2013).  High expression of basal cytokeratin 
5 and 17, a signature of normal breast basal/myoepithelial cells, is a characteristic of the basal-
like subtype (Perou et al., 2000).  The most recently identified tumor group per molecular 
classification is the claudin-low subtype which is highly related to basal tumors regarding 
molecular signature and are triple negative clinically.  The claudin-low tumors have a distinct 
signature of a subset of gene expressions with low expression of cell junction proteins like 
claudins and E-cadherin.  These tumors have been found to be enriched with mesenchymal and 
tumor-initiating cell gene signature (Perou, 2011).   
HER2 overexpressing or HER2 enriched tumors, as suggested by the name mostly 
overexpress HER2 receptor tyrosine kinase protein and often show amplification of this locus. 
Though a fraction of HER2 enriched tumors shows expression of endocrine receptors, most of 
these tumors have high pathological grade and are negative for ER-α expression (Hoadley 
Katherine A., 2014).   
COMMON AND RECURRENT GENETIC ALTERATIONS: The extensive volume of data 
generated by The Cancer Genome Atlas Network on DNA copy number and somatic mutations 
in 792 patients of breast cancer was used to identify the frequency of each genetic alteration 
across all the cancer subtypes  (Cancer Genome Atlas, 2012).  Genomic profiling of breast 
cancer subtypes has shown that each breast cancer subtype has a specific set of recurring genetic 
alterations.  Mutations of tumor suppressor P53, ‘the guardian of the genome,' are mostly found 
in basal-like, HER2 positive and luminal B subtypes of breast tumors, while these mutations are 
primarily absent in luminal B subtype of cancer.   
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TP53 mutations have been the only recurrent mutations in basal-like tumors with an incidence 
rate of more than 10%. Carriers of BRCA1 germline mutations have been shown to be 
predisposed to developing basal-like tumors (Hoadley Katherine A., 2014).  Thus, an association 
with the mutations of tumor suppressor P53 and with hereditary mutations of BRCA1 could be 
an essential reason for basal-like tumors with high incidence rate among the African-American 
population (Huo et al., 2009) and tumors of younger patients.  Basal-like tumors are relatively 
enriched for low-level copy number gains and losses (Hoadley Katherine A., 2014).  
Luminal A tumors have been shown to have the highest number of recurrently mutated 
genes. The long list of genes which are frequently mutated (more than 5%) includes transcription 
factors [like GATA3, NCOR1, FOXA1, TP53], cell-junction proteins [CDH1], cellular kinases 
and phosphatases [AKT1, PIK3CA, MAP3K1, PTEN].  However, the total number of mutations 
and copy number changes is lowest in this subtype suggesting that these alterations are likely to 
be driver mutations.  Phosphatidylinositol 3-kinase, catalytic, α polypeptide (PIK3CA) mutations 
are most frequent in the luminal A subtype (Hoadley Katherine A., 2014; Saal et al., 2005).  
High-level DNA amplification has been shown to be very frequent in luminal B subtype of 
tumors including the regions on chromosome 8q and 11q containing the MYC oncogene and 
CCND1 (Cyclin D1) genes respectively.  Amplifications of these genes might play a vital role in 
the higher proliferation rate of these tumors.  Recurrent mutations are found in PIK3CA, 
GATA3, PTEN, and TP53 genes (Hoadley Katherine A., 2014).  
As mentioned before, high-level amplification of the locus 17q harboring HER2/ERBB2 
gene has been reported to be common in HER2 positive tumors. Tumors of the Her2 subtype 
have highest single nucleotide mutation rate, but a small number of recurrently mutated genes 
TP53 (71%) and PIK3CA (35%) (Cancer Genome Atlas, 2012). 
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Therapeutic strategies and responses for breast cancer subtypes  
Molecular subtypes of tumors are predictive of clinical outcome. Individuals with luminal A 
subtype have a more favorable outcome while individuals with HER2 enriched and basal-like 
tumors generally have the worst consequences  (Sorlie et al., 2001).  Studies have also shown 
that these different molecular subtypes have distinct responses to therapy and thus different 
therapeutic approaches are taken to treat each of these subtypes. Luminal A and B subtypes of 
tumors are typically responsive to endocrine therapy [aromatase inhibitors (e.g., Anastrozole) 
and estrogen receptor modulators (e.g., Tamoxifen)].  However, luminal A tumors are less 
sensitive to chemotherapy while luminal B tumors have a higher pCR (pathological complete 
response) rate to neoadjuvant chemotherapy (administered before primary treatment of surgery 
or radiation to shrink tumor size). Luminal B tumors are also more sensitive to adjuvant 
chemotherapy (administered after primary treatments to control relapse) (Rouzier et al., 2005).  
Targeted therapy with trastuzumab, a monoclonal antibody against HER2 with a combination of 
chemotherapy is the most effective therapeutic strategy for HER2 positive cancers (Hayes et al., 
2007). Very recently, combination therapy of palbociclib (an inhibitor of cyclin-dependent 
kinases CDK4 and CDK6) with targeted endocrine therapies for HER2 negative, hormonal 
receptor-positive advanced breast cancers have been approved by FDA (National Cancer 
Institute).  The basal-like subtype has drawn a lot of attention from the researchers because 
unlike the other subtypes the basal-like subtype does not have any effective targeted therapy. The 
clinicians have to trust on systemic chemotherapeutic regimens, which mostly target cell 




Intratumor and intertumoral heterogeneity of breast cancer 
Breast tumors like most of the tumors of other organs show both intratumor and intertumoral 
heterogeneity. Intratumor heterogeneity arises from the presence of cancer cells with variable 
phenotypes in a single tumor.  The cells in a tumor typically show different degrees of basal-like 
and luminal features with gene signatures of luminal and basal cells of breast epithelium. This 
heterogeneity might arise from the intrinsic heterogeneity of the breast epithelial cells and the 
type of cells initiating the tumor (Polyak, 2011). However, it has also been shown that a 
particular cell population in a tumor might lead to multiple clone types owing to the 
accumulation of genetic alterations. Intertumoral heterogeneity arises from the presence of 
different cell types within tumors at varying frequencies (Polyak, 2011) (Figure I.4, lower 
panel).  
At the clinical level, the tumors are studied by pathologists for expression of hormone 
receptors or HER2, and a tumor is classified into a subtype depending on expression status of the 
major population of the cells, and a treatment therapy is designed.  Thus, basal-like tumors 
mostly have cancer cells with a basal-like phenotype, whereas luminal tumors are composed 
mostly of luminal breast cancer cells. However, that might lead to a growth advantage of a rare 
clone of cells (Marusyk et al., 2014) which might be unaffected by the therapy and might lead to 
tumor relapse, with the relapsing tumor having an entirely different character.  Thus, tumor 
heterogeneity is a considerable problem to clinicians as each tumor is a mixture of cell-types 
which might need different therapeutic intervention and no tumors are alike regarding cell type 
frequencies.     
12 
 
CCN FAMILY OF PROTEINS: AN OVERVIEW 
The CCN family of proteins is comprised of six highly conserved homologous secreted proteins. 
The CCN acronym used to name the family owes its origin to the first three family members 
namely, cysteine-rich angiogenic inducer 61 (CYR 61, also known as CCN1), connective tissue 
growth factor (CTGF, also known as CCN2) and nephroblastoma overexpressed (NOV, also 
known as CCN3). The other three members of the family are WNT inducible signaling pathway 
proteins named WISP1 (or CCN4), WISP2 (or CCN5) and WISP3 (or CCN6) (S. K. Banerjee & 
Banerjee, 2012; Jun & Lau, 2011) (Figure I.5). Each of the CCN family members had multiple 
names as multiple groups discovered the members independently while working with different 
biological systems. The various names are listed in the table below. Later, these proteins were 
identified to be either the same or other similar proteins sharing structural identity with CYR61, 
CTGF, and NOV (Holbourn, Perbal, & Ravi Acharya, 2009). A consensus was reached in the 
meeting of the International CCN society in 2000, and a unified nomenclature for the CCN 
proteins (CCN1-CCN6) was first described in the literature in 2003 (Brigstock et al., 2003). 
CCN proteins have been shown to be secreted from cells and localized in the extracellular matrix 
around the cells. Extracellular localization of the CCN proteins and their ability to modulate 
multiple cellular functions have led the investigators to classify the CCN proteins as 
matricellular proteins, a subset of extracellular matrix proteins which primarily plays regulatory 
roles rather than performing structural functions (Jun & Lau, 2011).  
Structural similarities and differences of CCN proteins  
All the six members of CCN family of proteins have similar modular structures with an amino-
terminal secretory signal peptide. CCN5 (also known as WISP2) being an exception, all the other 
five CCN members have identical modular structures with four conserved domains.  The 
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domains following the signal peptide in the amino-terminal end are the insulin-like growth factor 
binding protein (IGFBP) domain, the Von Willebrand factor C (VWC) domain, the 
thrombospondin type 1 repeat (TSR) domain and the cysteine knot carboxy-terminal (CT) 
domain (Holbourn et al., 2009; Jun & Lau, 2011).  The domains of the CCN family proteins are 
named according to the proteins to which the domains bear sequence homology and structural 
similarity (Holbourn, Acharya, & Perbal, 2008; Holbourn et al., 2009).  CCN5 lacks the fourth 
CT domain and thus has a lower molecular weight compared to other family members (Figure 
I.5, lower panel). Individual exons encode each domain of the CCN family proteins, a common 
strategy found in multi-modular human proteins, which bears evolutionary proof for exon 
shuffling resulting in diverse protein products from reshuffled building blocks.  Thus, a typical 
CCN protein prototype is encoded by a transcript carrying five exons followed by a long 3’ 
untranslated region (3’UTR) (Kubota, Hattori, Nakanishi, & Takigawa, 1999).  All the CCN 
proteins as suggested by the name of its first member cysteine-rich angiogenic inducer 61 
(cyr61) are rich in cysteine residues. 38 conserved cysteine residues are spread across the four 
domains of the CCN proteins with exceptions to CCN5 and CCN6. CCN5 lacks the ten cysteine 
residues of the fourth CT domain, and CCN6 lacks the four cysteine residues in its VWC domain 
(Holbourn et al., 2008; Holbourn et al., 2009; Jun & Lau, 2011; Pennica et al., 1998).  Each CCN 
molecule has a flexible variable linker or hinge region that separates the molecule into two 
halves, the amino-terminal half comprised of the IGFBP and the VWC domain and the C-
terminal half composed of the TSP and the CT domain (Holbourn et al., 2009; Jun & Lau, 
2011).The primary structural design and the arrangement of the domains are conserved in the 
CCN family proteins. However, there are significant sequence homologies between each of the 
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members, and all the members are unique which leads to a functional divergence (S. K. Banerjee 
et al., 2016; Holbourn et al., 2008) (Figure I.5, lower panel). 
Table representing diverse nomenclature of CCN family proteins:  
 
Distinct biological roles of CCN family proteins  
The high degree of homology and similar structure of the CCN proteins initially indicated that 
the proteins might have similar and redundant functions.  However, it has been established that 
the members of the CCN protein family serve both distinct and overlapping biological roles 
(Holbourn et al., 2008; Jun & Lau, 2011) (Figure I.5 lower panel).  These highly conserved 
proteins have been shown to bind many of the same receptors owing to the conserved receptor 
binding sites and in many cases function through similar mechanisms to regulate a common set 
of biological processes. But, the specific physiological effects exerted by the CCN family 
proteins differ depending on the family member, interacting molecules, and the responding cell.  
           CCN 
NOMENCLATURE 
ALTERNATIVE NAMES USED IN LITERATURE 
           CCN1 
           CCN2 
           CCN3 
           CCN4 
           CCN5 
           CCN6 
CYR61, CTGF-2, IGFBP10, IGFBP-rP4, CEF10 
CTGF, IGFBP8, IGFBP-rP2, HBGF-0.8, ecogenin, FISP12, Hcs24  
NOV, NOVH, IGFBP9, IGFBP-rP3 
Wisp-1, Elm-1 




Multiple studies established that CCN proteins localized in extra-cellular matrix support 
cell adhesion and spreading in different cell types.  The process of cell adhesion is mediated by 
the cell-surface integrin receptors which lead to other cellular responses like cell migration, 
proliferation and altered expression of specific downstream genes.  For example, the human skin 
fibroblasts interact with CCN1 and CCN2 through α6β1 integrins and heparan sulfate 
proteoglycans (HSPGs).  This interaction results in cell-adhesion and activation of adhesion-
dependent cellular events including the rapid formation of focal adhesion complexes, actin 
cytoskeleton reorganization, the formation of filopodia and lamellipodia (Chen, Chen, & Lau, 
2001).  
As mentioned before the effects of the CCN proteins on cell proliferation and migration 
are cell-specific and context dependent. In a study on fibroblasts, it has been shown that the 
CCN1, CCN2 and CCN3 proteins enhance DNA synthesis that has been induced by other 
mitogenic growth factors. Interactions of the CCN proteins with the αVβ3 integrins have been 
implicated in this process (Chen & Lau, 2009).  Similarly, in chondrocytes and osteoblasts, 
CCN2 promotes DNA synthesis though it has been shown to induce a G1 cell cycle arrest in 
mesangial cells (Jun & Lau, 2011). CCN1, CCN2, and CCN3 also stimulate migration in the 
fibroblasts and the endothelial cells and promote invasiveness of certain cancer cells (Chen & 
Lau, 2009).  Interestingly, though CCN1 and CCN2 have been shown to enhance proliferation 
and migration of vascular smooth muscle cells (Fan, Pech, & Karnovsky, 2000; Grzeszkiewicz, 
Lindner, Chen, Lam, & Lau, 2002), CCN3 and CCN5 inhibit these processes (Jun & Lau, 2011; 
Lake, Bialik, Walsh, & Castellot, 2003). 
Adhesion of the endothelial cells to the extracellular matrix mediated by CCN1, CCN2 or 
CCN3 through αVβ3 integrin supports cell survival (Chen & Lau, 2009).  But these CCN 
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proteins as cell adhesion substrates in fibroblasts can also promote apoptosis by interacting with 
α6β1 integrin (Todorovic, Chen, Hay, & Lau, 2005).  It has been shown that CCN1, CCN2, and 
CCN3 proteins can facilitate tumor necrosis factor (TNF) mediated apoptosis. These proteins can 
enhance the apoptotic activity of other TNF family cytokines such as the FAS ligand and TNF-
related apoptosis-inducing ligand (Chen & Lau, 2010; Chen, Mo, & Lau, 2001; Jun & Lau, 
2011). However, though under a different context and in different cells, other members of CCN 
family proteins have been shown to inhibit TNF mediated apoptosis (Jun & Lau, 2011). CCN1 
can induce cellular senescence in fibroblasts by acting as a cell adhesion molecule through its 
binding to α6β1 integrin and cell-surface HSPGs.  Studies also show that CCN1 activates the 
RAC1-dependent NADPH oxidase 1 to induce reactive oxygen species (ROS) production, 
leading to activation of the cellular tumor antigen p53 and the retinoblastoma-associated protein 
(pRb), resulting in senescence (Jun & Lau, 2010b).  It has been proved that CCN1-induced 
senescence of the fibroblasts functions as a critical mechanism for limiting fibrosis during wound 
healing (Jun & Lau, 2010a, 2011). 
CCN proteins are established as potent angiogenic inducers, as some of the members of 
the CCN family promote proliferation, chemotaxis and induce tubule formation in the 
endothelial cells. This effect is mediated through direct binding of CCN proteins to αVβ3 
integrins (Babic, Kireeva, Kolesnikova, & Lau, 1998; Jun & Lau, 2011; Kubota & Takigawa, 
2007; Maity et al., 2014).  CCN proteins have also been shown to regulate angiogenesis by 
influencing expression level and activities of vascular endothelial growth factors (VEGFs).  
Regulation of angiogenesis by the CCN proteins lead to the critical roles played by these proteins 
in embryonic development and tumorigenesis (Inoki et al., 2002; Kubota & Takigawa, 2007). 
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CCN proteins have been shown to directly bind to Bone Morphogenetic Proteins (BMPs) and 
influence differentiation of osteoblasts and chondrocytes, thus playing a critical role in skeletal 
development (Jun & Lau, 2011). A study on CCN2 protein first indicated that the CCN proteins 
could interact with members of the BMP and TGFβ family, regulating the binding affinity of 
BMPs and TGFβ for their respective receptors (Abreu, Ketpura, Reversade, & De Robertis, 
2002). However, studies indicate that the roles played by CCN proteins in this context are also 
diverse and oppose each other. It has been observed that CCN2 promotes differentiation of 
chondrocytes and osteoblasts favoring the development of bone and cartilage (Kubota & 
Takigawa, 2007). But, independent studies have also shown both CCN2 and CCN3 can bind to 
BMP2 and negatively regulate its functions in promoting chondrogenic and osteogenic 
differentiation (Maeda et al., 2009; Minamizato et al., 2007). Interestingly, CCN4 can bind to 
BMP2 enhancing its function in osteogenesis (Ono, Inkson, Kilts, & Young, 2011). 
The functions of CCN proteins, as discussed earlier, represent only a few of the diverse 
roles played by the family.  Most of the CCN functions depend on integrin binding and 
diversifies depending on the types of integrins expressed by the cell type.  Also, binding of CCN 
proteins to cell-matrix and growth factors in the cell environment leads to alteration of the 
cellular responses.  Thus, these direct and indirect influences exerted by the CCN proteins play a 
crucial role in modulating the outside-in cell signaling mediated by cell surface receptors 





Identification of CCN5 (Wisp2) gene  
The rat orthologue of CCN5 (WISP-2), rCop-1 was first identified in Rat Embryonic Fibroblasts 
(REFs) as a new member of the CCN family of genes in the year 1998. The study found a 
significant correlation between loss of expression of the CCN5 with cell transformation by 
inactivation of P53 and concomitant expression of a constitutively active H-Ras. Thus, this study 
suggested that CCN5 may be a negative regulator of tumorigenesis (R. Zhang et al., 1998).  In 
the same year, CCN5 (WISP-2) and CCN4 (WISP-1), was identified in a genetically engineered 
mouse model.  These studies indicated that CCN5/WISP-2 is a Wnt inducible gene (Pennica et 
al., 1998).  The study also showed expression of these genes in the adult human tissues and 
mapped human CCN5 gene in the long arm of the chromosomal 20 at cytogenetic location 
20q12-q13.1. Moreover, this study also found a significant downregulation of CCN5 expression 
in about 80% of the human colon tumor tissues (Pennica et al., 1998).  Subsequently, two 
independent studies reported that the CCN5/WISP2 is a serum and estrogen-inducible gene 
(Inadera et al., 2000; Zoubine, Banerjee, Saxena, Campbell, & Banerjee, 2001).   
The transient expression of CCN5 has been detected in fetal lung, adult skeletal muscle, 
colon, ovary, and breast (S. K. Banerjee & Banerjee, 2012; S. K. Banerjee et al., 2016; Das et al., 
2017). CCN5 has been implicated in having an important role in carcinogenesis, with relevance 
to human breast disease (S. K. Banerjee & Banerjee, 2012; S. K. Banerjee et al., 2016; Das et al., 
2017). Most studies show that, CCN5 expression correlate inversely with the aggressiveness of 
cancers in breast (S. K. Banerjee & Banerjee, 2012; Ferrand, Stragier, Redeuilh, & Sabbah, 
2012; Fuady et al., 2014), pancreas (G. Dhar et al., 2007), salivary gland (Kouzu et al., 2006), 
gallbladder (Z. Yang et al., 2014)  and gastric tissue (Ji et al., 2015). This observation suggests 
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tumor suppressor/anti-invasive activity of CCN5 (S. K. Banerjee & Banerjee, 2012; S. K. 
Banerjee et al., 2016; J. W. Russo & Castellot, 2010).  
The CCN5 expression is detected in both normal and non-invasive breast cancer cell lines and 
tissue samples (i.e., ADH and DCIS) (S. K. Banerjee & Banerjee, 2012; Das et al., 2017).  
CCN5-overexpressed breast cancer cells are less aggressive compared to CCN5-under expressed 
or negative breast cancer cells (S. K. Banerjee & Banerjee, 2012; S. K. Banerjee et al., 2016; Das 
et al., 2017). CCN5 expressing breast cancer cells (e.g., MCF-7, BT-474, ZR-75-1, T-47D) are 
always ER-α positive, while CCN5-negative cells are mostly triple-negative (Human cell lines: 
MDA-MB-231, MDA-MB-468, HCC-70, BT-20, MCF-DCIS and Mice cell lines: MVT-1 and 
4T1) (S. K. Banerjee & Banerjee, 2012; S. K. Banerjee et al., 2016; Fritah, Redeuilh, & Sabbah, 
2006), and are enriched with tumor-initiating cells (TICs)/cancer stem cells. Thus, at least in 
breast cancer, CCN5 can be considered a good prognostic marker (Das et al., 2017).  However, 
further supporting data are required to establish the hypothesis, and thus, the current studies are 
the milestones to achieve these goals. 
Signaling pathways regulating CCN5 expression  
Since the discovery of the CCN5 protein, multiple studies have focused on the signaling 
pathways that directly or indirectly influence CCN5 expression.  Apart from the evidence for 
direct transcriptional regulation of CCN5 by Wnt and estrogen-mediated signaling; indications 
for P53 mediated repression and influences of growth factor signaling have also been shown by 
different independent studies as mentioned earlier. 
WNT SIGNALING MEDIATED REGULATION OF CCN5 EXPRESSION: Previous studies, 
which was first identified CCN5 gene in a mouse mammary tumor model, indicated that CCN5 
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is the second family members of Wnt-1-induced signaling proteins, and thus coined the name of 
this protein was WISP-2 (Pennica et al., 1998).  Although the mechanism of regulation of 
CCN5/WISP-2 expression is unclear, a study demonstrated direct transcriptional regulation of 
CCN5 by β-catenin in fibroblast cells (Tanaka, Morikawa, Okuse, Shirakawa, & Imai, 2005). 
Moreover, physiological activators of Wnt signaling have also been shown to induce CCN5 
expression in different cell lines. Upregulated expression of the Wnt-1 protein in the 
hepatocellular carcinoma cell line Huh-7 and treatment of osteoblast cell line with a small 
molecule inhibitor of GSK-3β enzyme caused an increase in CCN5 mRNA transcription.  
Therefore, we can anticipate that CCN5 regulation by Wnt1 could be mediated through GSK-3β/ 
β-catenin pathway. 
ROLE OF ESTROGEN MEDIATED SIGNALING IN EXPRESSION OF CCN5: Role of 
estrogen-mediated regulation of CCN5 expression was evident from early studies carried out 
independently in different labs (S. Banerjee et al., 2003; Inadera, Dong, & Matsushima, 2002; 
Inadera et al., 2000; Saxena, Banerjee, Sengupta, Zoubine, & Banerjee, 2001; Zoubine et al., 
2001). In differential expression studies, it was noticed that CCN5 is significantly overexpressed 
in estrogen receptor-positive breast cancer cell lines compared to other normal and cancer cell 
lines of the breast (Saxena et al., 2001; Zoubine et al., 2001). Also, it was shown that treatment 
of ER-α-positive cells with estrogen leads to increase in mRNA transcript and protein levels of 
CCN5 (S. Banerjee et al., 2003; Inadera et al., 2002; Inadera et al., 2000). Addition of 17β-
estradiol to MCF-7 cells in culture increases expression of CCN5 mRNA and protein in a dose-
dependent and time-dependent manner which can reach maximum levels by 72 h of treatment (S. 
Banerjee et al., 2003; Inadera et al., 2002; Inadera et al., 2000).  The hormones that interact 
specifically with ER-α can induce the expression of CCN5. Several other hormones and steroids 
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(e.g., dexamethasone and tri-iodothyronine) do not affect CCN5 expression, whereas it has been 
shown that different xenoestrogens can induce CCN5 expression (Inadera et al., 2002).  Also, 
upregulation of CCN5 expression by estrogen was entirely blocked by the pure anti-estrogen 
inhibitor, ICI 182,780 (S. Banerjee et al., 2003; Inadera et al., 2000).  Incidentally, one of these 
early studies extended this observation to a pathologic context by showing a strong positive 
correlation between expression of CCN5 protein and estrogen receptor alpha (ER-α) positivity in 
human breast cancer sample (S. Banerjee et al., 2003).  Furthermore, studies have shown that 
CCN5 gene promoter has estrogen response elements (EREs). ER-α which is the direct mediator 
of estrogen action binds to the CCN5 promoter in an estrogen-dependent fashion (Fritah et al., 
2006).Progesterone was also shown to induce CCN5 protein in ER-positive human breast cancer 
cells (S. Banerjee et al., 2003). 
ROLE OF SIGNALING PATHWAY CROSSTALKS IN CCN5 EXPRESSION MCF-7 breast 
cancer cells treated with the Protein Kinase A activator, CT/IBMX (cholera toxin plus 3-
isobutyl-1-methylxanthine) exhibits an increase in CCN5 mRNA level. However, the same study 
established that treatment of MCF-7 cells with 12-O-tetradecanoyl phorbol-13-acetate (TPA), a 
protein kinase C (PKC) activator, completely prevented CCN5 mRNA induction by estrogen 
although it did not affect another estrogen-responsive gene, pS2 (Inadera, 2003). It has been 
speculated that the effects of PKA signaling on CCN5 expression might be exerted through 
decreased expression of the microRNA, miR449, which has been bio-informatically shown to be 
able to target CCN5 mRNA (Iliopoulos, Bimpaki, Nesterova, & Stratakis, 2009; J. W. Russo & 
Castellot, 2010). However, in a contradicting study, another PKC activator phorbol 12-myristate 
13-acetate (PMA) has been shown to upregulate CCN5 expression through the involvement of 
the MAPK mediated signaling pathways (Sengupta et al., 2006).  
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Activation of MAPK pathway and PI3K-AKT mediated signaling pathway have been implicated 
to play a role in the regulation of CCN5 expression. Epidermal growth factor (EGF) induces 
expression of CCN5 mRNA in MCF-7 cells in a dose- and time-dependent manner and can act 
synergistically with estrogen. The effect was possibly mediated through activation of the PI3K, 
and MAPK signaling pathways as the use of inhibitors (wortmannin and U0126 respectively) 
against the mentioned pathways abrogated the effect of EGF treatment on CCN5 expression (S. 
Banerjee, Sengupta, Saxena, Dhar, & Banerjee, 2005). A similar set of studies also established 
that IGF-1 could induce CCN5 mRNA expression in a dose and time-dependent manner and 
knockdown of CCN5 abrogate the ability of IGF-1 to stimulate MCF-7 cell proliferation (K. 
Dhar, Banerjee, Dhar, Sengupta, & Banerjee, 2007). However, the IGF-1 mediated stimulation 
of CCN5 expression was shown to be dependent on activated MAPK pathway only, as opposed 
to EGF mediated activation, where both MAPK and PI3K mediated signaling were shown to 
play roles. Both EGF and IGF-1 mediated expression of CCN5 was dependent on estrogen-
mediated signaling as the effects were abrogated by treatment with anti-estrogen ICI 182-780. 
REPRESSIVE ROLE OF P53 PROTEIN LEVEL ON CCN5 EXPRESSION:  An inverse 
relation between the expression level of CCN5 and P53 proteins has been indicated in multiple 
studies involving cancer cell lines and tissues. Pancreatic adenocarcinoma samples showed a 
significant inverse relationship between the expression level of P53 and CCN5 (G. Dhar et al., 
2007). Similarly, ectopic expression of P53 mutants in the ER-α positive breast cancer cell lines 
MCF-7 and ZR-75-1, downregulated CCN5 mRNA expression, eliciting a possible repressive 
role played by P53 on CCN5 expression (G. Dhar et al., 2008). Notably, an increase of P53 
protein level is frequently associated with stabilizing mutations of P53 where the mutants play a 
dominant negative role leading to oncogenic transformation. 
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ROLE OF HIF-2α IN CCN5 EXPRESSION: Hypoxia-inducible factor-2α (HIF-2α) has been 
implicated in the regulation of CCN5 expression in multiple studies (Aprelikova, Wood, Tackett, 
Chandramouli, & Barrett, 2006; Fuady et al., 2014; Stiehl et al., 2012). CCN5 was identified as 
one of the few genes in MCF7 which was preferentially regulated by HIF-2α rather than HIF-1α 
under hypoxic conditions. It was also shown that transcription factor ELK-1 binds in the 
promoter region of CCN5 at a position close to the hypoxia response elements (HREs) and 
directly interacts with the HIF-2α protein in driving CCN5 expression (Aprelikova et al., 2006). 
Another study also claimed that HIF-2α/AREG/WISP2-expressing tumors were associated with 
luminal tumor differentiation and are expected to show a better response to standard treatments 
and thus validated their report of more prolonged patient survival in breast cancer with high 
levels of HIF-2α (Stiehl et al., 2012).  Another study also showed that high WISP-2 tumor levels 
were associated with increased HIF-2α expression and a better prognosis. Also, a gain of 
aggressive phenotypes of breast cancer cells can be phenocopied by silencing HIF-2α expression 
(Fuady et al., 2014). 
Regulation of cellular functions by CCN5  
As mentioned in a previous section in this chapter CCN proteins have been shown to modulate 
multiple cellular functions through their interactions with the cell surface receptors (mostly 
integrins) and their direct binding capability with ECM components and other growth factors. 
CCN5 though lacking the CT domain can influence an array of these cellular functions as 
elucidated by multiple studies performed in different cell lines.  
• PROLIFERATION: Overexpression of CCN5 or CCN5 treatment in culture media has 
been shown to induce growth arrest in vascular smooth muscle cells (VSMCs); and also 
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in human uterine normal myometrial and uterine leiomyoma tumor cells (Delmolino, 
Stearns, & Castellot, 2001; Lake et al., 2003; Lake & Castellot, 2003; Mason, Lake, 
Wubben, Nowak, & Castellot, 2004). Thus, CCN5 was widely referred to as a growth-
arrest-specific gene by these groups. A similar anti-proliferative effect of CCN5 was 
noticed in studies with human umbilical vein endothelial cells (HUVECs) and murine 
pre-adipocyte cell line (Inadera, Shimomura, & Tachibana, 2009; J. W. Russo & 
Castellot, 2010).As reported by multiple studies and discussed in the next chapter here, 
CCN5 expression and treatment with CCN5 leads to inhibition of proliferation of triple 
negative breast cancer cell line MDA-MB-231 both in in-vitro and in-vivo xenograft 
models (Fritah et al., 2008; Haque et al., 2015).   
• MOTILITY AND MIGRATION: Cellular motility and migratory capabilities of cells 
hold keys for invasive cellular properties. It has been implicated to play a role in multiple 
disease progression including cancer. CCN5 has been known to play a critical role in 
inhibiting cellular motility in numerous cell culture studies. In rat vascular smooth 
muscle cells and smooth muscle cells derived from human uterine myometrial tissue, 
alteration of CCN5 expression level shows a negative correlation between CCN5 
expression and cellular motility (Lake et al., 2003; Lake & Castellot, 2003; Mason et al., 
2004). Similarly, CCN5 has been extensively studied as an anti-invasive gene in breast 
cancer in multiple laboratories (S. K. Banerjee & Banerjee, 2012; Fritah et al., 2008). 
Studies with triple negative breast cancer cell line MDA-MB-231 has shown evidence for 
the capability of CCN5 to induce an adverse effect on cellular motility. Ectopic 
expression of the CCN5 protein in MDA-MB-231 cells and knockdown of CCN5 
expression in MCF7 cells lead to an increase in cellular motility and migration in-vitro 
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(S. Banerjee et al., 2008; Fritah et al., 2008). Similarly, treatment of MDA-MB-231 cells 
with MCF7 cell conditioned medium (rich in secreted CCN5) led to a lesser motility of 
the MDA-MB-231 cells as exhibited by Boyden chamber assay. However, such an anti-
motility effect on MDA-MB-231 cells was not noticed when treated with conditioned 
medium of CCN5 ablated MCF7 cells (S. Banerjee et al., 2008; Fritah et al., 2008). Also, 
another study published in the same year showed that pre-treatment of mutant P53 
transfected MCF7 cells with recombinant CCN5 protein leads to a decrease of cellular 
motility in a Boyden chamber assay (G. Dhar et al., 2008). 
Both cellular phenomena, proliferation, and motility, are key hallmarks of the cancer cells. Thus, 
restriction of aberrant proliferation and motility of cancer cells can be two critical roles of CCN5 
protein that can be implemented in designing new direction of therapeutics.    
CCN5 as a micromanager of breast cancer progression 
As indicated in the previous sections of this chapter, the role of CCN5 in breast cancer 
progression has been studied extensively in-vitro which suggests that CCN5 might play a critical 
negative role in breast cancer pathogenesis.  Studies indicate that loss of CCN5 might be an 
essential step in gaining of plasticity, motility and invasiveness of breast cancer cells and 
multiple genetic insults including gain of P53 mutations have been implicated in loss of CCN5 
expression (S. Banerjee et al., 2008; S. K. Banerjee & Banerjee, 2012; G. Dhar et al., 2008; 
Fritah et al., 2008).  The expression of CCN5 was observed to be high in precursor lesions of 
human breast cancer at stages of Atypical Ductal Hyperplasia (ADH) and Ductal Carcinoma In-
Situ (DCIS) while its expression gradually decreases to undetected or minimal level from 
moderately differentiated to poorly differentiated invasive breast cancer samples (S. Banerjee et 
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al., 2008; S. Banerjee et al., 2003).  In a similar study, a negative correlation between CCN5 
staining and P53 staining in human breast cancer sections was reported (G. Dhar et al., 2008).  
As previously discussed, modulation of CCN5 level in breast cancer cells influences the 
proliferative capacity and the motility of the cells in-vitro (S. Banerjee et al., 2008; Das et al., 
2017; Fritah et al., 2008).  Expression of matrix metalloproteinases (MMPs) has been implicated 
in playing a pivotal role in gaining invasive potential of breast cancer cells.  Ablation of CCN5 
expression has been shown to upregulate the expression level matrix metalloproteinases, MMP2 
and MMP9 in MCF7 cells (S. Banerjee et al., 2008). One of the most widely studied phenomena 
implicated in gaining of invasive potential of breast cancer cells is epithelial to mesenchymal 
transition (EMT).  Though debated, most of the researchers believe and have been successful in 
partially proving that cancer epithelial cells lose their epithelial characteristics of apicobasal 
polarity, basement membrane adhesion and cell-cell junctions in the course of time to express a 
more motile mesenchymal phenotype.  This phenotype helps the cells to sculpt through the 
matrix and invade surrounding tissues. Independent studies have shown that downregulation of 
CCN5 expression in MCF7 cells leads to decrease of expression of markers for the epithelial 
phenotype (e.g., E-cadherin) (S. Banerjee et al., 2008; Ferrand et al., 2014).  Conversely, 
treatment of MDA-MB-231 cells leads to upregulation of epithelial marker expression while a 
robust decrease of mesenchymal markers was noticed (Das et al., 2017).  Two studies provided 
further insights into the mechanisms of CCN5 mediated regulation of EMT.  
It was indicated in one study that CCN5 negatively regulates the miR-10b levels in breast 
cancer cells. miR-10b has been shown to play a critical role in the initiation of metastasis (Ma, 
Teruya-Feldstein, & Weinberg, 2007).  It was shown in the study that depletion of CCN5 in 
breast cancer cells leads to stabilization and activation of HIF-1α (hypoxia-inducible factor-1α) 
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which results in Twist-1 mediated (J. Yang et al., 2004) expression of miR-10b (Haque et al., 
2011).  Another study implicated the role of CCN5 in negative regulation of TGF-β signaling 
pathway. It was shown that downregulation of CCN5 expression in breast cancer cells leads to a 
robust upregulation of expression of TGF-β receptor-II (TGF- β-RII).  The study concludes from 
its observations that CCN5 might act as a direct transcriptional repressor of TGF- β-RII gene by 
binding to its promoter region, which leads to repression of TGF-β signaling mediated EMT of 
cancer cells (Sabbah et al., 2011). 
In very recent studies, loss of CCN5 expression has been implicated in a gain of stem 
cell-like characteristics of breast cancer cells (Das et al., 2017; Ferrand et al., 2014).  Cancer 
stem cells are believed to be a subpopulation of cancer cells which have been sighted as one of 
the key reasons for tumor relapse.  Though the origin of the cancer stem cells remains highly 
debated, it has been argued that stem-like cancer cells can arise from the epithelial cells upon 
accumulation of oncogenic mutations.  It has been shown that loss of CCN5 in MCF7 breast 
cancer cells can promote the emergence of a cancer stem cell-like phenotype as the cells showed 
a high expression of CD44 and increased activity of aldehyde dehydrogenase activity, which are 
signatures of breast cancer stem cells. Also, inoculums of a lower number of CCN5 negative 
cells were capable of tumor formation after injection into the mammary fat pad of 
immunodeficient mice (Ferrand et al., 2014).  It was shown in another study, that CCN5 
expression was minimal in the subpopulation of MCF7 cells which showed enrichment of gene 
expression of stem cell-like signature. This population of cells exhibited a lower expression of 
the epithelial marker proteins and a higher expression of mesenchymal markers which however 
was altered after ectopic expression of CCN5. It was also shown that, compared to the CCN5 
positive population, the CCN5 negative MCF7 cells possess higher tumorigenic potential when 
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injected subcutaneously in nude mice. However, ectopic expression of CCN5 in the CCN5 
negative subpopulation of cells ablated higher tumorigenicity of those cells (Das et al., 2017). 
 
OVERALL OBJECTIVES AND SIGNIFICANCE OF THE STUDY 
At present, there are immense gaps in our understanding of the mechanisms by which CCN5 
destroys TNBC growth and metastasis. This Ph.D. dissertation has addressed these deficiencies 
carefully and, provided new mechanistic insights into the function of CCN5 in preventing or 
delaying the growth and aggressive phenotypes of TNBC.  Since CCN5 downregulation is 
detected in various cancers, its study will be relevant to other cancers as well.  Of note, because 
restoring CCN5 prevents TNBC growth and progression with no or minimal side effects, small 
molecule drugs can be designed to restore CCN5 in TNBC for therapeutic utility.  
Based on the premise, we hypothesized that CCN5 could induce cell-cycle arrest in 
TNBC cells and HER2 positive tumors.  In the following chapters, in support of the hypothesis, 
we have proved using in-vitro cell line studies and in-vivo mice model studies that CCN5 
expression can play a critical role in delaying tumor progression by inducing arrest at cell-cycle 
checkpoints. We have also proved that CCN5 induces expression of ER-α in normal and 
malignant breast epithelial cells which leads to the therapeutic sensitivity of the cells. Thus, in 
the immediate next chapter (second chapter) we have elaborated the mechanism by which CCN5 
induces cell cycle arrest in triple negative cancer cells. In the third chapter, we extended our 
hypothesis from the observations of the first chapter and elucidated the mechanism by which 
CCN5 induces expression of ER-α in breast epithelial cells both in-vitro and in CCN5 transgenic 
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mice model. Finally, in the fourth chapter, our transgenic mice studies unravel a novel 












Fig.I.1: Breast cancer structural arrangement and epithelial bilayer: The human breast ductal network 
is comprised of 10-20 main ducts that drain out through individual openings in the nipple. The ducts 
branches into subsegmental ducts that ends into Terminal Ductal Lobular Units (TDLUs). Each of 
the ducts and the alveoli is lined by two layers of epithelial cells – Luminal epithelial cells (LECs), 
which lines the lumen and myoepithelial cells, between the LEC layer and the basement membrane.  
(Used with permission from Eric Wong and Sultan Chaudhry. McMaster Pathophysiology Review, 




























Fig.I.2: Histologic appearance of human breast ductal and lobular architecture:  Hematoxylin and 
eosin staining of an adult human breast tissue (non-lactating). (*)- denotes a single lobular unit (**)- 
indicates the fibrous connective tissue interspersed between lobules (*)- denotes cross sectional view 
of a mammary duct. The original image has been used from websource www.breastpathology.info 

























Fig.I.3: Progression of breast cancer: The figure depicts the gradual progression of breast cancer in a 
breast ductal epithelium from hyperplasia to invasive carcinoma. The arrow denotes the gradual 
progression of breast carcinoma from DCIS stage to Invasive cancer. Original figure source has been 



























Fig.I.4: Clinical subtypes of breast cancer and heterogeneity: The figure (upper panel) illustrates the 
three clinical subtypes of breast cancer (lower panel) depicts intra-tumor and inter tumor 





















Fig.I.5: Domain structure of a typical CCN protein (upper panel) and individual CCN members 
(lower panel): The figure (upper panel) shows the domains of a typical CCN protein with the 
conserved integrin binding sites and corresponding integrin types (Jun & Lau, 2011). The figure 
(lower panel) also depict domain arrangement of individual CCN members with amino acid 
positions, the direct interacting partners and down-stream actions (S. K. Banerjee et al., 2016). Both 
figures used from the cited articles with permissions. [IGF-Insulin-like growth factor; SP-Signal 
Peptide; BMP-Bone morphogenetic protein; FN-Fibronectin; LRP-Lipoprotein receptor related 
protein; FN-Fibronectin; HSPG-heparan sulfate proteoglycan; GF-growth factors; TGFβ- tumor 

















CHAPTER II: Role of CCN5 in promoting growth arrest of Triple 




KIP1/CIP1 proteins as cyclin-dependent kinase inhibitors  
Cell cycle progression in normal non-cancerous cells is a multistep process.  It is finely tuned by 
the coordinated activities of different cell-cycle regulator protein-complexes.  These regulatory 
proteins are mostly composed of cyclin family of proteins, whose actions are dependent on their 
ability to bind their corresponding cyclin partners to form an active complex leading to the 
ramifying downstream influences on the effector proteins (Besson, Dowdy, & Roberts, 2008). 
Another group of proteins named cyclin-dependent kinase inhibitors (CKIs/CDKIs) bind to the 
CDK proteins to inhibit their catalytic activities leading to cell cycle arrests at definite cell cycle 
stages (Besson et al., 2008) and thus act as brakes to the cell cycle machinery. The cells without 
the CDKI activities lead to uncontrolled CDK-cyclin complex formation and actions leading to 
uncontrolled cell cycle progression associated with common human cancers (Coqueret, 2003). 
There are two major families of CDK inhibitors (CKIs) namely INK4 family and KIP/CIP family 
of proteins who serve a critical function of regulating the cell cycle progression by their 
association with cyclin-dependent kinases (CDKs). The INK4 family members (P16INK4A, 
P15INK4B, P18INK4C, and P19INK4D) bind to CDK4 and CDK6 and block their association 
with D-type cyclins leading to inhibition of the kinase activity of CDK4 and CDK6. In contrast 
to the INK4 family members, CKIs from the CIP/KIP family (P21CIP1, P27KIP1, and P57KIP2) 
have capabilities to bind to all cyclin–CDK complexes and primarily inhibit the kinase activity of 
CDK2 and CDK1 (Otto & Sicinski, 2017). Growth inhibitory signals are known to block the G1-





P27KIP1, a non-classical tumor suppressor  
P27 also known as KIP1 protein belongs to the KIP/CIP family of proteins and has been one of 
the most widely studied CKI protein since it’s identification. Being encoded by the CDKN2B 
gene in human, P27 protein is related to another cyclin-dependent kinase inhibitor 
P21(Toyoshima & Hunter, 1994).  The P27Kip1 protein has been reported to be localized in both 
the nucleus and cytoplasm of a cell.  The nuclear component of P27Kip1 participates in all cell 
cycle phases preventing the activities of all cyclin–CDK complexes as needed without 
dissociating them. It is well established that downstream effectors of multiple signaling pathways 
and various microRNAs regulate the expression level of P27Kip1 for cell cycle regulation in 
normal and malignant cells (Chu et al., 2008; Nourse et al., 1994; Polyak et al., 1994; Sherr & 
Roberts, 1999).  The protein P27Kip1 is widely considered as a tumor suppressor protein (Bloom 
& Pagano, 2003; Chu et al., 2008; Slingerland & Pagano, 2000). Moreover, various mouse 
model studies have further established the tumor suppressor function of the P27Kip1 protein 
(Besson, Assoian, & Roberts, 2004; Chu et al., 2008).  Although from a functional perspective 
view, P27Kip1 protein has been classified as an atypical tumor suppressor protein, there have 
been contradictory findings. Multiple studies have found evidence that directs to the fact that in 
some instances P27Kip1 plays a decisive role in tumorigenesis in various organs including the 
colon, esophagus, prostate, and breast (Besson et al., 2004).  It has been found out from further 
studies that the cellular localization of P27Kip1 plays a vital role in its function and cytoplasmic 
accumulation of the protein is liable for tumorigenesis (Baldassarre et al., 1999; Chu et al., 2008; 
Sgambato, Cittadini, Faraglia, & Weinstein, 2000).  Accumulation of cytoplasmic P27Kip1 
might just lower the nuclear concentration of P27Kip1 and put a check in its tumor suppressive 
function, or cytoplasmic P27Kip1 might directly exert oncogenic functions or both. These 
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functions may suppress cellular apoptosis and increase cell motility thus leading to the pro-
tumorigenic role of P27Kip1 (Asada et al., 1999; Blagosklonny, 2002; Motti et al., 2005).  
Regulation of P27KIP1 protein level by SCF-Skp2 
A family of molecular adaptors, the F-box proteins function as substrate-recognition subunits of 
SCF-type (Skp–Cullin–F-box type) ‘E3’ complexes, which ligate proteins to ubiquitin chains, 
allowing recognition for proteasomal degradation(K. I. Nakayama & Nakayama, 2005). The 
prototypical SCF complex contains an F-box protein (which is p45SKP2, i.e., S-phase kinase-
associated protein 2 in the SCF-SKP2 complex), SKP1, CDC53/CUL-1 and RBX/ROC1 (Figure 
II.1a).  The ability of Fbox proteins to recognize a substrate largely depends on specific 
phosphorylation levels of the substrate(Amati & Vlach, 1999). SCF-Skp2 E3 ligase enzymatic 
activity holds the key to the proteolytic turnover of multiple proteins involved in cell cycle 
control and transcriptional regulation of cell cycle (Kossatz et al., 2004).  The half-life and 
stability of P27Kip1 are regulated by the ubiquitination and degradation process through the S-
phase kinase-associated protein 2 (Skp2)-containing SCF (SCF-Skp2) complex.  Previously, it 
has been shown that Skp2 associates explicitly with a P27 carboxy-terminal peptide that is 
phosphorylated at Thr187, (Figure II.1a,b) but not with the non-phosphorylated peptide. This 
indicates that CDK-dependent phosphorylation of P27kip1 on Thr 187 (T187) is critical for 
Skp2-mediated degradation of P27kip1(Figure II.1a,b) (Carrano, Eytan, Hershko, & Pagano, 
1999; Tsvetkov, Yeh, Lee, Sun, & Zhang, 1999). 
Role Akt pathway in FOXO3a mediated regulation of P27KIP1 expression level 
FOXO family of transcription factors belong to the Forkhead family of transcriptional regulators 
characterized by a conserved DNA-binding domain termed the ‘forkhead box.’  Among the 19 
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subgroups of Forkhead family, FOXO subgroup has four members namely, FOXO1, FOXO3, 
FOXO4, and FOXO6. The FOXO family of transcription factors is directly affected by the 
activity of PI3K pathway as those are one of the major group of direct substrates of the protein 
kinase Akt. Direct Akt mediated phosphorylation of FOXO factors at three key conserved 
regulatory sites (Thr32, Ser253, and Ser315 in the FOXO3a sequence) triggers rapid 
relocalization of FOXO proteins from the nucleus to the cytoplasm (Greer & Brunet, 2005).  
Thus, subcellular localization of FOXO3a is directly dependent on PI3K/AKT activity. In 
absence of active PI3K/Akt signaling FOXO3a transcription factors are localized in the nucleus, 
where they cause cell cycle arrest, by upregulating a series of critical target genes, one of which 
is P27Kip1 (Figure II.2) (Greer & Brunet, 2005; Nakao, Geddis, Fox, & Kaushansky, 2008; S. 
Zhang et al., 2013). In the absence of active PI3K/Akt signaling phosphorylated FOXO3a 
proteins bind to 14-3-3 proteins, which results in the export of FOXO3a from the nucleus into 
the cytoplasm leading to their sequestration from the target genes like P27Kip1, and eventual 
proteasomal degradation (Figure II.2). Thus, spatial regulation of FOXO3a transcription factor 
inhibits cell cycle progression at the G1/S transition through controlling the transcription of 




MATERIALS AND METHODS 
Cell culture condition 
In these studies, ER-positive MCF-7 cell line and MDA-MB-231 triple negative breast cancer 
cell lines were used. These cell lines were obtained from American Type Culture Collection 
(ATCC, Manassas, VA) and were grown in DMEM containing penicillin and streptomycin (100 
units/mL) and supplemented with 10% fetal bovine serum (FBS). The cells were cultured at 
37oC in a humidified chamber with 5% CO2. Most of the experiments were performed with 60% 
confluency cells. 
Cloning and Transfection 
CCN5-specific shRNA or mismatched shRNA and CCN5 cDNA were cloned in the pSilencer 
1.0-U6 (Ambion Inc, Grand Island, NY, USA) and pZsGreen1C1 (Clontech Laboratories, 
Mountain View, CA, USA) plasmids, respectively. shRNA sequence was designed to target 
CCN5 mRNA transcript. CCN5 cDNA was reverse transcribed with specific primers from 
MCF7 RNA and cloned in pS-1.0-U6 according to the manufacturer’s instructions. For 
transfection experiments, breast tumor cells were transfected with the plasmids using the lipid 
micelle-based Lipofectin reagent following the transfection protocol provided by the vendor 
(Invitrogen, Grand Island, NY, USA). Electroporation of siRNAs against P27Kip1 and FOXO3a 
was accomplished using Neon Transfection System (Invitrogen, Grand Island, NY, USA) 
following cell line specific protocol provided by the vendor.  
Cell proliferation assays 
MDA-MB-231 cells (vector or CCN5 construct transfected) were grown in the absence of serum 
for 72 h and then 10% fetal bovine serum was added, and the cells were grown for different time 
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points as required for the experimental design. 10,000 cells per well were plated onto 96-well 
tissue culture plates. For the study of the effect of hrCCN5 on MDA-MB-231 proliferation, cells 
were treated with hrCCN5 for 48h after seeding. To perform the crystal violet assay, at 
experimental time points media from the wells with the cells were drained and washed with PBS 
thrice.  Following that Crystal violet stain is added to each well and incubated for 20 mins.  Next, 
crystal violet is washed off in standing water till no free satin remains. Lastly, the plate is dried, 
and the crystal violet stained cells are solubilized using 10% acetic acid and incubated for 30 
mins.  Colorimetric measurement is made at a 600nm wavelength with the help of a spectrometer 
and reading from each well is considered as the final cell density in corresponding well. 
Tumor xenograft studies 
All animal studies were performed with the approval of the IACUC of Kansas City VA Medical 
Center. For subcutaneous tumor growth, 8-week old female nude mice (N = 5) were injected 
with  2 ×106 cells subcutaneously. The cells for each injection were suspended in 50 microliters 
of PBS buffer and mixed with equal volume of Matrigel (Corning, NY, USA) and kept on ice 
until injection. Injections were made subcutaneously at the hind limb of each mice. The length 
(L) and width (W) of each tumor were measured by calipers twice per week. Tumor volume 
(TV) was calculated by the formula TV = 0.5xLxW2. Finally, the tumors were harvested at time 
point according to the needs of experiments. 
Nuclear-cytosolic fractionation 
Nuclear and cytoplasmic protein lysates were prepared according to the manufacturer’s 
instructions with brief modifications, Semi-confluent (~60%) MCF-7 and MDA-MB-231 cells 
were scraped into cold PBS and collected by centrifugation at 500 × g for 5 min. The cells were 
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washed once with PBS and centrifuged, and the cell pellet was re-suspended into ice-cold 
cytoplasmic extraction reagent 1 (CER1) and incubated on ice. After 10 min, ice-cold CER II 
was added to the tube. Samples were spun at 16,000 × g for 5 min to generate the cytosolic 
fraction (supernatant). The insoluble (pellet) fraction was re-suspended in ice-cold nuclear 
extraction reagent (NER). The pellet was homogenized by vortexing and was centrifuged at 
16,000 x g for 10 min to generate nuclear fraction (supernatant). 
Western Blot analysis 
Equal amounts of protein were subjected to 7.5-10% SDS-PAGE, and the gel-fractionated 
proteins were transferred to nitrocellulose membranes (Bio-Rad) and reacted with specific 
antibodies. Blots were developed using ECL kits (Pierce, Rockford, IL) and bands were detected 
and analyzed using Carestream Molecular image station (Carestream Health, Inc. Woodbridge, 
CT, USA). 
Immunofluorescent staining 
MDA-MB-231 cells were grown in two-well chamber slides containing DMEM supplemented 
with 10% serum in the presence or absence of recombinant CCN5 protein (100 ng/ml) for 48 h. 
The cells were first washed with PBS followed by fixation with with 2% paraformaldehyde. 
Then, the cells were permeabilized with 1 × -Triton X (or with methanol), washed with PBS and 
blocked with 5 % goat serum blocking solution (Invitrogen, Grand Island, NY, USA) for 10 min. 
Finally, the cells are incubated with the anti P27Kip1 antibody (Cell Signaling Technologies, 
Danvers MA, USA) at a dilution of 1:300 in PBS, followed by a final incubation with the FITC-
conjugated secondary antibody (1:1000 in PBS for one h) along with nuclear DAPI staining. The 
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expression of P27Kip1 was visualized by confocal microscopy (Leica Microsystems, Buffalo 
Grove, IL, USA). 
Cycloheximide treatment for protein stability assay  
MDA-MB-231 cells were seeded at a confluency of 60 percent of growth surface area and were 
treated with Cycloheximide (Sigma, St. Louis, MO, USA) solution at a final concentration of 
25µM in complete DMEM supplemented with 10% FBS. The treatment was continued for 8hrs 
and protein was extracted from the cells at each time point of 0, 1, 2, 4 and 8hrs for western 
blotting.  
AKT inhibitor (LY294002) treatment  
MDA-MB-231 cells were seeded at a confluency of 60 percent of growth surface area. Inhibitor 
of PI3KAkt activity, LY294002 was used to treat the semi-confluent cells at a final concentration 
of 10mM in complete DMEM supplemented with 10% FBS. The treatment was continued for 
8hrs and protein was extracted from the cells in lysis buffer supplemented with phosphatase 







Effect of CCN5 overexpression and recombinant CCN5 treatment on TNBC (MDA-
MB-231) cell viability and cell-cycle  
Crystal violet based cell viability assays were performed in both induced CCN5 overexpressing 
MDAMB231 cells and in the presence of human recombinant CCN5 protein (hrCCN5) to 
evaluate any possible role of CCN5 protein on cell-survival and proliferation of triple-negative 
breast cancer cells MDA-MB-231. MDA-MB-231 cell lines with stable transfection of the only 
GFP-overexpressing vector [MDA-MB-231CCN5(-)] and with GFP fused CCN5-overexpressing 
constructs[MDA-MB-231CCN5(+)] were grown under a serum-deprived condition for 72h and 
subsequently were cultured in complete media (with 10% FBS) for 24-72hrs timepoints.  The 
results from the crystal-violet staining of the cells demonstrate that ectopic expression of CCN5 
induces growth inhibition of MDA-MB-231 cells significantly in a time-dependent manner 
(Figure II.3a).  Similar crystal violet assays were performed in presence different doses of 
hrCCN5 (0-1000ng/ml) in cell culture medium to determine the effect of human recombinant 
CCN5 protein (hrCCN5) on MDA-MB-231 cell viability. A dose-dependent growth inhibition of 
MDA-MB-231 cells was observed when cells were grown in the presence of hrCCN5 for 48 h 
(Figure II.3b).  Further insight into the CCN5 induced growth arrest of MDA-MB-231cells was 
brought in with flow-cytometry based cell-cycle analysis of control and 48h of CCN5 treated 
MDA-MB-231 cells. The cell numbers in the G0/G1 phase was significantly increased with a 
concomitant reduction of cell numbers in S and G2/M phases in the CCN5-treated cells as 
compared with the control (Figure II.3c). These results indicate that CCN5-induced inhibition of 




Effect of CCN5 on tumor progression in TNBC (MDA-MB-231) xenograft model 
Once the CCN5-mediated growth inhibitory effect on MDA-MB-231 cells was established under 
in-vitro conditions, the study was extended to an in-vivo xenograft model experiment. MDA-
MB-231-xenograft tumors were established with both MDA-MB-231CCN5(+) cells and MDA-
MB-231CCN5(−) cells.  The effect of CCN5 overexpression, on tumor growth progression, was 
evaluated by monitoring the tumor volume increase in both groups of the mice. The nude (nu/nu) 
mice inoculated with MDA-MB-231CCN5(+) cells displayed reduced tumor volume increase 
relative to MDA-MB-231CCN5(−) cell-generated tumors.  After 3 weeks of tumor cell 
inoculation the control group of mice had a significantly larger volume of tumor as compared to 
the experimental group of mice with CCN5 expressing cells (Figure II.3d) Throughout the study 
period that extended for a month the tumors from MDA-MB-231CCN5(+) cells maintained a 
significantly lower volume as compared to the control tumors and a growth arrest was noted in 
those tumors.  
Role of P27Kip1 in CCN5-induced growth inhibition of TNBC cells 
MDA-MB-231 cells were transfected with short interfering RNA (siRNA) specific for P27Kip1 
to block the expression of P27Kip1 to test the status of the P27Kip1 protein in CCN5-induced 
growth inhibition of MDA-MB-231 cells.  Firstly, the extent of knockdown was evaluated in the 
protein extracts from scrambled siRNA transfected, and P27Kip1 siRNA transfected MDA-MB-
231 cells by Western Blotting (Figure II.3e), and subsequently, the effect of hrCCN5 protein on 
cell proliferation was tested. As expected, hrCCN5 protein significantly reduced the proliferation 
of scrambled-transfected MDA-MB-231 cells, whereas this inhibitory effect of CCN5 was 
decreased significantly in P27-siRNA-transfected cells (Figure II.3e lane4) as compared to the 
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scrambled-siRNA transfected cells treated with hrCCN5. This observation indicates that cell 
growth inhibition by CCN5 is mediated by P27Kip1 and could be prevented by blocking 
P27Kip1 expression in MDA-MB-231 cells. 
Role of CCN5 on P27Kip1 expression and its subcellular localization  
As it was observed that CCN5 reduces the growth rate of MDA-MB-231 by arresting the cell 
cycle at the G0/G1 stage through P27Kip1 regulation, it was tested whether the presence of 
CCN5 plays a role in the regulation of the P27Kip1 protein expression. Firstly, the relative 
expression of the P27Kip1 protein in MDA-MB-231 cells was tested in the presence of different 
concentrations of hrCCN5 and for various time points. It was found that the levels of P27Kip1 
protein were significantly elevated in CCN5-treated cells in a time and dose-dependent manner 
(Figure II.4a).  Second, to determine whether CCN5 plays any role in the distribution of 
P27Kip1 in the nucleus and cytoplasm of breast cancer cell lines, the nuclear and cytosolic 
fractions were isolated from extracts of CCN5-positive MCF-7 cells, CCN5-silenced MCF-7 
cells, CCN5-negative MDA-MB-231 cells and CCN5-overexpressed MDA-MB-231 cells. The 
status of P27Kip1 protein expression in individual fractions was measured by western blotting. 
Results showed a decreased nuclear-to-cytoplasmic ratio in CCN5-silenced MCF-7 cells as 
compared to the CCN5-positive MCF7 cells, whereas this ratio was increased in CCN5-
overexpressed MDA-MB-231 as compared with CCN5-negative MDA-MB-231 cells (Figure 
II.4b).  In a similar experiment, the influence of hrCCN5 on the nuclear-to-cytoplasmic ratio of 
P27Kip1 in MDA-MB-231 cells treated and untreated with hrCCN5 was tested and observed to 
be increased in treated cells (Figure II.4c).  These results were further confirmed by 
immunofluorescence analyses, which indicated that hrCCN5 treatment increases the P27Kip1 
protein level in the nucleus when compared with the untreated cells (Figure II.4d).  Collectively, 
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these studies reveal that presence of CCN5 in the micro-environment leads to an enrichment of 
P27Kip1 in the nucleus of aggressive TNBC cells. 
CCN5 enhances stability of P27Kip1 protein in TNBC cells 
The P27Kip1 protein levels and functions in cells are also governed by post-translational 
modifications of the protein in the cell which regulates the stability of the protein.  To determine 
whether CCN5 has any role in maintaining the protein stability of P27Kip1 MDA-MB-231 cells 
were treated with a protein synthesis inhibitor, cycloheximide (CHX), in the presence or absence 
of hrCCN5 for different time points.  Following the blocking of P27Kip1 protein translation by 
CHX treatments, P27Kip1 protein status was determined in the whole cell protein extracts. In 
CCN5 untreated MDA-MB-231 cells after CHX treatment, the P27Kip1 protein level started 
decreasing after one hour and declined to a minimal level by 4hrs. of treatment (Figure II.5a). In 
the presence of hrCCN5, the initial protein level of P27Kip1 was higher than the control cells 
and even after 8hrs. Of CHX treatment the protein level of P27Kip1didnot decreases 
significantly (Figure II.5a). In a related experiment, it was shown that not only CCN5 treatment 
of MDA-MB-231 cells augments P27Kip1 expression level, but the elevated level of P27Kip1 
protein is also maintained even after 48hrs of withdrawal of CCN5 from the culture medium 
(Figure II.5b). These results indicate that the presence of CCN5 protein augments the P27Kip1 
protein stability in MDA-MB-231 cells. 
CCN5 influences SKP2 mediated degradation of P27Kip1 protein in TNBC cells 
Treatment with hrCCN5 significantly reduced the protein level of Skp2 in MDA-MB-231 cells 
in a time-dependent manner as found out by western blot (Figure II.6a).  Observation of an 
increase in P27Kip1 stability post CCN5 treatment and western blot showing a decline of Skp2 
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protein level in MDA-MB-231 cells after CCN5 treatment indicate that upregulation of P27Kip1 
by CCN5 through improvement of P27Kip1 protein stability could be carried out by blocking the 
Skp2 production and thus it’s enzymatic activity.  As phosphorylation of P27Kip1 at T187 is 
critical for Skp2 mediated degradation of P27Kip1, the effect of CCN5 treatment on T187 
phosphorylation levels in MDA-MB-231 cells was observed in CCN5 treated cell extracts and it 
was discovered that CCN5 treatment drastically reduces the T187 phosphorylation levels 
(Figure II.6b).  Collectively, these studies indicate that CCN5 suppresses both Skp2 expression 
and P27Kip1 phosphorylation at T187 in MDA-MB-231 cells and thus protects P27Kip1 from 
degradation. 
Upregulation of P27Kip1 by CCN5 is mediated through the stabilization of 
FOXO3a transcription factor via inhibition of PI3K/AKT pathway 
FOXO3a (Forkhead Box O 3a), a transcription factor has been shown to play a significant role in 
controlling the transcription of P27Kip1 in various cells. As an upregulation of P27Kip1 
transcription with decreased cell survival and G1 arrest was observed after treating MDA-MB-
231 cells with hrCCN5, the expression level of FOXO3a protein in CCN5-treated MDA-MB-231 
cells was determined. Immunoblot analyses revealed an upregulation of FOXO3a protein level in 
CCN5-treated MDA-MB-231 cells in a time-dependent manner (Figure II.7a). In addition to an 
upregulation of FOXO3a expression level, it was also noticed that CCN5 treatment led to an 
increase in localization of FOXO3a in the nucleus as compared to the untreated cells (Figure 
II.7b). As nuclear transport and cytosolic-nuclear localization of FOXO3a is subject to the 
phosphorylation of Ser318, Ser253 and Thr32 residues in FOXO3a protein, the role of CCN5 
treatment on phosphorylation levels of the mentioned residues was observed by western blotting. 
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A decrease in the phosphorylation level at Ser318 and Ser253 was noticed in CCN5 treated 
MDA-MB-231 extracts (Figure II.7c).  
 It has been already established from previous studies and mentioned earlier that PI3K/AKT 
pathway activity directly regulates the phosphorylation levels of FOXO3a protein leading to its 
cytoplasmic accumulation and degradation. Given the importance of the role of AKT activity and 
capabilities of CCN family proteins to interact with cellular integrins, the status of the activated 
phosphorylated form of AKT in MDA-MB-231 cells after CCN5 treatment was checked. 
Western blotting against the phosphorylated form of AKT at Ser473 (p-AKT) showed a 
significant decrease of p-AKT levels in CCN5-treated cells as compared with untreated cells, 
whereas the expression level of total AKT protein was unchanged in both treated and control 
groups (Figure II.7d).  A marked decline of Cyclin D1 and Bcl-2 protein expression level in 
CCN5-treated cells was also observed (Figure II.7d) as both proteins are critical downstream 
targets of the PI3K/AKT pathway and are regulated by FOXO3a mediated transcription.  
Next, to discern a link between CCN5-induced inactivation of AKT and induction of FOXO3a 
and P27Kip1, experiments were designed to investigate whether an AKT inhibitor exerts a 
similar effect as hrCCN5 and augments FOXO3a and P27Kip1 expression in MDA-MB-231 
cells. It was found that levels of p-AKT and p-FOXO3a (S253) and p-P27Kip1 (T187) were 
significantly reduced whereas the total P27 level was markedly elevated in the presence of the 
PI3K/AKT inhibitor, LY294002 (Figure II.8). No effect of AKT inhibitor treatment was 
observed on the levels of total FOXO3a protein. Then it was determined whether the CCN5 
treatment mimics the AKT inhibitor’s action in breast cancer cells and it was found that 
overexpression of CCN5 in MDA-MB-231 cells mimic the Akt inhibitors’ effect on MDA-MB-
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231 cells (Figure II.8). To investigate whether FOXO3a is a critical intermediate molecule that 
needs to be stabilized by CCN5 to exert its regulatory effect on P27Kip1 protein levels in MDA-
MB-231 cells, FOXO3a expression was silenced by siRNA specific for FOXO3a in MDA-MB-
231 cells, and P27Kip1 levels were detected in these cells before and after hrCCN5 treatment. It 
was observed that though hrCCN5 enhances both FOXO3a, as well as P27Kip1 protein levels in 
control siRNA-transfected cells, this effect of CCN5, was nullified when FOXO3a expression 
was abolished from the cells through RNAi-based silencing. (Figure II.9) Collectively, these 






The antitumorigenic role of CCN5 in breast cancer, though established in multiple studies, is not 
yet completely understood (S. K. Banerjee & Banerjee, 2012).  In this section, mechanisms of 
P27Kip1 regulation by CCN5 in triple negative breast cancer line MDA-MB-231 cells has been 
elucidated. CCN5 mediated signaling has been shown to contribute to the increased protein level, 
activity and nuclear relocalization of P27Kip1 leading to cell growth inhibition and possibly 
invasion suppression in aggressive TNBC cells.  The expression level of P27Kip1, its subcellular 
distribution and corresponding prognostic value in breast cancer have been studied for decades. 
Although the prognostic significance of P27Kip1 in breast cancer is debatable there has been 
consensus on the fact that heterogeneous distribution of P27Kip1 protein plays a key role in 
aberrant cell cycle progression in cancer cells (Barbareschi et al., 2000; De Paola et al., 2002; 
Tan et al., 1997; Troncone et al., 2004; Viglietto et al., 2002).  In studies performed in our 
laboratory, in corroboration with previous studies, the heterogeneous distribution of P27Kip1 
was noted in human breast samples.  Though both high and low levels of P27Kip1 expression 
were detected in infiltrating ductal adenocarcinoma samples, and the localization of P27Kip1 
was observed to be predominantly in the cytoplasm.  In pre-neoplastic lesions such as atypical 
ductal hyperplasia (ADH) and ductal carcinoma in-situ (DCIS), the P27Kip1 expression is very 
high and was mostly located in the nucleus. Interestingly, a positive correlation as observed 
between the nuclear localization of P27Kip1 and CCN5 expression in both human breast tissue 
samples and breast cancer cell lines (Haque et al., 2015). The dichotomous function of P27Kip1 
depending on its subcellular localization in the nucleus and cytoplasm in cancer cells creates a 
debate as for whether to classify it as a tumor suppressor or an oncogene (Besson et al., 2008; 
Blagosklonny, 2002; Sgambato et al., 2000; Viglietto et al., 2002) . The growth-arresting activity 
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of P27Kip1 depends on its nuclear localization whereas aberrant shifting to cytoplasm impairs 
the growth-arresting function (Baldassarre et al., 1999; Jiang, Zhao, & Verfaillie, 2000; Viglietto 
et al., 2002).Studies in this section test the hypothesis that P27Kip1 protein level and trafficking 
could be regulated by CCN5 mediated signaling in breast cancer cells leading to the 
manifestation of the growth-inhibitory action of CCN5. The findings of this section involving, 
CCN5 depleted and overexpressing breast cancer cell lines and treatment of hrCCN5, provide 
evidence that CCN5 can act as an upstream regulator of P27Kip1 expression level and 
localization. Previous studies on P27Kip1, in various normal and cancer cells, suggest that 
P27Kip1 protein levels can be increased in a cell mainly by enhancement of its stability (half-
life) (Slingerland & Pagano, 2000) through the regulation of ubiquitination. and eventual 
degradation via a ubiquitin ligase complex, SCF-Skp2 (Carrano et al., 1999; Kossatz et al., 2004; 
K. Nakayama et al., 2004; K. I. Nakayama & Nakayama, 2005; Spruck et al., 2001). 
Furthermore, P27Kip1 levels have been shown to be directly regulated at the transcriptional 
level, and localization of FOXO3a transcription factor plays a vital role in this event.(Greer & 
Brunet, 2005; S. Zhang et al., 2013). The observations listed in this section indicates that 
upregulation of P27Kip1 in MDA-MB-231 cells via CCN5 can be mediated both by increased 
stability of P27Kip1 and transcriptional activation involving stabilization and nuclear 
localization of FOXO3a transcription factor. The stability of P27Kip1 could be maintained by 
CCN5 through repressing Skp2, a key adaptor molecule necessary for binding of the SCF-Skp2 
complex to P27Kip1. Also, CCN5 can stabilize P27Kip1 by blocking the phosphorylation of 
P27Kip1 at T187 which is necessary for substrate recognition of SCF-Skp2 enzyme complex, 
resulting in prevention of Skp2-mediated degradation of P27Kip1(Figure II. 1a,b) (Carrano et 
al., 1999).In parallel, it has been shown that CCN5 upregulates P27kip1 mRNA expression in 
53 
 
MDA-MB-231 cells through the increase of expression level as well as increased nuclear 
translocation of FOXO3a. The changes in stability and subcellular localization of FOXO3a are 
the results of the phosphorylation status of specific serine and threonine residues which are direct 
substrates of Akt kinase activity (Greer & Brunet, 2005; Nakao et al., 2008; S. Zhang et al., 
2013). Because CCN5 blocks Ser318 and Ser253 phosphorylation in MDA-MB-231 cells via 
inhibiting AKT activity, the nuclear translocation of FOXO3a by CCN5 could be mediated 
through repressing the AKT induced phosphorylation of S318 and S253 of FOXO3a (Figure 
II.2). However, interestingly, though not studied here, previous studies have shown that Akt can 
directly phosphorylate P27Kip1 protein at T157 which leads to cytoplasmic localization of 
P27Kip1 thus precluding its capability to induce cell cycle arrest (Shin, Rotty, Wu, & Arteaga, 
2005; Viglietto et al., 2002). In addition to Skp2 expression regulation leading to stability of 
P27Kip1 and direct transcriptional activation via FOXO3a, CCN5 might reduce cytoplasmic 
localization of P27Kip1 by inhibiting its direct phosphorylation of P27Kip1 at T157 by Akt. This 
regulation of P27Kip1 was found to be a direct mechanism regulated by Akt that sustains 
proliferation of breast cancer cells.  
CCN5 like other CCN family members after being secreted localizes outside the cell and thus is 
likely to exert its function via cell-surface receptors. It is widely established that various 
functions of CCN family proteins are mediated through integrin receptors (Haque et al., 2012; 
Jun & Lau, 2011). Also, previously it has been shown that integrins differentially regulate the 
proliferation of CD34+ normal and leukemic cells through the regulation of P27Kip1 (Jiang et 
al., 2000). Studies investigating roles of CCN family proteins suggest a context-dependent role 
of integrin receptors in various tissue types. Results from an extension of these studies in this 
section indicate that CCN5 exerts its effect through α6 and β1 integrins to regulate P27Kip1 
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expression. The conclusion was derived from the observation that the treatment of α6 and β1 
integrin antibodies block CCN5-induced upregulation of P27Kip1 mRNA and protein in MDA-
MB-231 cells. Also, CCN5 protein has been shown to be directly interacting with the integrins 
(Haque et al., 2015). Overall, to exert the growth arrest function, CCN5 enhances P27Kip1 
expression as well as its nuclear translocation through the regulation of Skp2 and AKT/FOXO3a 
molecular signaling pathways (Figure II.10). Thus, inducing activation of CCN5 in aggressive 
breast cancer cells has the potential to affect growth arrest of these aggressive cells when applied 
























Fig.II.1a: This schematic figure shows binding of SCF-SKP2 ubiquitin ligase complex composed of 
SKP1, CUL-1, RBX and SKP2 proteins to p27Kip1 with T187 phosphorylation, critical for 
recognition of p27 as a substrate for ubiquitination and degradation. The phosphorylation of 
p27Kip1 is carried out by Cyclin-CDK2 complex. (Amati & Vlach, 1999). Figure used from the 
















Fig.II.1b: Regulation of p27Kip1 by signaling pathways:  In early G1, phosphorylation at S10 
increases leading allowing CRM1-dependent nuclear export and KPC-mediated proteolysis of 
cytoplasmic p27Kip1. ABL and SRC phosphorylate p27 in early G1 which results in activation of 
cyclin E–CDK2 leading to T187 phosphorylation of p27 and proteolysis through SCFSKP2. In early 
to mid G1, PI3K activity phosphorylates P27 at T157 blocking nuclear import and promoting the 
assembly of cyclin D–Cdk–p27 complexes. (Chu, Hengst, & Slingerland, 2008). Figure used from 























Fig.II.2: Regulation of p27Kip1 by Akt: Active Akt signaling leads to phosphorylation of FOXO3a 
transcription factors resulting in their cytoplasmic relocalization, sequestration from DNA binding 
leading to decreased p27Kip1 expression. Inactivated or repressed Akt signaling leads to nuclear 


















Fig.II.3: Effect of CCN5 on TNBC cell growth: (a) Cell survival assay was performed by crystal 
violet staining. All quantitative data are presented as mean±s.e.m. of at least eight sets of 
experiments. *P<0.03 vs corresponding CCN5(−), **P<0.001 vs corresponding CCN5(−). P-value 
was generated by two-tailed t-test. (b) Crystal violet cell survival assay with MDA-MB-231 cells, 
treated with different concentration of hrCCN5 protein for 48 h. All quantitative data are presented 
as fold ±s.e.m. of at least eight sets of experiments. *P<0.01 vs untreated cells, **P<0.001 vs 















Fig.II.3: Effect of CCN5 on TNBC cell growth: (c) Flow-cytometric cell-cycle analysis of MDA-
MB-231 cells treated with vehicle or hrCCN5 protein(100ng/ml). All quantitative data are presented 
as mean ±s.e.m. of at least three sets of experiments. *P<0.01 vs untreated cells; #P<0.03 vs 
untreated cells. P-value was generated by two-tailed t-test. (d) Measurement of the size of xenograft 
tumors of MDA-MB-231CCN (+) or MDA-MB-231CCN5 (−) cells subcutaneously into the female 
nude mice (N= 5 per group). All quantitative data are presented as mean ±s.e.m. *P<0.006. P-value 





























Fig.II.3e: Role of p27Kip1 in CCN5 mediated cell growth inhibition: Cell growth inhibition by 
hr.CCN5 was measured with p27Kip1 or scrambled-siRNA transfected MDA-MB-231 cells. Crystal 
violet cell viability assays were performed. The western blot illustrates the efficiency of p27Kip1-
siRNA (upper panel). All quantitative data are presented as mean ±s.e.m. of at least three sets of 
experiments. *P<0.001vs CCN5-untreated control siRNA (lane 1) and **P<0.014 vs CCN5-treated 








Fig.II.4a: Effect of CCN5 on p27Kip1 expression: Western blots demonstrating p27Kip1 protein 
levels in MDA-MB-231 cell lysates treated with vehicle or hrCCN5 protein in a time- and dose-
dependent manner. The images are representatives of three independent experiments. Bar graph 
represents quantitative analysis of relative p27Kip1 protein level.  All quantitative data are presented 
as mean ± SEM of at least three sets of experiments. *P < 0.001 vs untreated. P value was generated 





















Fig.II.4: Effect of CCN5 on p27Kip1 localization: Western blots demonstrating relative cytosolic 
and nuclear p27Kip1levels in CCN5-depleted MCF-7 cells (b, left panel), CCN5 overexpressed 
MDA-MB-231 cells (b, right panel) and hrCCN5-treated (100 ng/ml for 48 h) or vehicle-treated 
(control) MDA-MB-231 cells (c). Blots against GAPDH, Lamin B1 and β-actin are used as quality 














Fig.II.4: Effect of CCN5 on p27Kip1 localization: (d) Immunofluorescence images from confocal 
microscopy of MDA-MB-231 cells treated with hrCCN5 protein or vehicle control for 48 h, against 
p27Kip1 antibody. P27Kip1 immunostaining is shown in green, and nuclei, counterstained with 4′, 




















Fig.II.5: Stabilization of p27Kip1 in TNBC cells exposed to recombinant CCN5. (a) Western blots 
from lysates of MDA-MB-231 cells which were either exposed to cycloheximide (25 μg/ml) or pre-
treated with hrCCN5 protein (100 ng/ml) for 24 h followed by a combination treatment of hrCCN5 
and cycloheximide (lower panel). The images are representative of three independent experiments 
and all quantitative data are presented as mean ± s.e.m. *P<0.001. P-value was generated by two-
way analysis of variance. b) Western blots demonstrating relative p27Kip1 protein levels in MDA-
MB-231 cell extracts, after withdrawing hrCCN5 treatment (100 ng/ml) at indicated time points. All 
quantitative data are presented as mean ± s.e.m. of at least three sets of experiments. *P<0.001 vs 


















Fig.II.6: Expression level of Skp2 and phosphorylation levels of p27Kip1 after hr.CCN5 treatment : 
(a) Western blots demonstrating relative Skp2 protein level in vehicle- and hrCCN5 (100 ng/ml)-
treated MDA-MB-231 cells. Fold changes were normalized to β-actin, a loading control. All 
quantitative data presented as mean± s.e.m. *P<0.001 vs control, **P<0.0001 vs control. P-values 
were determined with two tailed t-test. (b) Western blots demonstrating relative p-p27Kip1(T187) 
protein level in MDA-MB-231 cells treated with hrCCN5 (100 ng/ml). Fold changes were 
normalized to β-actin and all quantitative data presented as mean ±s.e.m. *P<0.01 vs CCN5(−), 











Fig.II.7: FOXO3a regulation by CCN5 in breast cancer cells. (a) Relative FOXO3a protein level in 
hrCCN5 protein (100 ng/ml)-treated (time-dependent) MDA-MB-231 cell extracts were assessed by 
western blotting. Fold changes were normalized to β-actin and all quantitative data presented as 
mean±s.e.m. *P<0.001 vs CCN5 untreated (0 h). P-values were determined with two-way analysis of 
variance. (b) Relative FOXO3a protein levels in cytosolic (Cyt) and nuclear (Nuc) fractions of 
untreated or hrCCN5 (100 ng/ml)-treated MDA-MB-231 cells were assessed using western blotting 
(left panel). GAPDH and Lamin B1 are used as quality and loading controls. Fold changes were 
normalized to respective loading controls and all quantitative data (nuclear-to-cytoplasmic ratio) are 
presented as mean ±s.e.m. of three sets of experiments (right panel). *P<0.01 vs untreated cells. P-














Fig.II.7: Regulation of FOXO3a and Akt phosphorylation by CCN5 signaling. (c) Representative 
images of western blots demonstrating relative levels of FOXO3a and different phosphorylated 
forms of FOXO3a in vehicle- and hrCCN5-treated MDA-MB-231 cell extracts. Bar graph represents 
quantitative analysis of relative levels of FOXO3a and different phosphorylated forms of FOXO3a. 
Fold changes were normalized to β-actin. All quantitative data are presented as mean ± SEM of at 
least three sets of experiments. *P<0.02 vs corresponding untreated, **P< 0.001 vs corresponding 
untreated. P value was generated by two-tailed t test. (d) Representative images of western blots 
demonstrating relative levels of p-AKT, AKT (left panel), CyclinD1 and Bcl2 (right panel) in 











Fig.II.8: Akt inhibitor treatment mimics CCN5 overexpression: Relative levels of phosphorylation in 
AKT, FOXO3a and p27Kip1 in MDA-MB-231 cells treated with an AKT inhibitor LY294002 
(10mM) or vehicle for 3 h were determined using western blot analysis. Fold changes were 
normalized to β-actin, a loading control (left panel). Relative levels of phosphorylation in AKT, 
FOXO3a and expression level of p27Kip1in vector alone- or CCN5-vector-transfected MDA-MB-
231 cell extracts were determined using Western blot analysis. Images are representative of three 





















Fig.II.9:  CCN5 mediated upregulation of p27Kip1 is FOXO3a dependent: Representative images of 
western blots demonstrating relative levels of FOXO3a and p27Kip1 in FOXO3a-depleted MDA-
MB-231 cells treated with hrCCN5. Bar graph represents quantitative analysis of relative levels of 
FOXO3a and p27Kip1 in FOXO3a-depleted MDA-MB-231 cell treated with hrCCN5. Fold changes 
were normalized to β-actin. All quantitative data are presented as mean ± SEM of at least three sets 
of experiments. *P<0.0001 vs control siRNA. **P<0.001 vs control siRNA and #P<0.003 vs control 


















Fig.II.10: CCN5 signaling network for p27Kip1-dependent TNBC cell growth arrest:  Schematic 
representation of CCN5 mediated transcriptional regulation of p27Kip1 by nuclear localization of 
FOXO3a and nuclear localization and stabilization of p27Kip1(through downregulation of Skp2 and 
dephosphorylation at T187) and leading to cell cycle arrest. CCN5 binds to integrins α6β1to exert its 
inhibitory effect on Akt phosphorylation(inhibition) which in turn leads to the aforesaid 
transcriptional activation (through Foxo3 dephosphorylation) and nuclear localization of p27Kip 

























CHAPTER III: Role of CCN5 in inducing expression of Estrogen 
Receptor -α in normal breast epithelial cells and triple-negative breast 




Estrogen Receptor -A member of Nuclear Hormone Receptor family  
Nuclear hormone receptors were discovered from the studies that aimed to investigate the 
cellular mediators of lipophilic, cell membrane permeable hormones (Mangelsdorf et al., 1995). 
It was long established that these hormones along with their cellular mediators played diverse 
physiological roles (Mangelsdorf et al., 1995). An array of ligands was shown to bind directly 
and specifically to their corresponding receptor protein partners. The expression level of the 
receptors and their distribution in different tissues led to tissue-specific accumulation and activity 
of these ligands. Since the discovery, a large superfamily of nuclear receptors of about 150 
members has been identified both in vertebrates and invertebrates. Ligands for some of these 
receptors have been recognized while the others are still putative orphan receptors as their 
ligands have not been yet discovered (Mangelsdorf et al., 1995). The receptors for estrogen, 
progesterone, retinoic acid, vitamin D and thyroid hormone are few common widely studied 
examples of nuclear hormone receptor. Nuclear hormone receptors are defined as ‘a family of 
hormone-activated transcription factors that can initiate or enhance the transcription of genes 
containing specific hormone response elements’(MacGregor & Jordan, 1998).  
Estrogen receptor was first discovered in rat uterus, with the help of radioactively labeled 
estrogen in 1962 by Jensen and Jacobson, who also demonstrated organ-specific retention of 
estrogen (MacGregor & Jordan, 1998). Estrogen receptor was identified as a member of the 
conserved superfamily of nuclear receptors and was one of the first RNA polymerase II 
transcription factors to be cloned (S. Green et al., 1986; Greene et al., 1986; Mangelsdorf et al., 
1995). Eventually, in 1996 with the discovery of a second receptor for estrogen, two distinct 
receptors for estrogen namely, Estrogen receptor-α (ER-α) and Estrogen receptor-β (ER-β), have 
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been shown to exist (S. Green et al., 1986; Kuiper, Enmark, Pelto-Huikko, Nilsson, & 
Gustafsson, 1996). Both estrogen receptors play distinct roles in estrogen-mediated signaling in 
different physiologic and pathologic context. 
Estrogen Receptor-α (ESR1) gene structure and promoter organization 
Human estrogen receptor gene (ESR1) spans across a length of 300kb of the ‘q’ arm of the 
chromosome 6 (Gosden, Middleton, & Rout, 1986). The complex genomic organization of the 
ESR1 gene and its promoter region has been extensively studied, and a consensus nomenclature 
of the promoter region has been widely accepted (Kos et al., 2001). The promoter region of 
ESR1 extends for 150kb while the protein coding region extends for another 140kb. The protein 
coding region is comprised of 8 exons and seven introns. The protein-coding exons are named 
numerically one to eight (1-8). The transcription of the ER-α gene is carried out from 7 possible 
promoter regions comprised of upstream seven exons which are named alphabetically (A-F and 
T). Alternative usage of the promoter and RNA splicing leads to multiple transcript variants of 
ER-α. However, all the splice variants are generated using a conserved splice acceptor site 
located at +163 position in exon1 upstream of the translation start site at +223 position. Thus, all 
the splice variants of ER-α mRNA have a different 5-׳UTR region but encode the same protein of 
size 66kDa (Figure III.1a). 
Estrogen receptor protein structure and dynamic changes upon estrogen and anti-
estrogen binding 
Both the estrogen receptors ER-α and ER-β have similar domain structure with six functional 
domains which are characteristic signature of the nuclear receptor family of proteins 
(Figure.III.1.b). The N-terminal domain is known as activation function domain 1 (AF1 or A/B 
domain). It is poorly conserved in ER-α and ER-β leading to differential binding with other 
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transcription factors(Nilsson & Gustafsson, 2002).The next domain is DNA binding domain 
(DBD or C domain) which is highly conserved and carries two zinc finger binding motifs 
helping in direct recognition and binding of cis-estrogen response elements (EREs) in target gene 
promoter. Next to the DNA binding domain is the hinge region (D domain) which has a Nuclear 
Localization Sequence (NLS) and the sites for post-translational modifications of the protein 
(Sentis, Le Romancer, Bianchin, Rostan, & Corbo, 2005; C. Wang et al., 2001). The C-terminal 
region of the protein (E/F domains) have overlapping ligand binding domain (LBD) and 
activation function domain 2 (AF2). The ligand binding domain also carries dimerization 
sequence for ER-α. The AF2 domain is critical for ligand-dependent binding of other 
transcription co-factors. The ligand binding domain shows structural changes in the presence of 
ligands that regulate ER-α activity. One mobile α-helical arm of the ligand binding domain 
named H12 changes position depending on the presence of an agonist or antagonist.  Upon 
binding of an agonist like estrogen, the arm position allows binding of co-activators to an 
exposed hydrophobic groove of an AF2 domain. Anti-estrogens displace the H12 arm in a way 
that it blocks the binding of co-activators to the AF2 domain (Brzozowski et al., 1997) (Figure 
.III.1.d).  Thus, in the presence of ligands, the ligand binding domain regulates the AF2 
mediated co-activator binding and transcriptional activity (White, 1998). 
Estrogen receptor classical and non-classical transcriptional activities 
In the absence of ligands, ER-α exists as monomers and remains bound to chaperone proteins 
(e.g., Hsp90, Hsp70) forming heteromeric complexes (Pratt & Toft, 1997).  After binding, ligand 
ER-α undergoes a conformational change and dissociates from the chaperone complex.  These 
activated ER-α proteins form dimers in the nucleus to carry out the downstream transcriptional 
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activities.  In the nucleus, ER-α can drive target gene transcription by both classical and non-
classical genomic pathways.  
In case of a classical genomic function, the ER-α dimers bind directly to the Estrogen Response 
Elements (EREs) present at the upstream promoters of the estrogen-responsive genes 
(Griekspoor, Zwart, Neefjes, & Michalides, 2007; Sanchez, Nguyen, Rocha, White, & Mader, 
2002; White, 1998). ER-α binding to the EREs is followed by the recruitment of coactivators and 
components of the RNA polymerase II transcription initiation complex for transcriptional 
activation.  
In case of a non-classical nuclear function, the ER-α binds to other DNA-bound transcription 
factors thus regulating the downstream gene transcription indirectly.  Few popular examples are 
binding of estrogen bound ER-α to the AP1 (Activation Protein 1) and SP1 (Specificity Protein 
1) transcription factors leading to the transcriptional activation of the corresponding downstream 
genes (Bjornstrom & Sjoberg, 2005; Kim, Barhoumi, Burghardt, & Safe, 2005).  The ability of 
ER-α to bind to other transcription factors helps it to transcriptionally regulate even the genes 
which lack ERE sites in their promoter.  Estrogen receptor-mediated estrogen signaling leads to 
downregulation of pro-apoptotic factors, transcriptional repressors, cell cycle inhibitory proteins 
and upregulation of genes related to cell cycle progression and DNA synthesis. 
Regulation of estrogen receptor-α expression in breast cancer cells 
 A significant proportion of all the breast cancer patients have ER-α positive tumors where most 
of the cancer cells profoundly express ER-α. The cell proliferation in these tumors is driven by 
ER-α mediated transcription of cell cycle progression genes. The expression level of ER-α 
decides the estrogen sensitivity and endocrine therapy responsiveness of the breast tumors.  
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Estrogen receptor expression can be regulated - at transcriptional level by the cis-promoter 
elements and trans-factors; at post-transcriptional level by alteration of RNA stability (Ing, 2005; 
Pinzone, Stevenson, Strobl, & Berg, 2004) and regulation of translation efficiency (Ing, 2005); 
and at post-translational level by ligand (Laios et al., 2003; Laios et al., 2005; Long & Nephew, 
2006), cofactor and phosphorylation (Valley et al., 2005) dependent regulation of  protein 
stability and degradation.  
Transcriptional regulation of ER-α expression 
 The proximal promoters A and B have been studied widely as these were the first regulatory 
sites of ER-α regulation to be discovered (Kos et al., 2001).  Expression from these two 
promoters has been established to be a significant player for ER-α overexpression in breast 
cancer.  The majority of ER-α promoter activity resides within the promoters A and B, between -
245 bp and +212 bp relative to the first described transcription start site at exon 1 (S. Green et 
al., 1986). The minimal promoter encompassing the mentioned region has multiple conserved 
transcription factor binding sites (e.g., GC box for binding of Sp1 and Sp3 binding,).  
It has been shown that ER-α can regulate its expression from the minimal promoter by 
interacting with the Sp1 transcription factors bound to the GC box in the minimal promoter 
(deGraffenried, Hilsenbeck, & Fuqua, 2002; deGraffenried, Hopp, Valente, Clark, & Fuqua, 
2004). A wide variety of transcription factors regulate expression of ER-α from the minimal 
proximal promoter as well as from the distal promoter elements. ERBF1- transcription factor has 
been shown to drive ER-α transcription from promoter C (Tanimoto, Eguchi, Yoshida, Hajiro-
Nakanishi, & Hayashi, 1999). p53 can also activate the ER-α transcription from the minimal 




  In multiple studies, it has been shown that transcriptional regulation of ER-α expression 
can be dictated by chromatin remodeling. A transcription factor AP2γ (ERF-1) induces DNase1 
hypersensitive sites at the promoter A of ER-α gene in human mammary epithelial cells (and 
possibly also at promoter B and C in ER-α overexpressing breast cancer cells).Thus, these 
phenomena lead to trans-activation of ER- α expression (McPherson, Baichwal, & Weigel, 1997; 
McPherson & Weigel, 1999; Schuur, McPherson, Yang, & Weigel, 2001).  
 ER-α transcription has been shown to be regulated through chromatin remodeling in breast 
cancer, by direct binding of pRb2/pl30 complex within the promoter A. It engages a multi-
protein complex differentially recruiting specific chromatin modifying enzymes including 
histone methyltransferase SUV39H1, DNMT1 (DNA methyltransferase 1), HDAC1(Histone De-
acetylase 1) and HAT (Histone Acetyl Transferase) p300. It has been proposed that., in MCF-7 
cells, the high activity of p300 within the pRb2/pl30 complex induces the activation of ER-α 
transcription from promoter A by maintaining an open state chromatin (Macaluso, Cinti, Russo, 
Russo, & Giordano, 2003; Macaluso, Montanari, & Giordano, 2005; Macaluso et al., 2007). In 
the ER-negative MDA-MB-231 cells, the pRb2/pl30-based multiprotein complex represses ER-α 
gene transcription by chromatin condensation through the recruitment of DNMT1 and 
concomitant dislocation of HAT p300. Both DNMT1 and HDAC1 are established as important 
factors involved in the epigenetic silencing of many genes including ER-α. 
Transcriptional regulation of ER-α by FOXO3a transcription factor and possible 
role of CCN5  
The transcription factor FOXO3a has also been implicated in the regulation of ER-α gene 
transcription. As discussed in detail in the previous chapter, FOXO3a, a member of the 
mammalian Forkhead Box (FOX) family of transcription factors has been shown to regulate 
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expression of multiple genes implicated in cell cycle progression. In a study using breast cancer 
cell lines, it has been identified that the nuclear localization of FOXO3a, correlates with ER-α 
expression(Guo & Sonenshein, 2004). The study using Chromatin Immuno-Precipitation and 
reporter assays have shown that FOXO3a can directly bind and regulate transcription of ER-α 
from promoter B of the gene. As the previous chapter describes, it has been established that - 
CCN5 through modulation of the PI3K-AKT pathway influences phosphorylation status of 
FOXO3a, leading to nuclear localization and stabilization of FOXO3a (Haque et al., 2015). In 
multiple studies, our lab has noticed a direct correlation between ER-α and CCN5 expression 
which was an expected observation given the established fact that, CCN5 is an estrogen-
responsive gene under direct transcriptional regulation of ER-α (S. Banerjee et al., 2003; Fritah 
et al., 2006; Inadera et al., 2000). However, conversely other published studies have shown, and 
in multiple experiments, our lab has noticed that ER-α expression level can be influenced by 
presence and expression level of CCN5 in breast cancer cells (Fritah et al., 2008). All these 
collective preliminary observations led us to investigate the possible role of CCN5 in the 
expression of ER-α in normal and cancerous breast epithelial cells.  
Estrogen receptor-α (ER-α) mediated roles of estrogen in breast physiology and 
cancer 
Since its discovery estrogen receptor-α (ER-α), the estrogen-dependent transcription factor, 
encoded by the ESR1 gene has been widely studied.  These studies established its essential role 
in the estrogen-dependent development of the female reproductive system, reproductive 
functions, neuroendocrine functions, cardiovascular functions and breast carcinogenesis (Emmen 
& Korach, 2003; Ferguson & Davidson, 1997; Korach et al., 2003; Nilsson & Gustafsson, 2002).  
79 
 
A subset of non-proliferating epithelial cells expresses ER-α in rodent and human normal 
mammary gland tissues (R. B. Clarke, Howell, Potten, & Anderson, 1997; J. Russo, Ao, Grill, & 
Russo, 1999; Seagroves, Lydon, Hovey, Vonderhaar, & Rosen, 2000).  However, it has been 
shown in studies conducted in mice that ER-α absolutely critical for the growth and 
morphogenesis of the adult mammary gland (Mallepell, Krust, Chambon, & Brisken, 2006).  
Consequently, studies from the same group suggested that the ER-α-mediated paracrine 
signaling pathways through activation of amphiregulin expression (Ciarloni, Mallepell, & 
Brisken, 2007; LaMarca & Rosen, 2007) promote proliferation of the neighboring ER-α-negative 
epithelial cells and morphogenesis in the mammary gland (Mallepell et al., 2006).  
Role of estrogen in breast cancer was first indicated in studies that date back to the end of the 
19th century. In 1896, British physician Beatson discovered that ovariectomy resulted in tumor 
regression in premenopausal women with metastatic breast cancer (MacGregor & Jordan, 1998).  
Soon after this discovery, another study reported that about one-third of all of the breast cancer 
patients show tumor regression after ovariectomy (MacGregor & Jordan, 1998).  This 
background knowledge, after the discovery of estrogen receptors, translated to the development 
of the first ER assays in the 1960s (by Jensen and his colleagues) as a predictive test.  The test 
was designed to determine whether and which breast cancer patients would respond to estrogen 
ablation by ovariectomy (in premenopausal women) or adrenalectomy (in postmenopausal 
women).  This test, in a way, laid the foundation for modern endocrine therapies for ER-α 
positive breast cancers.  
Though most of the typical mammary epithelial cells do not express ER-α, the majority (~75%) 
of human breast cancers and precursor lesions express high levels of ER-α (Allred, Brown, & 
Medina, 2004). In a transgenic mouse model study, it has been shown that ER-α overexpression 
80 
 
in mammary epithelial cells is associated with the precursor lesions (Frech et al., 2005). 
Moreover, higher ER-α expression was observed in the mammary epithelial cells of female 
populations who are at higher risk for breast cancer as compared to the populations at relatively 
lower risk (Lawson et al., 1999).To our interest studies have noticed that deregulation, 
dysfunction or suppression of ER-α involve in tumor aggressiveness, metastasis and possibly 
hormone resistance (Harrell et al., 2006).  
 Endocrine therapy strategies and use of tamoxifen as an effective treatment drug 
As mentioned previously in this chapter, it has been observed for a long time that estrogen 
ablation by ovariectomy prevents the progression of estrogen receptor-positive breast cancer, 
which paved the way for modern endocrine therapy strategies.  Approximately 80% of the breast 
cancers are ER-α positive and are dependent for their growth on estrogen and functional ER-α 
(Ali & Coombes, 2002; Kohler et al., 2015).  Endocrine therapies which are widely practiced 
clinically involves three classes of drugs – a) Aromatase Inhibitors (AIs), b) Selective estrogen 
receptor modulators (SERMs) and c) Selective estrogen receptor downregulators (SERDs).  
a) Aromatase Inhibitors (AIs):  AIs act by preventing the formation of estrogen from androgens 
in postmenopausal women through inhibition of the aromatase enzymes. Anastrozole 
(Arimidex®), letrozole (Femara®) and exemestane (Aromasin®) are the 3 FDA-approved AIs 
for the treatment of ER-α-positive breast cancer in postmenopausal women.  Adjuvant therapy 
(therapy used to treat breast cancer patients after primary treatments mostly surgery and radiation 
therapy) with an aromatase inhibitor in early stage breast cancer for post-menopausal patients 
reduces the risk of recurrence and improves survival. It acts better compared to an adjuvant 
tamoxifen (SERM) treatment (Early Breast Cancer Trialists' Collaborative, 2015).  The 
aromatase inhibitors are approved and used to treat postmenopausal women as initial therapy for 
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metastatic or locally advanced hormone-sensitive breast cancer or women with advanced breast 
cancer whose disease has worsened after treatment with tamoxifen (Mauri, Pavlidis, Polyzos, & 
Ioannidis, 2006). 
b) Selective Estrogen Receptor Modulators (SERMs): SERMs are named so as these drugs bind 
to estrogen receptors in such a way that they can potentially both block estrogen activity (as 
estrogen antagonists) in some tissues and mimic estrogen effects (as estrogen agonists) in other 
tissues. Examples of SERMs approved by the FDA for treatment of breast cancer are tamoxifen 
(Nolvadex®) and toremifene (Fareston®). 
Tamoxifen (Figure.III.1.c) has been used for more than 40 years now as the first line treatment 
of early and advanced ER-α-positive breast cancers in both pre- and post-menopausal women 
(Jordan, 2007).  Tamoxifen is activated by its active metabolites including 4-hydroxytamoxifen 
in the body, which outcompetes estrogen in binding the Ligand Binding Domain of ER-α (Ring 
& Dowsett, 2004).  This phenomenon results in the blocking of the Activation Function 2 region 
(AF2) of the receptor and inhibition of ER-α- mediated transcription through recruitment of co-
repressors such as NCoR and SMRT (K. A. Green & Carroll, 2007).  However, tamoxifen 
exhibits beneficial and estrogen-like effects in tissues like bones, thus preventing osteoporosis in 
post-menopausal women (Jordan, 2007).  Also, the partial-agonist activity of tamoxifen in the 
uterus has been shown to increase the risk of endometrial cancer (Fisher et al., 1998). 
Tamoxifen is FDA-approved for adjuvant hormone therapy of premenopausal and 
postmenopausal women with early-stage ER-α positive breast cancer as these women who 
receive at least five years of tamoxifen therapy after surgery has reduced risks of breast cancer 
recurrence. (Untch & Thomssen, 2010) .  Both the FDA-approved SERMs for breast cancer 
treatment, tamoxifen and toremifene are used to treat metastatic breast cancer.  Multiple large 
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clinical trials have shown that five years of tamoxifen treatment, reduced the risk of developing 
invasive breast cancer by about 50% in postmenopausal women who were at increased risk 
(Cuzick et al., 2015; Vogel et al., 2006). Tamoxifen was the first drug to be approved by FDA 
for breast cancer prevention after successful clinical studies(Fisher et al., 1998). 
c) Selective Estrogen Receptor Downregulators (SERDs): Pure-anti-estrogen drugs such as 
FDA-approved fulvestrant (Faslodex®), have been found to be effective for treatment of 
tamoxifen non-responsive tumors. SERDs like fulvestrant bind to ER-α with much higher 
affinity than tamoxifen and downregulate the cellular levels of the receptor by targeting them for 
degradation via the 26S proteasomal complex.  Fulvestrant prevents receptor dimerization and 
blocks the nuclear localization of the receptor.  Most importantly, fulvestrant has no estrogen 
agonist activity since it blocks both the AF1 and AF2 sites of the receptor, resulting in complete 
downregulation of ER-α mediated transcription(Osborne, Wakeling, & Nicholson, 2004).  FDA 
approves Fulvestrant for postmenopausal women with metastatic ER-α positive breast cancer 
that has relapsed and spread after treatment with other anti-estrogen therapies including 
tamoxifen(Howell, 2006). 
Mechanisms of endocrine therapy resistance 
Tamoxifen treatment in approximately 70% of ER-positive breast cancers result in tumor 
remission and improve the overall survival.  However, all patients with metastatic disease and 
almost 40% of patients with early-stage breast cancer receiving adjuvant tamoxifen therapy 
eventually have a relapse of cancer. The cancer cells acquire resistance to tamoxifen despite 
continued expression of ER-α or loss of ER-α expression (Ali & Coombes, 2002; R. Clarke, 
Tyson, & Dixon, 2015; Ring & Dowsett, 2004).  De-novo resistance to tamoxifen can be noticed 
in ER-α negative tumors, but interestingly a significant fraction of ER-α positive tumors also 
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show resistance to tamoxifen from the beginning of treatment. As reviewed in several 
publications, different mechanisms that could contribute to tamoxifen resistance have been 
proposed including - ER-α mutation, increased prevalence of ER-α protein variants, alteration of 
the expression and activity of ER-α co-factors and of cell cycle regulators, as well as reduced 
intra-tumoral levels of metabolically activated tamoxifen (Ali & Coombes, 2002; R. Clarke et 
al., 2015; Nass & Kalinski, 2015).  Besides these, two widely studied mechanisms for tamoxifen 
resistance are - cross-talk of ER-α mediated signaling with the MAPK and AKT mediated 
signaling pathways activated by the receptor tyrosine kinases (HER2/EGFR and IGF-IR) 
(Osborne, Shou, Massarweh, & Schiff, 2005) and loss of ER-α expression (Ali & Coombes, 
2002; R. Clarke et al., 2015; Kurebayashi, 2003; Nass & Kalinski, 2015). 
Loss/lack of ER-α expression and its significance in endocrine therapy resistance: Lack of ER-α 
expression in 30% of the breast tumors and loss of ER-α expression in initially ER-α positive 
tumors after prolonged hormonal treatments are major hurdles for the clinicians in the treatment 
of breast cancer.  Both adaptive mechanisms and selective mechanisms have been proposed as 
the reason behind ER-α loss.  While adaptive mechanism suggests that the ER-α expressing cells 
evolve and gradually stop expressing the receptor, the selective mechanism argues that the 
tumors being heterogeneous mass of cells, the ER-α negative cells are selected over the ER-α 
positive ones after prolonged endocrine treatment (Allred et al., 2004).  The underlying 
molecular mechanisms that lead to ER-α loss is still an enigma (Kurebayashi, 2003).  Loss of 
critical transcription factors driving ER-α expression like ERBF-1 has been suggested as a 
possible reason for ER-α loss (Yoshida et al., 2000).  
  An inverse relationship exists between EGFR/HER-2 expression and ER-α level in breast 
cancer. Overexpression of these growth factor receptors is associated with decreased sensitivity 
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to endocrine therapy and poor prognosis (Ciocca et al., 1992; Konecny et al., 2003). It has been 
established that sustained growth factor signaling mediated by the tyrosine kinase receptors and 
activated cell survival pathways (MAPK and PI3K pathways) lead to decrease and loss of ER-α 
expression (Creighton et al., 2010; Massarweh & Schiff, 2006; Oh et al., 2001; Saceda et al., 
1996) which eventually results in endocrine non-responsiveness.  
It has been described in an elegant study that suppression of hyperactivated PI3K-AKT pathway 
leads to stabilization and nuclear localization of the transcription factor FOXO3a which activates 
ER-α expression from promoter B (Guo & Sonenshein, 2004).  This study and the findings 
discussed in this chapter establish a link between the activated cell survival pathways and 
downregulation of ER-α transcription.  
Epigenetic silencing of the ER-α gene has also been proposed as one of the mechanisms for lack 
or loss of ER-α expression. Recruitment of a transcriptional repression complex including 
DNMT1 (causing methylation of CpG islands in ER-α promoter) and HDAC1 (inducing 
chromatin condensation by deacetylation of histones) in the proximal promoters of the ER-α 
gene might cause ER-α silencing in ER-α-negative breast cancer cell lines. Hypermethylation of 
CpG islands in the promoter region of the ER-α gene is directly correlated with lack of ER-α 
expression in some ER-α-negative breast cancer cells. Also, in some studies, ER-α expression 
was recovered by treatment with DNMT1 and HDAC inhibitors (Sharma, Saxena, Davidson, & 




MATERIALS AND METHODS 
Chemicals reagent and antibody sources  
All the chemicals and drugs including 4-hydroxytamoxifen (Tam or 4OH-Tam), 17β-estradiol 
(E2) and tamoxifen citrate were purchased from Sigma-Aldrich (St Louis, MO, USA). CCN5 
human recombinant protein (hrCCN5) was obtained from PeproTech (Rocky Hill, NJ, USA). 
Doxycycline (Dox) was purchased from Takara Bio (Mountain View, CA, USA). Antibodies for 
western blot analysis, immunofluorescence, immunohistochemical staining were obtained from 
following vendors: Anti-ERα (Cell Signaling, Danvers, MA, USA; and Abcam, Cambridge, MA, 
USA), anti-pER-α (Cell Signaling), Anti-CCN5 (Abcam), anti-Akt (Cell Signaling), anti-p-Akt 
(Cell Signaling), mouse Anti-FLAG/DDK (Origene, Rockville, MD, USA), mouse anti-β-actin 
(Sigma), anti-Integrin α6 (Millipore, Billerica, MA, USA) and anti-Integrin β1 (Millipore). 
These companies provided the authentication certificates for all these chemicals, drugs and 
antibodies. 
Experimental animals 
Wild-type, FVB/N mice, were obtained from Taconic Biosciences (Hudson, NY, USA) and were 
housed in animal care facilities of the Kansas City Veterans Administration Medical Center 
(KCVAMC). All the transgenic mice strains used for the in-vivo studies, mentioned in this 
chapter, were generated and maintained in the FVB/N background. MMTV-rtTA transgenic 
mice (carrying reverse tetracycline transactivator expressing transgene under control of Mouse 
Mammary Tumor promoter) were obtained as a generous gift from Dr. Lewis Chodosh’s 
laboratory in University of Pennsylvania. Tet-op-CCN5/GFP conditional transgenic mice 
(carrying transgenes CCN5 and GFP under a tetracycline-regulated operator) were generated at 
the University of Kansas Medical Center Transgenic facilities under the guidance of Dr. Melissa 
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Larson. Doxycycline-inducible mammary specific conditional transgenic mice were obtained 
from mating between the MMTV-rtTA transgenic mice and the Tet-op-CCN5/GFP transgenic 
mice at the animal care facilities of KCVAMC. 
Construction of the targeting vector to generate Tet-op-CCN5-GFP mice  
The objective of this procedure was to generate a mouse strain carrying the human CCN5 gene 
under the control of a Tet-operator (tetracycline controlled promoter). The first aim was to clone 
the coding sequence of the human CCN5 gene (765 bp) at the multiple cloning site (MCS) 
positioned downstream of the Tetracycline-regulated promoter in the pTRE-Tight BI-AcGFP-1 
vector (Takara Bio, Cat#631066) (Figure III.3a.ii ).  
The pTRE-Tight BI-AcGFP-1 vector construct carries a modified Tetracycline Response 
Element sequence (TRE) that provides a tighter control of gene expression and eliminates any 
chance of leaky transgene expression in the absence of the inducer (tetracycline). The 
tetracycline operator (TRE) sequence is flanked by two minimal CMV (cytomegalovirus) 
promoters which drive bi-directional gene expression. This vector also carries a green 
fluorescence protein gene sequence (Ac-GFP1) under control of one of the CMV promoters, and 
thus the expression of Ac-GFP1 is regulated by the TRE. Downstream of the other CMV 
promoter, lies the Multiple Cloning Site (MCS) which can be engineered to introduce a 
transgene according to study’s need. Thus, once the transgene has been cloned into the construct, 
both the GFP and the inserted transgene will be under control of the same tetracycline operator 
(TRE) sequence (Figure III.3a.iii).  
  The PRK5-hCCN5 vector was primarily obtained from Dr. Pennica (Genentech Inc., San 
Francisco, CA, USA). CCN5 cDNA fragments were amplified by PCR using forward and 
reverse primers with KpnI, and NheI restriction sequences tagged respectively. The PCR 
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amplified fragments were cloned into the multiple cloning site of the vectors at the KpnI and 
NheI restriction sites. The recombinant clones were validated by restriction digestion analysis 
and PCR with primers against human CCN5.  
The founder mice line was generated by injecting the linearized construct into fertilized oocytes 
that were harvested from super-ovulated mice of FVB/N background. Finally, all the progenies 
(Tet-op-CCN5) were screened for the presence of the transgene using PCR analysis with the 
transgene-specific primer sequences (mentioned in section- ‘Tail DNA extraction and 
genotyping’). All founders were genetically identical (FVB/N) as they were of fully inbred 
genetic background. 
Generation of MMTV-rtTA/Tet-op-CCN5-GFP conditional bi-transgenic mice and 
doxycycline treatment to validate inducible CCN5 expression 
Tet-op-CCN5-GFP-transgenic mice were bred with heterozygous MMTV-rtTA mice to generate 
MMTV-rtTA/Tet-op-CCN5-GFP-conditional transgenic mice. Tail DNA genotyping (described 
below) of the mice litters were performed at the age of 3 weeks to screen for the progeny mice 
carrying both MMTV-rtTA and Tet -op-CCN5-GFP transgenes.  
After the genotype confirmation, we determined whether CCN5 is expressed conditionally in a 
mammary epithelial-specific and doxycycline-dependent manner. To determine the time and 
dose of doxycycline treatment optimal for the CCN5 induction, the drinking water of the mice 
were replaced, with 10% sucrose solution (and left overnight) carrying doxycycline ranging from 
2 to 4 mg/ml concentration, twice a week. The control mice were fed with only 10% sucrose 
solution. The doxycycline treatment was carried out for two different time periods (45 and 90 




Tail DNA extraction and genotyping 
At three weeks of age individual mice from mice, litter was numbered, and a tail tip tissue up to 
3mm of length was excised with sterile scissors. 50µl of The QuickExtract DNA Extraction 
Solution (Epicentre Bio) was added to each of the tail tissue samples, and the tissues were finely 
minced. Tail DNA extraction was carried out following the QuickExtract DNA Extraction 
Protocol provided by the vendor. Briefly, the minced tissue suspension was vortexed for 15 
seconds and incubated at 65ºC for 6 minutes. The suspension was again vortexed for 15 seconds 
and then incubated at 98ºC for 2 minutes. After a quick spin, the supernatant was collected, and 
one µl of the sup was used for PCR amplification of the transgenes. 
Primer sequences used for genotyping are as follows: 
(1) CCN5 Forward: 5’-TCGAGGTAGGCGTGTACGGT-3’ 
(2) CCN5 Reverse: 5’-TATGTTTCAGGTTCAGGGG-3’ 
(3) rtTA Forward: 5’-TGCCGCCATTATTACGACAAGC-3’ 
(4) rtTA Reverse: 5’-ACCGTACTCGTCAATTCCAAGGG-3’ 
Cell lines, cell- culture conditions, and transfection  
MDA-MB-231, MCF-7, and ZR-75-1 cell lines were procured from American Type Culture 
Collection (ATCC, Manassas, VA, USA). These cells were maintained in Dulbecco’s modified 
essential medium (DMEM) supplemented with 10% FBS and 1% Penicillin-Streptomycin 
solution (Gibco,Thermo Fisher Scientific, Waltham, MA, USA) . HMECs were obtained from 
LONZA (MD, USA) and maintained in MEBM (mammary epithelial basal medium) with vendor 
provided growth factor combinations.  All the cell lines were grown in a humidified incubator 
with 5% CO2 at 37 °C.  
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Transfections used for ectopic overexpression and shRNA mediated gene silencing were 
performed with the help of Neon Transfection System (Thermo Fisher Scientific, Waltham, MA, 
USA) following manufacturers instruction. Cells were trypsinized and seeded on the preceding 
day of transfection in a manner that the cells reach a confluency of 70% on the day of 
transfection. Next day, the cells were trypsinized, washed with sterile DPBS, counted and then 
suspended in Buffer R (resuspension buffer). 1X106 cells were mixed with plasmid DNA (5–10 
μg) or siRNA (100nM concentration). The cell suspension was then electroporated for 
transfection at a vendor specified (specific for each cell line) voltage pulse using Neon 
Transfection System. For si-RNA mediated gene knockdown studies, validated si-RNA oligos 
were purchased from Cell Signaling Technologies (Danvers, MA, USA). 
Cell viability study using crystal violet assay 
Cell viability assay was performed per our previously published method. The breast cancer cells 
were seeded in quadruplicates in 96-well cell -culture plates. Approximately 60–70% confluent 
serum-deprived MCF-7 cells were treated with the CCN5 antibody (500 ng/ml) for a period of  
48 h and followed by treatment with  E2 (10 nM) and Tam (10 μM) alone or together for another 
48 h. MDA-MB-231 cells were treated with Tam (10 μM) and hrCCN5 (250 ng/ml) together for 
48 h. Cellular viability was measured using crystal violet-based assay (as described earlier in the 
previous chapter). The viability studies were also carried out in CCN5-shRNA transiently 
transfected MCF-7 cells following a similar protocol.  
RT-PCR analysis 
Total RNAs were extracted from mouse breast tissue samples using the Trizol reagent 
(Invitrogen, Thermo Fisher Scientific) following an extraction procedure as suggested by the 
vendor. An equal amount of RNA samples (1µg) were used for reverse transcription with the 
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help of a PCR based reverse transcription RNA amplification kit (Perkin Elmer, Waltham, MA, 
USA). PCR amplifications were carried out with human CCN5, mouse ER-α and mouse GAPDH 
(for loading control) -specific primers. The sequences of the primers were:  
human CCN5 Forward: 5′CCTACACACACAGCCTATATC-3′   
human CCN5 Reverse: 5′CCTTCTCTTCATCCTACCC-3′  
mouse ER-α Forward:   5′TTCTCCCTTTGCTACGTCAC-3′  
mouse ER-α Reverse: 5′ATCGCTTTGTCAACGACTTC-3′ 
mouse GAPDH Forward:  5′CTGCTGTCTTGGGTGCATTGG-3′  
mouse GAPDH Reverse: - 5′CTCGGCTTGTCACATCT–3′  
Immunofluorescent staining  
Cells were fixed with methanol for a period of 20 min followed by a step of permeabilization 
with 0.1% Triton X-100/PBS for 5 min. Next, the samples were blocked with a ready-to-use 
blocking solution (Histostain kit, Invitrogen). Finally, the cells were incubated with mouse-anti-
FLAG/DDK and rabbit anti-ER-α antibody overnight at 4 °C. Cells were then labeled using 
fluorescent conjugated anti-rabbit IgG (Alexa Flour 488, Molecular Probes, Eugene, OR, USA), 
and the nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). Lastly, the cells 
were mounted with antifade mounting reagent (Molecular Probes) and examined under a 
fluorescence microscope (Leica). 
Probe preparation and in situ hybridization 
The DIG-labeled PCR-based probe preparation and in-situ hybridization were carried out 
following the protocol described in previously published reports (S. Banerjee et al., 2003; 
Stephenson, Banerjee, Saxena, Cherian, & Banerjee, 2002). Briefly, 5-μm paraffin sections were 
deparaffinized, hydrated and digested with proteinase K for 10 min followed by fixation in 1% 
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formaldehyde in Phosphate Buffered Saline (1X). Then the slides were thoroughly washed with 
RNase-free ddH2O for 5 min. The sections were then incubated in a humidified chamber 
overnight at 37 °C with the DIG-labeled PCR-generated probe against CCN5 (250 ng/ml). The 
slides were washed three times with PBST (PBS with 0.1% Tween-20). Finally, alkaline 
phosphatase-conjugated anti-DIG antibodies were incubated for one h. The complexes were 
detected with the substrate chromogen combination of BCIP (5-bromo-4-chloro-3-indolyl 
phosphate) and NBT (Nitro Blue Tetrazolium chloride). The sections were counterstained with 
nuclear fast red stain. 
Western blot analysis 
For analysis of protein expression level using western blots, cells were harvested in a lysis buffer 
and subjected to SDS-PAGE electrophoresis and western blotting as described in the previous 
chapter. After incubation with primary antibodies, the blots were incubated with HRP- 
conjugated secondary antibodies. Finally, the blots were incubated with Super Signal Ultra 
Chemiluminescent (Pierce, Thermo Fisher Scientific) substrate and chemiluminescence signals 
were imaged and measured using Kodak ID Image Analysis Software Version 3.6 (Carestream, 
Rochester, NY, USA). 
Luciferase reporter Promoter assay 
The MDA-MB-231 cells were transfected with promoter reporter vector, pLightSwitch_LR 
(Active Motif, Carlsbad, CA) carrying the promoter sequence of human ESR1 (ER-α) gene or  
the sequence carrying human Estrogen Response Element (ERE) cloned into the multiple cloning 
site (MCS) of the vector, at a position immediate upstream to the Renilla Luciferase reporter 
gene. The transfected MDA-MB-231 cells were cultured in the presence or absence of hrCCN5 
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protein in OptiMEM media. The concentration of CCN5 in the medium was 250 ng/ml. A set of 
cells were treated with the antibodies against different integrin receptors, and the rest were left 
untreated. The difference of luciferase activities between each experimental sample was 
measured using Lightswitch™ luciferase assay system (Active Motif) following the protocol 
provided by the manufacturer. 
In vivo treatment with CCN5 and Tamoxifen:  
MDA-MB-231 xenograft model was used for this in-vivo study. Briefly, MDA-MB-231 cells (1 
× 106 per injection) were resuspended in 50% Matrigel and were injected subcutaneously in right 
hind limb of the nude mice (N = 5 per experimental group). Once the average tumor volume 
reached 80–100 mm3, mice were randomized into four groups and treatment was started. 
Tamoxifen (2.5 mg/mouse) was administered orally three times a week, and hrCCN5 (2 mg/Kg) 
was injected twice a week intratumorally for a time period of 27 days. For combinatorial 
treatment, both Tamoxifen and hrCCN5 were given concomitantly. Tumor growth, RTV, %TGI, 
and body weight of the mice were measured using Studylog® measurement tools and software 
(Study log Inc, San Fransisco, CA, USA) three times a week. The tumor volume (TV) was 
estimated using the formula: TV (mm3) = L (length) x W2 (width) x 1/2 The RTV was calculated 
using formula: RTV = Vd/Vo, where Vd is the tumor volume of each day and Vo is the initial 
tumor volume as recorded at the beginning of the treatments. The %TGI (percentage tumor 
growth inhibition) was estimated at the final day of the study by using the formula: %TGI = [1-
(RTV treated group)/ (RTV control group) × 100]. 
 
 




CCN5 augments ER-α expression in normal human mammary epithelial cells 
(HMECs) and ductal epithelial cells of mouse mammary glands under in vitro 
conditions 
In-vitro experiments were designed to test our hypothesis that presence of CCN5 could influence 
ER-α expression. We tested whether treatment of human recombinant CCN5 (hrCCN5) is 
sufficient to upregulate the expression and activity of ER-α in normal mammary ductal epithelial 
cells. To examine the effect of hrCCN5 on the expression of ER-α and pER-α in the normal 
human mammary epithelial cell line (HMEC), the cells were treated with hrCCN5 at a dose of 
250 ng/ml for 48 h. The hrCCN5 treatment was done either in the presence or absence of a 
CCN5 neutralizing antibody (500 ng/ml). We observed in our western blots that both ER-α and 
pER-α levels were significantly increased in hrCCN5-treated HMECs compared to untreated 
cells (Figure III.2a). Further, we noticed that the effect of the hrCCN5 on ER-α expression was 
reduced in the cells which were treated with CCN5-antibody along with hrCCN5 (Figure 
III.2a). 
Our next aim was to determine whether the addition of hrCCN5 in the mouse mammary gland 
culture media could also enhance the levels of pER-α in mammary ductal epithelial cells. Whole 
mammary explants were cultured under in-vitro conditions in presence and absence of hrCCN5 
in the culture medium.  The treatment of the whole mammary gland explants was carried out for 
seven days. We observed an increased signal for immune-reaction against the p-ER-α protein in 
the ducts/lobules and ductal epithelial cells of the whole mammary explants, treated with 
hrCCN5 (250 ng/ml) in the culture medium (Figure III.2b).  
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Collectively, these results indicate that presence of CCN5 in the culture medium can influence 
the expression of ER-α in both human and mouse normal mammary epithelial cells and this 
influence is possibly exerted on the epithelial cells in a paracrine fashion. 
Validation of doxycycline-regulated overexpression of CCN5 in mouse mammary 
epithelial cells in CCN5 overexpressing conditional transgenic model 
The relevance of the in-vitro findings that indicated towards a role of CCN5 in inducing 
expression of ER-α was also tested in-vivo. A doxycycline(Dox)-inducible -CCN5 
overexpressing transgenic mouse model (MMTV-rtTA/Tet-On-CCN5-GFP) was developed.  
This conditional transgenic strain was obtained from the breeding of two separate transgenic 
strains of mice - a) MMTV-rtTA mice line and b) a novel Tet-On-CCN5-GFP mice line (Figure 
III.3a.i).MMTV-rtTA, as suggested by the nomenclature expresses, reverse tetracycline 
inducible transactivator protein (rtTA), which can bind to tetracycline response elements (TREs). 
However, rtTA can recognize tetracycline response elements (TREs) and drive downstream 
gene-transcription only after the rtTA protein is bound to tetracycline or doxycycline (a modified 
form of tetracycline). In MMTV-rtTA transgenic mouse line, the transgene is such designed that 
the transactivator protein (rtTA) expression is under control of a mammary epithelium-specific 
MMTV (mouse mammary tumor virus) promoter. Thus, the protein is expressed specifically in 
the mammary epithelial cells of MMTV-rtTA mice (Figure III.3a.iii). 
Tet-On-CCN5-GFP mice strain carries two bidirectional transgenes, CCN5 and GFP that is 
under control of a tetracycline-inducible operator carrying TRE sites transcription from which 
can be activated by rtTA factors bound to tetracycline or doxycycline.  Thus, the mice from 
MMTV-rtTA/Tet-On-CCN5-GFP bi-transgenic line are expected to express CCN5 protein 
specifically in mammary epithelial cells after doxycycline treatment (Figure III.3a.iii). 
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We validated the CCN5 overexpressing mouse model for expression of CCN5 specifically in the 
mouse mammary glands upon doxycycline (Dox) treatment.  Mice were selected from MMTV-
rtTA/Tet-On-CCN5/GFP transgenic lines and were either treated with Dox (2 mg/ml in 10% 
sucrose solution) or with only vehicle (10% sucrose solution). After 30 days of Dox treatment, 
age-matched and estrous stage-matched control, and Dox-treated mice were sacrificed. RT-PCR 
analysis of RNA extracted from mouse mammary glands exhibited a significant increase in the 
level of CCN5 transcript in Dox-treated mice (Figure III.3b.i).  In-situ hybridization against 
CCN5 transcript and immunohistochemical staining against CCN5 protein were performed in the 
sections of mammary tissues harvested from the control and Dox-treated mice. In both the cases, 
a significantly higher level of reaction against CCN5 was observed in Dox-treated mice tissues 
as compared to control mice (Figure III.3b.ii, Figure III.3c.i).  The mammary ducts/lobules of 
Dox-treated mice also exhibited expression of GFP, a marker for successful activation of the 
transgene gene by Dox-treatment, as the transgene also had a Dox-inducible GFP under the 
control of Tet- operator (Figure III.3c.ii). 
Conditional overexpression of CCN5 results in expression of ER-α in mammary 
epithelial cells in transgenic mouse model  
We tested the level of ER-α expression in the mammary ductal epithelial cells of the control 
(vehicle treated) and experimental mice (Dox-treated) after Dox treatment for different time 
points (1–3 months). RNA isolation followed by RT-PCR analysis showed that Dox-induced 
upregulation of CCN5 resulted in a dramatic increase in mRNA level of ER-α in mice mammary 
glands in Dox-treated mice (Figure III.4a).  Consistent with the RT-PCR observation, 
immunohistochemical analyses of sections from control and experimental mouse mammary 
tissues showed a significant increase in the number of CCN5- and ER-α-positive ducts and 
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lobules in the mammary glands of Dox-treated transgenic mice (10/10) compared to the glands 
of the control mice (Figure III.4b). Collectively, these data indicate that forcibly induced CCN5 
expression upregulates ER-α expression in mouse normal mammary epithelial cells. 
CCN5 promotes ER-α expression in human breast cancer cells 
To test whether CCN5 influences ER-α expression and activity in breast cancer cells, the effect 
of CCN5 ablation by CCN5shRNA (cloned in pENTR/ H1/TO) on ER-α expression in ER-α-
positive breast cancer cell lines MCF-7 and ZR-75-1 was investigated. In parallel, the impact of 
ectopic expression of CCN5 (upon transfection of pCMV6-CCN5-DDK) on ER-α expression 
and activity in ER-α-negative MDA-MB-231 breast cancer cell line was also investigated. Both 
experiments indicated that CCN5 is a positive regulator of ER-α in breast cancer cells.  We 
observed that knocking down CCN5 expression drastically reduces the ER-α expression in MCF-
7 cells and ZR-75-1 cells (Figures III.5a.i and III.5a.ii ), while CCN5-DDK (CCN5-Flag) 
overexpression induces ER-α expression in MDA-MB-231 cells (Figures III.5b).  
CCN5 influences ER-α expression at the transcription level in breast cancer cells by 
interacting with the integrins α6 and β1 
We performed the following experiment to understand the possible mechanism by which CCN5 
induces ER-α expression.  To elucidate the effect of CCN5 treatment, if any, on ER-α 
transcription, a luciferase reporter based promoter assay was designed.  We transfected a 
luciferase reporter plasmid (pLightSwitch_Prom) carrying the human ER-α (ESR1) promoter 
sequence into MDA-MB-231 cells. The cells were grown for 48 h after transfection and were 
treated with hrCCN5 (at a concentration of 250 ng/ml) or vehicle alone for another 48 h. We 
observed increased luciferase activity in ESR1-prom-transfected cells which were treated with 
hrCCN5 as compared to ESR1-prom transfected untreated cells or vector-transfected cells. 
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(Figure III.6, lane 2 or 3 vs. 4).  This observation suggests that CCN5 treatment can induce ER-
α expression at the transcriptional level. However, the hrCCN5-untreated ESR1 promoter -
transfected cells (lane 3) also exhibited a statistically significant increase of luciferase activity 
compared to empty reporter vector-transfected cells (lanes 1 and 2).  We speculated that there 
might be unknown serum component which could be responsible for this increase in luciferase 
activity.  
  In the previous studies, it has been already established that CCN family proteins 
including CCN5 exert their influences on various cellular activities through their direct binding 
to integrins including integrins α6, β1- and β3 (Haque et al., 2015; Jun & Lau, 2011).  We tested 
whether the CCN5-induced ER-α promoter activity is mediated through integrins. ER-α 
promoter-transfected MDA-MB-231 cells were treated with blocking antibodies against the α6, 
β1 and β3 integrins for 24 h followed by treatment with hrCCN5 protein.  We found that 
treatment with antibodies against the integrins α6 and β1 significantly impaired the hrCCN5 
induced effect on ER-α-promoter activity, while treatment with the blocking antibody against 
integrinβ3 was unable to interfere in the CCN5-mediated induction of ER-α.  The treatment of 
integrin antibodies alone had no detectable effect on ER-α-promoter luciferase activities. 
Regulation of ER-α expression by CCN5 can be mediated by PI3K-Akt-Foxo3a-
signaling 
It has been reported in previous studies that transcription factor FOXO3a can act as a regulator of 
ER-α gene transcription (Guo & Sonenshein, 2004). This FOXO3a mediated regulation of ER-α 
can be repressed by an activated PI3K/Akt-signaling pathway (Guo & Sonenshein, 2004). 
Recently, as discussed here in the previous chapter, our studies have shown that CCN5 enhances 
FOXO3a protein level by suppressing Akt signaling in MDA-MB-231 cells (Haque et al., 2015).  
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We performed experiments to test if CCN5-induced upregulation of ER-α is dependent on 
FOXO3a protein level in breast cancer cells. The MDA-MB231 cells were transfected with a 
FOXO3a-siRNA that abrogates FOXO3a expression to about 70% of the expression level as 
compared to scrambled siRNA transfected cells.Transfected cells were grown either in the 
presence or absence of hrCCN5 for 48 h. Western blotting for ER-α with the cell extracts 
revealed that though CCN5 treatment increased the ER-α level (Figure III.7a, lane 2), 
knockdown of FOXO3a expression by siRNA nullifies the CCN5 mediated effect on the ER-α 
expression level (Figure III.7a, lane 3). 
We observed a similar effect in the normal mammary epithelial cell line (HMEC).  In a very 
similar experimental design, HMEC cells were transfected with FOXO3a siRNA and scrambled 
siRNA before hrCCN5 treatment.  Immunofluorescence staining against ER-α was performed, 
and it was observed that CCN5 treated cells transfected with FOXO3a siRNA exhibited almost 
no staining for ER-α.  However, a signal for ER-α staining was detectable in scramble siRNA 
transfected cells treated with CCN5 (Figure III.7b). These studies, collectively, suggest that 
CCN5-induced upregulation of ER-α is mediated by the transcription factor, FOXO3a. 
Earlier studies have shown that FOXO3a expression level is negatively regulated by activated 
PI3K-Akt signaling as discussed herein the previous chapter. Previously published studies from 
our lab has established that CCN5 treatment reduces Akt phosphorylation levels in MDA-MB-
231 cells leading to FOXO3a stabilization (Haque et al., 2015). We can argue that suppression of 






ER-α induced by CCN5 in MDA-MB-231 cells is functionally active 
We performed an estrogen-response element (ERE) luciferase reporter assay in-vitro, in the 
presence or absence of estrogen (E2) in MDA-MB-231 cells. This experiment aimed to 
determine whether the ER-α, expressed after CCN5 treatment of cells, is functionally active. ER-
α binds directly to the conserved sequences known as the estrogen response elements (ERE) in 
the promoter region of a gene and carries out its transcriptional activity leading to downstream 
gene expression.  
First, MDA-MB-231 cells were transfected with the pLightSwitch_Prom vector carrying ERE 
upstream to a luciferase reporter gene.  The cells were then treated with either E2 (10 nM) or 
hrCCN5 alone or with a combination of both for 48h.  Finally, luciferase activity from each 
experimental group was measured as a readout of ER-α activity. E2-treatment significantly 
enhances luciferase activity in the hrCCN5-treated cells (Figure III.8a lane 3) as compared to 
vehicle-treated (lane 1) and only estradiol-treated cells (lane 4).  This study indicates that the 
hrCCN5-induced ER-α is functionally active as it can form E2-ER complexes and bind to EREs 
of DNA leading to gene transcription.  
Interestingly we observed that the luciferase-activity also markedly elevated in hrCCN5-treated 
cells in the absence of E2-treatment (lane 2).  We can argue that estrogen-independent activation 
of ER-α possibly caused due to phosphorylation of ER-α by CCN5 might have promoted ER-α-
ERE binding in-vitro in the absence of the ligand. 
Phosphorylation of ER-α plays an effective role in the regulation of the functional activity of ER-
α, and it is mediated by the controlling ER-α-ERE binding that modulates the expression of the 
downstream target genes. We examined the effect of the ectopic expression of CCN5 in MDA-
MB-231 cells or the shRNA-based depletion of CCN5 in MCF-7 cells, on the phosphorylation 
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level of ER-α at Ser104/106. The phosphorylation status of ER-α at Ser104/106 is considered as 
a marker for ER-α activity. We found that the level of phospho-ER-α (Ser104/106) was 
significantly increased in CCN5-transfected MDA-MB-231 cells as compared to the vector-
transfected cells. Also, the p-ER-α level is markedly reduced in CCN5-depleted MCF-7 cells as 
to their corresponding control cells (Figures III.8b.i and III.8b.ii).  
Together, these studies prove that the ER-α induced by CCN5 treatment or overexpression in 
MDA-MB-231 cells are functionally active and are capable of driving transcription of their 
target genes.  
Suppression of CCN5 expression reduces sensitivity of ER-α-positive breast cancer 
cells to estrogen and tamoxifen 
We aimed to investigate the possible effect of CCN5 depletion and inhibition on the response of 
ER-α positive breast cancer cell lines to estrogen(E2) and tamoxifen.  Consistent with previous 
findings we observed that E2 (10 nM) treatment for 48 h, significantly increased proliferation of 
ER-α positive MCF7 cells.  This pro-proliferative effect of E2 was significantly reduced when 
the cells, pre-treated with the CCN5-blocking antibody (CCN5Ab) for 48hrs were treated with 
the same dose of E2 in the presence of CCN5Ab (Figure III.9a.i). 
Moreover, we also observed that though not completely, CCN5Ab treatment of MCF7 cells 
partially reduced the cytotoxic effect of 4-hydroxytamoxifen in these cells. The cells, when 
treated with CCN5Ab before and during the 4-hydroxytamoxifen treatment (10 µM), responded 
to a lesser extent as compared to the cells which were not treated with the antibody (Figure 
III.9a.i ). The partial rescue of MCF-7 cells from the catastrophic effect of 4-OH-Tam can also 
be seen in CCN5 depleted shRNA- CCN5-transfected MCF-7 cells. , Control shRNA and CCN5-
shRNA transfected cells were treated with 4-OH-Tam at a dose of 10µM for 48h, and it was 
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observed that cell growth arrest induced by 4-OH-Tam in CCN5 depleted cells is significantly 
lower as compared to control cells (Figure III.9a.ii ). , Tamoxifen exerts receptor (ER-α)-
dependent and independent influence on breast cancer cells to induce growth arrest and 
apoptosis.  Thus, we argue that CCN5 ablation, which interrupts ER-α expression, may only 
partially promote desensitization to Tamoxifen.  
CCN5 treatment sensitizes triple negative MDA-MB-231 cells to tamoxifen  
The observations discussed so far in this chapter indicate strongly that CCN5-mediated signaling 
might play a critical role in ER-α-expression in normal and neoplastic breast cells. We extended 
our study to test its implication in possible therapeutic strategies against triple negative breast 
cancer.  
Firstly, we investigated the impact of 4-hydroxytamoxifen (at a dose of 10 μM) on MDA-MB-
231 cell growth both in the presence and the absence of hrCCN5 (250 ng/ml). The cell viability 
studies revealed a minimum growth inhibitory effect of Tamoxifen (10 μM for 48 h) on MDA-
MB-231 cells. An increased effect on cell growth arrest was observed when MDA-MB-231 cells 
were treated with 4-hydroxyamoxifen in conjunction with hrCCN5 for 48 h. A growth inhibition 
of MDA-MB-231 cells was also documented in the experimental sets with the treatment of only 
hrCCN5 (Figure III.9b). Collectively, the studies suggest that CCN5 boosts the Tamoxifen 
action in these cells through the activation of ER-α.  
The possible therapeutic potential of Tam-hrCCN5 combined treatment of triple negative breast 
cancer was further explored in an MDA-MB-231 xenograft model. In this xenograft model, 
while treatment of Tamoxifen alone led to no significant response in tumor growth, 
combinatorial treatment of hrCCN5 and Tamoxifen exhibited significant inhibition of tumor 
growth. Relative tumor volume (RTV) was measured for each time point of tumor volume 
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measurement, and percentage tumor growth inhibition (%TGI) relative to control tumors was 
calculated. A decrease in the relative tumor volume and the TGI increase of significant level was 
observed in the CCN5, and Tam treated tumors as compared to the tumors from other 
experimental groups (Figure III.10a).  We performed immunohistochemical staining against 
ER-α and CCN5 in the sections of the harvested tumors.  We detected an increased staining for 
ER-α in the CCN5 treated tumor sections while no such staining was observed in the tumor 
sections from the control groups (Figure III.10b).  Immunoreaction for CCN5 protein, which is 
normally absent in MDA-MB-231-tumor xenograft tissues, was detected in tumor samples of 
treated groups implicating the availability of hrCCN5 protein at the target sites (Figure III.10b). 
Importantly, no signs of morbidity or body weight loss were detected in these group of animals 







The experiments and observations discussed in this chapter provide two significant discoveries.  
First, these studies prove that CCN5 promotes ER-α expression in normal breast epithelial cells 
and breast cancer cells. CCN5-mediated induction of ER-α expression, at least in breast cancer 
cells, takes place at the transcriptional level.  Our studies indicate that CCN5 exerts its influence 
on the breast cancer cells through stabilization and nuclear localization of FOXO3A transcription 
factor which is a result of integrin-mediated suppression of PI3K-AKT signaling pathway 
(Figure III.11).  Second, we report that ER-α, restored by CCN5, is functionally active and 
renders triple-negative breast cancer cells MDA-MB-231 sensitive to tamoxifen. 
More than 70% of the human breast cancers show high expression of ER-α (Allred et al., 2004), 
which is an important biomarker for better prognosis as these tumors respond to hormonal 
therapies such as Tamoxifen treatment.  The non-responding tumors either do not express ER-α 
or show resistance despite ER-α expression.  As discussed in the introduction section only two-
thirds of the advanced ER-positive breast cancer patients respond to Tamoxifen (Kurebayashi, 
2003).A significant proportion of tumors, which respond initially, gradually become hormone-
independent and endocrine therapy resistant and lose ER-α expression.  Collectively, it is 
manifested that the disappearance of ER-α in breast cancer cells is one of the vital causes of 
relapse and aggressive behavior of this disease (Gruvberger et al., 2001; Kurebayashi, 2003; 
Nass & Kalinski, 2015). 
Our findings from in-vitro and mouse model studies indicate a strong link between CCN5 
signaling and ER-α expression.  The mechanism that we propose, based on these results and our 
previous work (Haque et al., 2015) is that CCN5 interacts with integrin α6β1 to suppress the 
PI3K/Akt-signaling which then activates FOXO3a. Activated FOXO3a, in turn, upregulates 
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activated form of ER-α and enhances the response of estrogen or estrogen antagonist. As 
discussed in the previous chapter (General Introduction), CCN5 is an estrogen response gene, 
and this study proposes the possibility of a feedback signaling loop between CCN5 and ER-α. 
However, we believe that this might be only one of the multi-dimensional mechanisms 
implemented by CCN5 to exert this effect.  Thus, suppression of PI3K-AKT pathway alone with 
an inhibitor will not be sufficient to replicate the effect of CCN5 treatment.  Epigenetic silencing 
of ER-α gene promoter has been implicated in lack or loss of ER-α expression (Sharma et al., 
2006; Yan, Yang, & Davidson, 2001). Interestingly, in a study, it has been shown that CCN5 
might directly localize into the cell nucleus and interact with histone deacetylases to affect 
transcriptional changes (Sabbah et al., 2011). Though the evidence of nuclear localization of 
CCN5 is sparse, we cannot rule out the possibility that it might also play a similar role in this 
case in addition to the mechanism we elucidated.  Also, it has been shown in multiple studies 
that activated Akt signaling directly phosphorylates at conserved Serine residues in activation 
function one domain of ER-α and leads to a reduction of tamoxifen activity (Massarweh & 
Schiff, 2006; Osborne et al., 2005).  Thus, CCN5 mediated suppression of PI3K-AKT pathway 
might be an additive in inducing tamoxifen sensitivity. 
ER-α is required for the Tamoxifen action as an antagonist of estrogen to prevent breast cancer 
cell growth.  The present in vitro and in vivo studies holds therapeutic significance by providing 
a mechanism-based rationale for combination therapy of Tamoxifen and CCN5 to treat triple 





































Fig.III.1: a) Genomic organization of ESR1 (ER-α) promoter: Boxes represent upstream exons with 
names according to the suggested nomenclature. Promoters are depicted as broken arrows. Numbers 
below exons correspond to the distance from the originally described transcription start site _1 in 
base pairs. Numbers between exons show the size of major introns in kilobase pairs. Broken lines 
symbolize observed splicing, and the common acceptor splice site in exon 1 is represented by an 
inverted triangle. The figure has been adapted from previous publication (Kos, Reid, Denger, & 
Gannon, 2001).b) Domain structure of ER-α protein depicting the Activation function domains, 
ligand binding domain and DNA binding domain. Pink line shows binding regions for co- activators. 
Blue line shows binding regions of co-repressors. The figure has been adapted from previous 






































17-ß estradiol Tamoxifen 
Fig.III.1: c) Chemical structure of estrogen and tamoxifen. d) Flexible H12 helical arm of ER-α in 
presence of different ligands: The backbone structure of unbound ERα (pink), ERα bound to 
estrogen (green) and ERα bound to tamoxifen(blue) show the differences in the position of helix 12 
which determine co-factor binding properties. The picture has been used from previously published 























Fig.III.2: CCN5 influences ER-α expression in normal HMECs and ductal epithelial cells of mouse 
mammary gland (a) Representative western blot and quantification of ER-α and p-ER-α (active 
form) protein level in HMECs treated with or without hrCCN5 (250 ng/ml) or in combination of 
hrCCN5 and CCN5 antibody (500 ng/ml) for 48 h. All data represent means ± s.e.m. of three 
independent experiments. P-values were calculated using one-way analysis of variance and two-
tailed unpaired Student’s t-test. (b) Immuno-histochemical localization and quantification of pER-α 
in the ducts and lobules of mouse mammary glands cultured as indicated for 7 days in the presence 
or absence of hrCCN5 (250 ng/ml). Arrows indicate the ER-α positive ductal cell in glands of 
different FVB/N mice. Scale bars, 100 μm. Data are presented as mean±s.e.m. P-values were 





























Fig.III.3: (a.i) Schematic flow of generation of MMTV-rtTA/ Tet-op-CCN5-GFP mice from crossing 
of MMTV-rtTA strain and Tet-op-CCN5-GFP strain of mice (Sarkar et al., 2017). (a.ii) Schematic 
map of the plasmid p-TRE-Tight-Bi-AcGFP1 showing bidirectional CMV promoters under control 
of a modified Tetracycline Response Element (TRE).Vector diagram used from Vector Information 

























Tet-op-CCN5-GFP mice MMTV-rtTA mice  
MMTV-rtTA/Tet-op-CCN5-GFP mice 
Fig.III.3: (a.iii) Schematic of the doxycycline regulated mechanism of CCN5 and GFP expression in 














Fig.III.3: Validation of conditional transgenic mice bearing CCN5 and GFP transgenes 
overexpressed in mammary epithelial cells by doxycycline (Dox) treatment. (b.i) RT-PCR for CCN5 
in the RNA harvested from mammary glands from Dox-untreated and treated mice. Lane 1.: ladder 
2: untreated mice gland RNA, 2: Dox-treated mice gland RNA and 3: MCF-7 RNA and 4: negative 
control (no RNA). GAPDH is used as loading controls. (b.ii) Localization of CCN5 mRNA 
expression (BCIP/NBT) in the mammary ducts from Dox untreated (−Dox) and Dox-treated (+Dox) 


























Fig.III.3: Validation of conditional transgenic mice bearing CCN5 and GFP transgenes 
overexpressed in mammary epithelial cells by doxycycline (Dox) treatment. (c.i) 
Immunohistochemical localization of CCN5 (DAB) in the ducts of mammary grands from Dox-
untreated (a) and Dox-treated (b–c) transgenic mice. Methyl green was used as counter staining. 
Scale bars, 100 μm. Red arrows indicate the CCN5 expression. (c.ii) Detection of direct fluorescence 
of GFP in the ducts of mammary glands from Dox untreated (− Dox) and Dox treated (+Dox) 
CCN5-transgenic mice. (a and c) The examples of bright fields in Dox untreated and treated 
samples, and (b and d) the examples of GFP-fluorescence in Dox untreated and treated samples 

























Fig.III.4: Conditional activation of CCN5 promotes ER-α expression in mammary epithelial cells of 
CCN5 transgenic mice. (a) Representative PCR with reverse transcription and quantification of ER-α 
in the RNA harvested from mammary glands from Dox-untreated and treated mice. M: molecular 
markers. (−): untreated gland, (+): Dox-treated. All data represent means ±s.e.m. of three 
independent experiments. P-values were calculated using two-tailed unpaired Student’s t-test (Sarkar 























Fig.III.4: Conditional activation of CCN5 promotes ER-α expression in mammary epithelial cells of 
CCN5 transgenic mice. (b) Immunohistochemical localization of CCN5 protein (upper panel) in the 
mammary glands of untreated and Dox-treated mice. Scale bars, 100 μm. The bar graph represents 
the quantitative estimation of CCN5-positive ducts/lobules in Dox- treated and untreated mouse 
mammary glands. Data are presented as mean±s.e.m. (n=5 mice). Immunohistochemical localization 
of ER-α (lower panel) in the mammary glands of untreated and Dox-treated CCN5-transgenic mice. 
Scale bars, 100 μm. The bar graph (represents the quantitative estimation of ER-α-positive cells in 
the ducts and lobules of Dox-treated and -untreated mouse mammary glands. Data are presented as 

























Fig.III.5: CCN5 increases ER-α protein levels in breast cancer cells. (a.i & a.ii) Representative 
western blots of CCN5 and ER-α in cell lysates of ER-α-positive breast cancer cell lines MCF7 (a.i) 
and ZR-75-1 (b.i) transfected with scrambled shRNAs or CCN5-specific shRNAs. The bar graph 
represents the relative protein expression levels of CCN5 and ER-α with respect to β-actin (loading 
control). Data are presented as mean ±s.e.m. of at least three independent experiments. P-values 















Fig.III.5 :(b.i) Representative western blots of ER-α in cell lysates of CCN5-FLAG (FLAGCCN5) 
tag transfected or vector (FLAG) -transfected MDA-MB-231 cells. CCN5 levels were detected with 
anti-FLAG antibody. The bar graph represents the relative protein expression levels of CCN5 and 
ER-α with respect to β-actin (loading control). Data are presented as mean ±s.e.m. of three 
independent experiments. P-values were calculated using two-tailed unpaired Student’s t-test. (b.ii) 
Representative photographs of immunofluorescent staining using anti-FLAG tag (upper panel, 
green) and anti-ER-α (lower panel, green) antibodies to show increase of ER-α expression in CCN5-
Flag transfected MDA-MB-231 cells compared to empty vector-transfected cells. DAPI was used to 
stain the nuclei (blue) and FITC-labeled secondary antibodies (green) are used for staining the 




























Fig.III.6: Integrins α6β1 and FOXO3a are required for CCN5-mediated regulation of ER-α 
expression in breast cancer cells.ER-α promoter luciferase reporter assay: MDA-MB-231 cells were 
transfected with empty construct or ER-α-Luc promoter construct followed by hrCCN5 protein (250 
ng/ml) treatment or vehicle alone for 48 h and either in the presence or absence of different 
neutralizing antibodies of integrins. A luciferase assay was performed following vendor provided 
protocol. EV:  empty vector, and ESR1 vector: ER-α promoter vector. Data are presented as mean± 
s.e.m. of eight independent experiments. P-values were calculated using two-tailed unpaired 

























Fig.III.7: (a) Representative western blots and quantification of ER-α in cell lysates of FOXO3a-
siRNA-transfected or scrambled siRNA-transfected MDA-MB-231 cells. Data are presented as 


















Fig.III.7:(b) Representative images of immunofluorescent staining for the detection of the effect of 
FOXO3a ablation on ER-α expression in HMECs, cultured in the presence or absence of hrCCN5 



















Fig.III.8: CCN5-induced expression of ER-α is functionally active in BC cells. (a) Functional 
luciferase assay. MDA-MB-231 cells were transfected ERE -luciferase reporter constructs or vector 
alone followed by E2 or hrCCN5 or combination treatment for 48 h and luciferase activity was 
measured. Data are presented as mean±s.e.m. of eight independent experiments. P-values were 





























Fig.III.8: CCN5-induced expression of ER-α is functionally active in breast cancer cells. (b.i) ER-α 
phosphorylation change in MCF-7 cells following CCN5 ablation by shRNA. Representative 
western blots of CCN5 and phospho-ER-α (Ser104/106) in cell lysates of scrambled shRNA or 
CCN5-shRNA transfected MCF7 cells (left panel). (b.ii) ER-α phosphorylation change in MDA-
MB-231 cells following CCN5 transfection. Representative western blots of FLAG-CCN5 and 
phospho-ER-α (Ser104/106) in cell lysates of FLAG-vector (FLAG) or FLAG-CCN5-vector 
(FLAG-CCN5) transfected MDA-MB-231 cells. (right panel). The bar graph represents the relative 
protein expression levels of p-ER-α with respect to β-actin (loading control). Data are presented as 
mean ±s.e.m. of at least three independent experiments. P-values were calculated using two-tailed 























Fig.III.9: CCN5 and Tamoxifen exhibits additive effect on TNBC cell growth in vitro and in vivo. 
(a,b) Cell viability assay. MCF7 (a.i), and MDA-MB-231(b) cells treated with 17β-estradiol (E2, 10 
nM) or 4-hydroxy-Tamoxifen (4OH-Tam, 1 μM) or both in the presence or absence of CCN5 
antibody (CCN5Ab, 500 ng/ml) or CCN5 recombinant protein (hrCCN5, 250 ng/ml) for 48 h. Cell 
viability was determined using crystal violet assay. (a.ii) Similar viability assays were performed 
with scramble -shRNA and CCN5-shRNA transfected MCF7 cells Data are presented as mean 
±s.e.m. of eight independent experiments. P-values were calculated using one-way analysis of 





















Fig.III.10: CCN5 and Tamoxifen exhibits additive effect on TNBC cell growth in in vivo. (a): 
Additive antitumor efficacy of CCN5 and Tam in xenograft model. MDA-MB-231 xenografts in 
female nu/nu mice (n=5) were treated with Tam (oral), hrCCN5 [intratumoral injection] or 
combination three times a week for 24 days. Growth curve was measured using RTV three times per 
week and %TGI was measured as end point tumor growth using analysis of variance and two-tailed 
unpaired Student’s t-test. Data are presented as mean±s.e.m. of five animals. (b) Hematoxylin and 
eosin staining and immunohistochemical localization of ER-α and CCN5 in tumor samples of MDA-


















Fig.III.11: Schematic representation of mechanism of induction ER-α expression in ER-α negative 
cells by CCN5. CCN5 binds to cell surface integrin receptors (α6 and ß1) leading to suppression of 
PI3K-AKT pathway. This results in stabilization and nuclear localization of the transcription factor 
















CHAPTER IV: Role of CCN5 in delaying Her2/Neu overexpression 




Membrane receptor tyrosine kinases 
Tyrosine kinases are a class of enzymes that catalyze the transfer of the γ-phosphate of ATP 
specifically to the tyrosine residues on protein substrates. Tyrosine kinase-dependent 
phosphorylation is one of the key covalent modifications of proteins which regulates multiple 
downstream signaling pathways.  Both, transmembrane receptor tyrosine kinases and 
cytoplasmic non-receptor tyrosine kinases play critical roles in cell signaling pathways.  The 
significance of tyrosine kinase catalytic activity mediated cell-signaling has been underscored by 
identification of many of these enzymes as oncogenes. 
A large family of nonreceptor tyrosine kinases (NRTKs) including the Src kinases, Jak (Janus 
kinase), and c-Abl (Abelson tyrosine kinase), serve as intracellular components of the signaling 
cascades. These cascades are triggered by the transmembrane receptor tyrosine kinases and by 
other cell surface receptors, e.g., G protein-coupled receptors and receptors of the immune 
system (Hahn & Weinberg, 2002; Hubbard & Till, 2000).  
Receptor tyrosine kinases (RTKs) comprise a large superfamily of receptors that are widely used 
by the cells to interpret and transduce the extracellular signals to the cytoplasm. RTKs are 
transmembrane glycoproteins and are activated by the binding of their cognate ligands.  The 
members of this superfamily of proteins have a common structural design with an extracellular 
ligand-binding domain, a membrane-spanning region and a cytoplasmic tyrosine kinase domain 
(catalytic domain).  Ligand binding promotes receptor dimerization, consequently stimulating 
kinase activity of the cytoplasmic kinase domain and triggering autophosphorylation of specific 
tyrosine residues which are positioned within the cytoplasmic domain of the receptors. The 
phosphorylated tyrosine residues serve as docking sites for other cytoplasmic proteins.  The 
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proteins that are recruited to these docking sites are either other proteins with enzymatic 
activities [e.g., PLC-γ (phospholipase C-γ), PI3K (Phosphatidylinositol-3-kinase), SRC-tyrosine 
kinase] or are adaptor proteins that in-turn recruits downstream factors involved in intracellular 
signaling cascades. One example of adaptor-mediated recruitment of signaling proteins, is the 
recruitment of SOS (Son of Sevenless), a guanine nucleotide exchange factor, by an adaptor 
protein GRB2 (growth factor receptor-bound protein-2), which leads to activation of RAS and its 
downstream signaling. Thus, binding of specific ligands to the extracellular domains of the 
RTKs transmits the extracellular signal by phosphorylating their specific tyrosine residues 
(autophosphorylation) and also on other signaling proteins that are recruited to the receptor 
(Hubbard & Till, 2000).  
RTKs, depending on the ligand and receptor type, activate numerous different signaling 
pathways that lead to cell growth, proliferation, differentiation, migration, or metabolic changes. 
The RTK superfamily includes multiple families of receptors which have distinctly different 
extracellular domain structures but similar cytoplasmic catalytic domains. The extracellular 
portion of the RTKs typically contains diverse globular domains such as immunoglobulin (Ig)-
like domains, fibronectin type III-like domains, cysteine-rich domains, and EGF-like domains. 
The diversity of domain types enables these proteins to interact with a diverse array of ligands. 
The domain organization of the cytoplasmic portion of RTKs is simpler, consisting of a 
juxtamembrane region (adjacent to the transmembrane helix), followed by the tyrosine kinase 
catalytic domain and a carboxy-terminal region. The juxta-membrane and carboxy-terminal 
regions vary in length among RTKs while the tyrosine kinase catalytic domain is mostly 
conserved in most of the members. Depending on the structural arrangement of the extracellular 
domains, the RTKs act as receptors for multiple growth factors.  These include insulin-like 
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growth factor (IGF), epidermal growth factor (EGF), transforming growth factor-α (TGF-α), 
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), and nerve growth factor (NGF).  
The human EGF receptor (HER) family  
The EGF-R (Epithelial Growth Factor-Receptor) family of receptors is comprised of four distinct 
protein members namely – ERBB1 (EGF-R), ERBB2 (HER2/Neu), ERBB3 (HER3) and ERBB4 
(HER4). These four ErbB membrane receptors share a similar structure with two cysteine-rich 
regions in their extracellular region, and a kinase domain flanked by a carboxy-terminal tail with 
tyrosine autophosphorylation sites.  The ErbB receptors have been shown to homodimerize with 
themselves and heterodimerize with other members of the ErbB family after binding to the 
ligands (Hubbard & Till, 2000; Yarden & Sliwkowski, 2001) (Figure IV.1a). The ErbB 
receptors are located at the basolateral surfaces of in the epithelial cells, which enable them to 
relay the signals originating from the mesenchyme to the epithelial cells (Yarden & Sliwkowski, 
2001). 
ErbB receptors bind to a diverse array of ligands including EGF, TGF-α, HB-EGF (heparin-
binding EGF), amphiregulin (ARG), epiregulin, β-cellulin and a large family of Neuregulins 
(NRGs). Some of these ligands bind to the ErbB receptors with a narrow specificity. EGF, ARG, 
and TGF-α act as specific ligands for ERBB1 (HER1) while NRG3 and NRG4 bind to ERBB4 in 
a specific fashion (Hynes & Lane, 2005; Yarden & Sliwkowski, 2001).  However, in some cases, 
ligands can bind to more than one distinct receptors in an overlapping fashion. Ligands like 
epiregulin and β-cellulin can bind to both ERBB1 and ERBB4; while NRG1 and NRG2 bind to 
both ERBB3 and ERBB4 (Hynes & Lane, 2005; Yarden & Sliwkowski, 2001).  ERBB2 (HER2) 
does not have an identified ligand and is thus named as an ‘orphan receptor.’ However, 
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cytoplasmic domain of ERBB2 exhibits strong kinase activity (Klapper et al., 1999).  Both 
ERBB3 and ERBB4 bind to Neuregulin family of ligands. ERBB3 which is devoid of any 
cytoplasmic kinase activity is incapable of autophosphorylation, and its phosphorylation is 
dependent upon its dimerization with ERBB2  (Graus-Porta, Beerli, Daly, & Hynes, 1997) 
(Figure IV.1a).  Overexpression of ERBB2 leads to a bias in heterodimer formation where one 
of the partners is ERBB2 thus leading to a broader ligand specificity, and ligands that are better 
at recruiting ERBB2 can compete and reduce the binding of other less effective ligands (Figure 
IV. 1a). 
After formation of the dimeric complexes, a vast array of phospho-tyrosine-binding proteins 
associate with the tail of each ErbB molecule.  The type of ligand and the heterodimer partners 
decide the tyrosine residues which are phosphorylated and thus, in turn, regulates the type of 
intracellular engaging molecules.  Though the ErbB members share some overlapping 
downstream signaling effects, the individual receptor can bind with a unique and distinct set of 
signaling proteins.  
The most commonly affected downstream signaling pathways are; - RAS- and Shc-activated 
mitogen-activated protein kinase (MAPK) pathway, the PI3K-mediated AKT pathway and the 
ribosomal protein S6 kinase (p70S6K/p85S6K) pathway, which can be activated downstream to 
AKT pathway (Hynes & Lane, 2005).  The activation of multiple signaling cascades, including 
the MAPK pathway, protein kinase C (PKC)-mediated pathway and the AKT pathway, leads to 
activation of distinct transcriptional machinery in the nucleus.  These involve a wide range of 
transcription factors including MYC, SP1 (Specificity protein1) and AP1 (Activator Protein1) 
(Yarden & Sliwkowski, 2001) (Figure IV.1b). 
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The output of cellular processes mediated by the ErbB receptors ranges widely from cell 
proliferation, migration, adhesion, differentiation, and apoptosis. The output varies depending on 
the cell type, interacting a ligand and the dimerization partners.  Although neither ERBB2 nor 
ERBB3 alone can be activated by a ligand, the ERBB2-ERBB3 heterodimer is the most 
transforming and mitogenic receptor complex and has also been also shown to increase cell 
motility on ligand binding (Graus-Porta et al., 1997; Yarden & Sliwkowski, 2001) (Figure 
IV.1a).  
Role of HER (ERBB) family of proteins in cancer:  
ERBB1 (EGFR) and ERBB2 (HER2) have been implicated in the development of many human 
cancers and the cancer patients with alterations in ERBB receptors tend to have a more 
aggressive disease with a prediction of a poor clinical outcome (Hynes & Lane, 2005).  
Potent mitogenic and transforming effects of the ERBB receptors lead to tumorigenesis, which is 
most cases arise from constitutively activated signaling mediated by the receptors. The 
constitutive activation of the ERBB signaling can result from - overexpression of the ligands; 
overexpression of an ERBB member leading to aberrant and more frequent dimerization; and 
mutations leading to structural alteration of the receptors leading to constitutive dimerization, 
activation along with recruitment of downstream signaling complex.  
The most prominent example of tumor progression owing to overexpression of an ERBB ligand 
is the role of TGF-α expression in ERBB1 expressing lung, colon and ovarian tumors leading to 
a poorer prognosis (Yarden & Sliwkowski, 2001).  Both overexpression and mutations leading to 
structural alterations of ERBB1 (EGFR) have been implicated in multiple cancer types.  
Overexpression of ERBB1, resulting from amplification of the gene locus is very frequently 
observed in brain tumors, and amplification of the ERBB1 gene occurs in 40% of gliomas 
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(Hynes & Lane, 2005; Yarden & Sliwkowski, 2001). Overexpression of ERBB1 is associated 
with higher grade, the higher proliferation of the tumors and reduced survival of the cancer 
patients. In gliomas, ERBB1 amplification is often accompanied by a common mutation (type 
III) that causes in-frame deletions within the extracellular domain of the receptor, resulting in a 
constitutively active receptor by structural rearrangements. Carcinomas of the breast, lung and 
ovaries have also been reported to express this variant of ERBB1 suggesting broader 
implications to human cancer (Ekstrand, Sugawa, James, & Collins, 1992; Moscatello et al., 
1995; Wikstrand, Reist, Archer, Zalutsky, & Bigner, 1998; A. J. Wong et al., 1992). 
Mechanism of ERBB2 (HER2) mediated signaling in breast cancer: 
ERBB2 was first discovered at Dr. Robert Weinberg’s lab in MIT as a 185 kDa oncoprotein, 
expression of which was specifically induced by transforming DNA of rat Neuroblastomas (Neu) 
(Padhy, Shih, Cowing, Finkelstein, & Weinberg, 1982). Soon after, the same lab established 
‘Neu’ as an ERBB related oncogene (Schechter et al., 1984). Successive studies discovered it to 
be a novel gene located at chromosome 17 in human with homology to the EGFR in the tyrosine 
kinase domain (Schechter et al., 1985) and with transforming capabilities (Hudziak, 
Schlessinger, & Ullrich, 1987). 
As mentioned in the General Introduction, amplification of ERBB2 locus (17q12) leading to 
overexpression of the receptor (ERBB2/HER2) is detected in a significant subset of breast 
tumors (25% of all invasive ductal carcinoma). ERBB2 gene amplification was shown to be 
associated with an increased risk of relapse and death for patients with early-stage breast cancer 
(Slamon et al., 1987).  After the discovery of the role of ERBB2 overexpression in breast cancer, 
implications of ERBB2 overexpression in other human cancers such as ovarian, gastric and 
salivary cancers were suggested (Hynes & Lane, 2005; Hynes & Stern, 1994; Slamon et al., 
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1989). Amplification of the ERBB2 gene, leading to its overexpression pushes the equilibrium of 
the ERBB dimers towards ERBB2 homodimer and heterodimer formation, leading to activation 
of downstream signaling pathways. Though ERBB2 is unable to bind a ligand of its own, it 
serves as the preferred heterodimeric partner of ligand-activated ERBB receptors (Tzahar et al., 
1996). Also, ERBB2 heterodimers have increased ligand binding affinities and can prolong 
signaling by delaying the ligand-induced receptor endocytosis (Emde et al., 2012). One of the 
important heterodimers is comprised of ERBB2 and ERBB3 (HER3) as it has been shown to be 
endowed with potent oncogenic activities (Wallasch et al., 1995) (Figure IV.1a).  
However, ERBB2 overexpression is frequently accompanied by the incidence of truncated forms 
of the receptor resulting from proteolytic cleavage, alternative translation initiation or alternative 
pre- mRNA splicing.  These truncated forms of ERBB2 are characterized by enhanced oncogenic 
potential (Emde et al., 2012).  A splice variant of ERBB2 with an in-frame deletion of 16 amino 
acids in the extracellular domain can induce ligand-independent activation of ERBB2 and has 
been shown to be oncogenic (P. M. Siegel, Ryan, Cardiff, & Muller, 1999).  
ERBB2 mediated signaling and significance of G1/S cell cycle checkpoints:  
As mentioned in the previous section of this chapter, ERBB receptors lead to potent activation of 
PI3K-AKT mediated, and RAS-MAPK mediated mitogenic signaling pathways.  Thus, ERBB2 
overexpression drives cell cycle progression by activation of the mentioned pathways. One of the 
critical checkpoints in the cell cycle is G1 to S phase transition checkpoint where an individual 
cell must decide on entering the S-phase by interpreting the extracellular signals.  This point is 
known as restriction point as once past this checkpoint a cell must commit to completing the 
cycle and engage a program of gene expression and protein regulation required for cell division.  
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The presence of ERBB2 overexpression-induced mitogenic signaling pathways leads to 
progression of the cell-cycle irrespective of the presence of an extracellular mitogenic signal. 
In a normal cell, the extracellular mitogenic signals lead to activation of PI3K-AKT and RAS-
MAPK signaling pathways, which in turn positively regulates transcription of Cyclin D proteins. 
Persistent mitogenic signaling leads to accumulation of Cyclin D which binds to Cyclin-
dependent kinases 4/6 forming an active kinase complex.  Transcription of Cyclin D, assembly 
of Cyclin D-CDK4/6 complex and stability of the complex is directly facilitated by active PI3K- 
AKT and RAS-MAPK pathways.  Accumulation of Cyclin D-CDK4/6 complex in cell nucleus 
leads to activation of Cyclin E–CDK2 complex which is achieved by the differential binding of 
P27KIP1 and P21CIP1 proteins to the complexes. The CIP/KIP proteins bind to Cyclin D- 
CDK4/6 complexes at a higher affinity as compared to Cyclin E-CDK2. The CIP/KIP proteins, 
however, show low or no inhibitory effect and instead stabilizes the Cyclin D-CDK4/6 complex. 
At a quiescent stage, the Cyclin D levels are low and accordingly, the Cyclin D-CDK4/6 
complex is also low in concentration.  At this point, the P27KIP1 protein binds and inhibits the 
activity of Cyclin E-CDK2 complex. After mitogenic stimulation, as Cyclin D-CDK4/6 complex 
accumulates, it sequesters the bound P27KIP1 protein, relieving the Cyclin E-CDK2 complex 
from its inhibitory actions.  At this point, both the Cyclin E-CDK2 complex and the Cyclin D-
CDK4/6-KIP1 complex collaboratively exerts their kinase activity to relieve cell-cycle inhibitory 
effects of Retinoblastoma protein (RB) family. At the quiescent stage, the RB protein maintains 
it active hypo-phosphorylated state and binds to the E2F transcription factors repressing E2F 
mediated transcription. It also recruits epigenetic repressors (e.g., HDAC) at promoter sites of 
E2F target genes.  After mitogenic activation, the Cyclin-CDK complexes phosphorylate RB. 
Hyper-phosphorylated RB is inactive and fails to bind E2F transcription factors and recruit 
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epigenetic repressions at E2F target gene promoters.  This repression of E2F targets leads to 
activation of E2F mediated transcription of its target genes which encodes for proteins needed 
for S phase as well as Cyclins E and A. ERBB2/ HER2 mediated cell signaling drives the cells 
constitutively past this checkpoint by activation of PI3K-AKT and RAS-MAPK pathways 
(Figure IV.1b) (Sherr & McCormick, 2002). 
Interestingly, the direct significance of E2F transcription factors has been established recently.  
The studies analyzed a database of 1172 expression data from a variety of mouse models of 
breast cancer which revealed the high activity of the E2F family of transcription factors (E2F1, 
E2F2, and E2F3) in the MMTV-Neu mouse model (with a mammary-specific expression of 
ERBB2/Neu).  The study also established that loss of any E2F delayed Neu-induced tumor onset 
in Neu transgenic mice while the loss of first two E2F proteins correlated with the decreased 
metastatic potential of the cancer cells.  Moreover, HER2 positive patients with high E2F1 
activity were shown to have worse outcomes such as distant metastasis-free survival and relapse-
free survival (Andrechek, 2015; Rennhack & Andrechek, 2015).  
However, cells exert another checkpoint through recruitment of another class of Cyclin D-CDK 
inhibitor proteins.  Four INK4 (Inhibitors of CDK4) proteins (P16INK4a, P15INK4b, 
P18INK4c, and P19INK4d) specifically inhibit the activity of cyclin D-dependent kinases to 
prevent phosphorylation of RB family proteins (Figure IV.1c.i, ii).  Role of P16INK4a (encoded 
by the CDKN2A locus) has been established in inducing cellular senescence, and a decrease of 
P16INK4A levels renders mice more prone to tumor formation after exposure to chemical 
carcinogens.  Loss of INK4a expression in high frequencies in multiple cancer types including 
breast cancer (30%), pancreatic cancer (80%) underscores the importance of INK4a regulation of 
G1-S checkpoint (Sherr & McCormick, 2002).  Interestingly, a mouse model study directed to 
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establish the role of Cyclin D-CDK4/6 complex in ERBB2 (Neu) overexpressing mammary 
tumors, showed that overexpression of a P16 (specific inhibitor of CDK4/6) transgene in Neu 
transgenic mice blocked tumorigenesis (C. Yang et al., 2004). 
The INK4a (CDKN2A) locus encodes a second gene product, from an alternative reading frame 
that overlaps sequences encoding P16INK4a (Figure IV.1c.i).  The alternative reading frame 
protein (P19ARF in mice and p14ARF in humans) is a potent tumor suppressor that activates 
p53 mediated cell-cycle arrest and apoptosis. ARF binds directly and inactivates action of 
MDM2 (HDM2 in human), that binds and facilitates degradation of P53 protein.  Thus, ARF 
stabilizes P53 and enables it to exert its tumor-suppressor action through cell cycle arrest and 
apoptosis (Sherr & McCormick, 2002) (Figure IV.1c.ii).  
Introduction to the transgenic Neu (ERBB2) mice used for this study 
The ERBB2 /Neu overexpressing mice model used in this study was established in 1992 in Dr. 
William Muller’s laboratory (Guy et al., 1992). The transgenic mice model expresses an 
inactivated wild-type rat Neu proto-oncogene as a transgene under direct regulation of Mouse 
Mammary Tumor Virus (MMTV) promoter. MMTV promoter drives expression of the Neu 
transgene in a mammary epithelium-specific manner.  Though multiple mice models expressing 
an activated rat Neu transgene (carrying activating mutations) were already established by the 
time (Bouchard, Lamarre, Tremblay, & Jolicoeur, 1989; Muller, Sinn, Pattengale, Wallace, & 
Leder, 1988), this mouse model aimed at investigating the role of overexpression of inactivated 
wild-type Neu in mammary carcinogenesis.  The strains of MMTV/activated Neu mice exhibited 
an early onset of transgene expression in the mammary epithelium of female mice which was 
associated with the synchronous and rapid development of tumors in the entire mammary 
epithelium. However, expression of unactivated Neu in the mammary epithelium resulted in the 
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development of focal mammary tumors after a long latency period.  The study describes the 
generation of 6 transgenic lines, of which the most well-characterized line (N202) is available 
from the commercial vendor and was used for the studies described here.  This particular mouse 
transgenic line had a tumor latency period of 205 days (50% of mice developed tumor by 205 
days), and 72 percent of the mice were shown to have lung metastasis by eight months of age 




MATERIALS AND METHODS 
Generation of MMTV-rtTA/ Tet-op-CCN5-GFP/MMTV-Neu (Tri-transgenic) mice 
The MMTV-Neu strain of mice was generated by Dr. William Muller at McGill University, 
Canada and is distributed under strain name FVB/N-Tg(MMTVNeu)202Mul/J (Stock No.: 
002376) by The Jackson Laboratory. Male and female MMTV-Neu mice were purchased from 
the mentioned vendor. The line of MMTV-Neu strain of mice was established and maintained in 
the Kansas City Veterans Administration Medical Center (KCVAMC) animal care facilities by 
breeding the purchased male and female mice of the strain. This mouse strain overexpresses a rat 
Neu oncogene under MMTV promoter and thus specifically in the mice mammary gland 
epithelial tissue. 
The tri-transgenic mice strain was generated by breeding the bi-transgenic mice carrying the 
MMTV-rtTA and Tet-op-CCN5/GFP transgenes with the MMTV-Neu transgenic strain (Figure 
IV.2). The details of the generation and maintenance of the bi-transgenic line have been 
discussed in the previous chapter. The mice obtained from the cross between the bi-transgenic 
line and the MMTV-Neu strain were genotyped by tail DNA extraction and PCR following the 
protocol described before. The primers used for the detection of the MMTV-rtTA and 
CCN5/GFP transgenes were also same as mentioned in the previous chapter. The Jackson 
Laboratory provided primer sequences and PCR cycle conditions for detection of Neu transgene. 
The mice carrying all the three transgenes were selected for further tumor incidence and tumor 
volume studies. Primer sequences used for the genotyping are as follows: 
(1) Neu Forward: 5’-TTTCCTGCAGCAGCCTACGC -3’ 




Doxycycline administration to tri-transgenic mice and tumor volume measurement 
The tri-transgenic mice (carrying three transgenes: MMTV-rtTA, Tet-op-CCN5-GFP, MMTV-
Neu) which were used for further studies were distributed into the vehicle-treated control and the 
doxycycline-treated experimental groups. Doxycycline was administered orally to the 
experimental group. The drinking water of the mice were replaced, with 10% sucrose solution 
(and left overnight) carrying doxycycline at a concentration of 2 mg/ml., twice a week. The 
control mice were fed with only 10% sucrose solution. The doxycycline treatment of the tri-
transgenic mice was started at five months age of individual mice. Each of the control and the 
Dox-fed experimental mice was checked for the appearance of palpable breast tumor once every 
week. After the appearance of mammary tumors, the length and width of the tumors were 
measured with slide-calipers once a week till the study endpoint. The mice were sacrificed 
approximately at eight months of age or earlier if the tumor burden of the mice exceeded 
permissible limit. 
Immunohistochemical staining  
The tumors which were harvested from the control and the experimental mice were divided into 
parts, and a part of each tumor was utilized for immunohistochemistry. The tumor parts were 
fixed in 10% formalin solution in PBS overnight at 4ºC, embedded in paraffin. Paraffin-
embedded tissue sections of 5µm thickness were used for immunohistochemical staining 
following previously published protocol. Rabbit monoclonal antibody against HER2 (Cell 
Signaling Technologies, Danvers, MA, USA; Cat # CST 2165) was used to stain the sections for 





Extraction of total RNA from mice mammary gland tissues 
Total RNA from mammary tumor tissues were extracted using Trizol Reagent (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA) and miRNeasy Mini Kit (Qiagen, Germantown, 
MD, USA). 50mg of tumor tissues were minced with the help of RNase contamination free 
sterile scissors and then homogenized by repeated passage through the syringes with 20G and 
25G needles. The mincing and homogenization steps were performed quickly on ice in the Trizol 
reagent to minimize RNA degradation. The homogenate was used for RNeasy mini spin column-
based RNA extraction following the protocol provided along with miRNeasy Mini Kit. To 
minimize the risk of genomic DNA contamination on-column DNase digestion was performed 
using the RNase-free DNase set (Qiagen) as recommended by the vendor.  
Mouse ‘Breast Cancer’ gene array using RT2 Profiler PCR Array 
Total RNA extracted from the control mice tumor tissues and Dox-fed experimental tumor 
tissues were used for RT-PCR analysis of 84 key genes which are commonly involved in the 
dysregulation of signal transduction in breast oncogenesis. The Mouse Breast Cancer RT2 
Profiler PCR Array (Qiagen, Cat # 330231 PAMM-131ZA) was used for the analysis. An equal 
amount of RNAs (500ng per sample) from the control and the Dox-treated samples were used for 
the cDNA synthesis. RT2 First Strand Kit (Qiagen), recommended for the PCR Arrays was used 
for the synthesis, and the vendor provided protocol was followed. The prepared cDNA samples 
were mixed with 2x RT2 SYBR Green qPCR Mastermix and nuclease-free water before loading 
on to the array plate wells. The PCR amplifications were carried out in the BioRadCFX96™ 
thermal cycler. The ΔCT values for individual genes were calculated, and the ΔΔ CT values for 
the quantification of the gene expression changes in experimental samples relative to the control 
samples were calculated in the online portal of the vendor (Qiagen Data Analysis Center).  
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Quantitative PCR (qPCR) validation of the genes upregulated in PCR Array  
The key cell cycle-related genes (P19ARF, P16INK4A, P21CIP1 and cyclin E) which were 
observed to be differentially expressed in the array were further validated using independent 
qPCR analyses. Fresh RNA was extracted from the tumor samples, and 1µg RNA of each sample 
was used to prepare cDNA using MuLV reverse transcriptase. SYBR-green-based qPCR analysis 
was performed in Step One plus real-time PCR system (Applied Biosystems, Thermo Fisher 
Scientific). The sequences of the primers are listed below: 
P19 Forward: 5’-GCTCTGGCTTTCGTGAACAT-3’ 
P19 Reverse: 5’-CGAATCTGCACCGTAGTTGA -3’ 
P16 Forward: 5’-AACGCCCCGAACTCTTTC -3’ 
P16 Reverse: 5’-CAGTTCGAATCTGCACCGTA -3’ 
P21 Forward: 5’-GTCTGAGCGGCCTGAAGAT -3’ 
P21 Reverse: 5’-TCTGCGCTTGGAGTGATAGA -3’ 
Cyclin E Forward: 5’-AAGCGAGGATAGCAGTCAGC -3’ 
Cyclin E Reverse: 5’-TCTGGGTGGTCTGATTTTCC -3’ 
Mouse GAPDH Forward: 5’-TGTTCCTACCCCCAATGTGT -3’ 





Elevated HER2/Neu expression in tri-transgenic mice 
Immunohistochemical staining against HER2 (Neu) oncoprotein exhibited a robust and 
comparable staining intensity in both the control and Dox-treated tumor sections. The staining 
intensity was found to be higher at the cell boundaries in keeping with the transmembrane 
localization of the HER2 protein. The similar staining intensity for HER2 indicated that both the 
control set and the Dox-treated set of tumors exhibited comparable levels of HER2 expression, 
which is the oncoprotein driving the tumorigenesis in the mouse model under study (Figure 
IV.3a). 
Elevated CCN5 expression in Doxycycline-treated tri-transgenic mice 
The gene expression quantification from the q-PCR analysis performed with the control and 
Dox-treated samples exhibited that CCN5 transcript levels in the tumors from Dox-treated mice 
were significantly higher as compared to the tumors from control mice (Figure IV.3b). This 
observation validated the Doxycycline regulation of CCN5 expression in the tri-transgenic 
mouse model. 
Reduced tumor burden in Doxycycline-treated CCN5 overexpressing tri-transgenic 
mice 
It was observed that by the study endpoint, at approximately 250 days of age of the mice, both 
tumor incidence and tumor burden were significantly diminished in Dox-treated CCN5 
overexpressing mice in comparison to the control mice. At the time of study endpoint, the Dox-
treated mice either did not develop any mammary tumors or the tumors which developed, were 
of significantly smaller volume as compared to the tumors in the control mice. We observed an 
increase in the tumor latency period (as the palpable tumor was noticed at a later time point in 
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Dox-treated mice) and also a decreased tumor growth rate in CCN5-overexpressing tri-
transgenic mice, which were manifested in the reduced tumor burden at endpoint (Figure 
IV.4a,b ).  
Upregulation of major Cdk-Inhibitors in CCN5 overexpressing HER2 tumors 
In the gene expression array studies, we noticed significant changes in the expression status of 
multiple genes in CCN5 overexpressing tumors relative to the control tumors which were related 
to cell-cycle regulation (Figure IV.5). These differentially expressed genes included two Cyclin 
dependent-kinase inhibitor loci (CDKN1A and CDKN2A) along with CCNE1(Cyclin E1).  The 
levels of these two transcripts were significantly upregulated (> 2.5 fold ) in the Dox-treated 
CCN5 overexpressing tumors.  The CDKN2A locus generates two transcripts for P16INK4A and 
P19ARF, and CDKN1A transcription leads to P21CIP1 expression. Interestingly, expression of 
cyclin E was also upregulated (2.8 fold) in the CCN5 expressing tumors.  
The results from the breast cancer panel gene array were validated by independent real-time q-
PCR assays (Figure IV.6a,b,c,d).  As mentioned, the CDKN2A locus transcribes into two 
mRNA transcripts resulting from alternative splicing and independent primers for both of these 
transcripts (P16INK4A and P19ARF) were designed for qPCR validation. Our initial results 
indicate that expression levels of both these transcripts were higher in CCN5 overexpressing 
tumors harvested from Dox-treated mice.  In corroboration of the gene array data, expression of 




The observations from studies of conditional overexpression of CCN5 in the Neu (ERBB2) 
overexpressing transgenic mouse model have been listed in this chapter. The preliminary 
findings indicate that CCN5 might play a role in delaying the tumor onset and tumor progression 
in ERBB2 (Neu) overexpressing breast tumors. As discussed in previous chapters, and also as 
previously published (Haque et al., 2015), it has been established that CCN5 can exert an 
inhibitory effect on PI3K-AKT mediated signaling pathway most likely through its interactions 
with the integrin receptors.  Overexpression of ERBB2 (Neu) receptors in cancer cells have been 
shown to drive mitogenic signaling primarily through activated PI3K-AKT and RAS-MAPK 
signaling pathways (Hynes & Stern, 1994; Yarden & Sliwkowski, 2001).  Thus, one logical 
anticipation was that CCN5 overexpression might be able to negatively influence cell 
proliferation in the Neu overexpressing mammary tumors and delay tumor progression. 
Interestingly, as mentioned in the observation section, the CCN5 overexpressing mice did show 
delayed tumor onset and slower progression. Though the activation status of the PI3K-AKT 
pathway has not been checked, the gene expression array did not show any change in Cyclin D1 
expression in CCN5 expressing tumors. The CyclinD1 expression is directly upregulated by 
activated PI3K-AKT and RAS-MAPK signaling. It might be a possibility that the effect of 
CCN5-induced suppression of PI3K pathway is compensated by activated MAPK pathway 
leading to similar expression status of CyclinD1 in control and Dox-treated tumors.  
It has been established that ERBB2 overexpression hotwires cell cycle progression through 
deregulation of G1-S transition checkpoint (Sherr & McCormick, 2002; Yarden & Sliwkowski, 
2001).  We observed upregulation of transcript levels of two CDK inhibitor (CDKN) loci, 
CDKN1A and CDKN2A in CCN5 overexpressing tumors. CDKN1A transcript translates into 
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P21CIP1 protein while alternative reading frames of CDKN2A locus gives rise to two proteins 
P16INK4A and P19ARF (P14ARF in human).  All of these three proteins enforce G1-S 
transition checkpoints.P21CIP1 inhibits CDK2 activity in early G1 phase. P16INK4A acts as an 
inhibitor to the CDK4/6 mediated phosphorylation and inactivation of retinoblastoma protein 
(Rb) and induces cellular senescence. P19ARF (P14 ARF) induces wild-type P53 mediated 
apoptosis or cell cycle arrest in response to aberrant mitogenic stimulation mediated activation of 
E2F transcription factors. CCN5 induced overexpression of these checkpoint gene transcripts 
indicates that CCN5 mediated negative regulation of Neu tumor progression might be through 
reinforcement of G1-S cell cycle checkpoint. For treatment of ERBB2 overexpressing tumors, 
clinicians rely primarily on monoclonal antibodies against the oncoprotein (e.g., trastuzumab) 
that prevents its dimerization or on inhibitors designed against tyrosine kinase activity of the 
receptor (e.g., lapatinib) (Emde et al., 2012). However, tumor cells (at the initial stage or after 
relapse) have frequently been shown to have deregulated downstream signaling pathways and 
exhibit resistance to the mentioned therapeutic strategies progressing through uncontrolled 
proliferation (Emde et al., 2012; Hynes & Lane, 2005).  As a response to this situation, multiple 
clinical trials have been trying to examine benefits of the use of CDK4/6 inhibitors as a 
therapeutic regimen to be used in conjunction to receptor antibodies or inhibitors (Corona et al., 
2017). Recently, a CDK4/6 inhibitor, Palbociclib has been approved by FDA for treatment of 
patients with endocrine receptor-positive metastatic breast cancer. In this context, observations 
of this study indicate a possible role of CCN5 in reinforcing CDKN mediated G1-S checkpoint 
































Fig.IV.1a: Overexpression of the ERBB2 (HER2/Neu) leads to heterodimerization with other 3 
ERBB partners. ERBB2 does not bind to a ligand while ERBB3 though having specific ligands 
(Neuregulins) does not have a kinase activity of its own. However, heterodimer of ERBB3 and 
ERBB2 induces most potent signaling. ERBB2 heterodimers shows slower ligand dissociation, 
relaxed ligand specificity, slower endocytosis of receptors and prolonged signaling activation. 
ERBB2 mediated signaling leads to increased cell proliferation, migration and decreased apoptosis. 










Fig.IV.1b:  The figure shows the major signaling pathways and transcription factors activated by 
signaling through ERBB1(EGFR)-ERBB2(HER2) and ERBB3(HER3)-ERBB2(HER3) 
heterodimers. Upon ligand binding induced heterodimer formation the intracellular signaling 
activation majorly takes place through PI3K-AKT and RAS-RAF-MAPK pathways. This eventually 
leads to prevention of apoptosis; release of P27KIP1 and FOXO3a mediated repression of CDKs; 
mTOR (mammalian Target of Rapamycin) mediated cell growth; activation of transcription factors 
like AP1(JUN/FOS), MYC which further drives cell proliferation (Emde, Kostler, Yarden, 
Association of, & Oncology of the Mediterranean, 2012). This figure in its current state has been 
































Fig.IV.1c: (i) INK4A locus leads to transcription of two different transcripts leading to translation of 
two different proteins P16INK4A and P19ARF . Regions of the locus indicated in green and purple 
translates to P16INK4A and P19ARF proteins respectively. The figure adapted and redrawn from 
previous publications (Hahn & Weinberg, 2002; Sherr, 2001). (ii) Mechanisms of both the proteins 
in inducing cell cycle arrest (discussed in detail in text). The figure has been redrawn according to a 




























Fig.IV.2: Generation of Tri-transgenic mice line (MMTV-rtTA/CCN5-GFP/MMTV-Neu): 
Conditional CCN5 overexpressing mice (which has been described in the previous chapter) was 
crossed with constitutive mammary specific Neu overexpressing mice (MMTV-Neu). Reverse 
tetracycline trans-activator (rtTA) and Neu are constitutively expressed in mammary epithelium. 

























Fig.IV.3: (a) Representative images of comparative immunohistochemical staining against Neu in 
control and doxycycline -fed tri-transgenic mice which shows comparable staining intensity (b) 
Quantitative representation of CCN5 transcript expression in tumors of control and dox-treated tri-
transgenic mice. Bar graph represents the fold change of CCN5 transcript in Dox treated mice as 
compared to control littermates. Error bars represent standard deviation from mean value. The Dox-
treated mice tumors, even which exhibited lower CCN5 expression, had higher concentration of 




































Fig.IV.4: (a) Representative images of control and Dox treated tri-transgenic mice showing smaller 
tumor volumes and tumor numbers in CCN5 overexpressing dox-treated mice (b) Quantitative 
representation showing lower tumor burden in Dox-treated mice. Each point represents an individual 
tumor. The number of tumors in treated mice was lower as compared to control mice. The tumor 



































Fig.IV.5: Graphical (bar graph) representation of the fold changes of gene expressions in Dox-
treated tumors relative to control tumors as observed from qPCR based gene expression array. 
Critical cell cycle and cell proliferation related genes and genes which were shown to be upregulated 
or down-regulated by at least 2-fold have been represented. Transcripts from CDKN2A locus were 
most differentially expressed (upregulation) in dox treated tumors. Down regulation of proliferation 























Fig.IV.6: (a-d) Bar graph representation of independent qPCR based validation of expression 
changes of key cell-cycle related genes observed in gene array. Both transcripts from INK4A 
(CDKN2A) locus (P16INK4A and P19ARF) were observed to be upregulated in CCN5 expression 
tumors. Upregulation of Cyclin E transcript and P21 CIP1 transcript was upregulated in Dox -treated 
























CHAPTER V: General Discussion 
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The diverse physiological and pathological roles of the CCN family proteins (CCN1-CCN6) 
have been extensively studied by multiple labs, pursuing different research interests.(S. K. 
Banerjee et al., 2016; J. W. Russo & Castellot, 2010).  However, CCN5 has been far less studied 
as compared to the other members of the family, especially the first two members (CCN1 and 
CCN2).  The roles played by CCN5 in impacting breast cancer progression and the possible 
signaling mechanisms by which CCN5 exert those roles, has been the central theme of the 
studies which are described in this dissertation.  
After the discovery of WISP2 (CCN5) gene, most of the preliminary studies were focused on the 
influence of CCN5 protein on cellular proliferation, motility, adhesion, and differentiation.  
However, these studies did not provide much information on the cell-signaling pathways that are 
impacted by CCN5.  Also, the studies were largely limited to the smooth muscle cells and other 
mesenchymal cells (e.g., osteoblasts and chondrocytes) (J. W. Russo & Castellot, 2010). But 
interestingly, rCOP1 (the rat homolog of CCN5) was identified for the first time as a gene, 
whose loss of expression was a key step to the transformation of the Rat Embryonic Fibroblasts 
(REFs) (R. Zhang et al., 1998).  In another study, which led to the independent identification of 
CCN5 (or WISP2, as named by this group), decreased expression of CCN5 was observed in the 
colon cancer tissues as compared to the normal tissues (Pennica et al., 1998).  Hence, since 
discovery, CCN5 was poised to be an important candidate for further research on cancer 
progression.  Soon after, multiple studies established that CCN5 is highly expressed in the 
estrogen receptor (ER) positive breast cancer cells and is under the direct transcriptional 
regulation of estrogen receptor-α (ER-α) (S. Banerjee et al., 2003; Inadera et al., 2002; Inadera et 
al., 2000). Since then, CCN5 has been established as a ‘micromanager’ of breast cancer as most 
of the studies point towards CCN5-mediated negative regulation of breast cancer progression (S. 
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Banerjee et al., 2008; S. K. Banerjee & Banerjee, 2012; Das et al., 2017; Ferrand et al., 2014; 
Fritah et al., 2008; Haque et al., 2011).  
The key findings described in this dissertation provide a deeper insight into the roles played by 
CCN5 in impacting breast cancer cell signaling. The first section of the study (Chapter II) 
establishes a role of CCN5 in inducing growth arrest of the triple negative breast cancer cells. 
CCN5 has been recognized as a growth arrest specific (gas) gene for the ability to induce cell 
cycle arrest and senescence (Lake et al., 2003; Lake & Castellot, 2003) but these studies did not 
investigate the influence of CCN5 on epithelial cancer cells. Rather, it was shown that CCN5 
was necessary for the estrogen receptor (ER-α) positive breast cancer cell proliferation, induced 
by estrogen and growth factors like IGF-1 and EGF (S. Banerjee et al., 2005; K. Dhar et al., 
2007). 
Role of integrin-mediated action of CCN5 in the suppression of the PI3K-AKT pathway in breast 
cancer cells is one of the important observations of the studies discussed here.  This discovery 
might have a profound impact on the future directions of CCN5 research as the PI3K-AKT 
pathway is one of the most frequently activated cell-proliferation pathways in human breast 
cancers (Manning & Cantley, 2007; Vivanco & Sawyers, 2002).  The direct influences of CCN5 
on the signaling cascade components, linking the integrin receptor-binding and the PI3K-AKT 
pathway inhibition, are yet to be experimentally elucidated.  But, our experiments with the 
integrin blocking antibodies established that the CCN5-mediated PI3K-AKT inhibition is 
dependent on binding of CCN5 to the integrin receptors (Haque et al., 2015).  Whether binding 
of CCN5 to the integrins, sequesters the integrin receptors from other activating binding partners 
or directly impose inhibitory conformational changes on the receptors, remains subject to 
investigation.  The CCN proteins have been shown to directly bind to several growth factors and 
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also other ECM molecules in the extracellular space (Jun & Lau, 2011).  Direct binding of CCN5 
to these factors might also interfere with the PI3K-AKT pathway activation in the cancer cells.  
The major impacts of CCN5 expression on the triple negative breast cancer cells which were 
discovered by our studies are - (i) promotion of cell-cycle arrest and (ii) induction of estrogen 
receptor-α (ER-α) expression. Both effects were dependent on inhibition of the PI3K-AKT 
pathway.  
The first discovery which has been described in the second chapter (Chapter II), indicates that 
CCN5-mediated AKT inactivation results in stabilization of the FOXO3A transcription factor 
leading to expression of the Cyclin-Dependent Kinase Inhibitor (CDKN) P27KIP1. This increase 
in expression leads to the growth arrest of the triple negative MDA-MB-231 cells both in-vitro 
and in the xenograft studies. The study also demonstrated that the phosphorylation status of both 
the P27KIP1 and FOXO3A proteins, depended on activation level of the PI3K-AKT pathway, as 
both of these proteins are direct substrates of the AKT. The phosphorylation status of P27KIP1 
and FOXO3A regulates the nuclear-cytoplasmic localization and stability of both the 
transcription factors. However, it is well-established that AKT also exerts its kinase activity on a 
wide repertoire of other proteins.  The substrates of AKT include apoptotic proteins such as BAD 
(Bcl2-associated death promoter), Bim (Bcl-2 interacting mediator of cell death), BCL-10 (B-
cell CLL/Lymphoma 10); nuclear receptors such as ER (Estrogen Receptor), AR (Androgen 
Receptor); histone acetyltransferases such as CBP (CREB Binding Protein); cell cycle regulators 
such as CDK2 (Cyclin-Dependent Kinase 2); other Forkhead box transcription factors like 
FOXO1A, FOXO4 (Manning & Cantley, 2007; Vivanco & Sawyers, 2002). AKT- mediated 
phosphorylation of almost all these substrates upon activation of the PI3K-AKT pathway leads to 
cell survival and proliferation.  So, we can argue that CCN5 mediated inhibition of the PI3K-
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AKT pathway must have a multi-faceted effect on the cancer cells which also might contribute to 
the arrest of cell proliferation and induction of apoptosis.  Further investigations into the 
phosphorylation status of the other AKT substrates will provide a broader understanding of other 
plausible mechanisms of CCN5 mediated action on cancer cell survival and proliferation.  
The third chapter of this dissertation (Chapter III) describes that CCN5 expression in MDA-MB-
231 cells and the mouse mammary epithelial cells influences ER-α expression status. We 
concluded from our observations that CCN5-induced AKT inhibition plays a key role in the 
induction of ER-α.  It was already established that, the CCN5-mediated PI3K-AKT inhibition 
increases the FOXO3A protein level in breast cancer cells and that FOXO3A directly drives 
transcription of the ER-α gene (ESR1) (Guo & Sonenshein, 2004).  We demonstrated that CCN5 
induces ER-α expression at the transcriptional level (in the mouse mammary epithelial cells and 
the triple negative cancer cell line MDA-MB-231) by inhibiting the PI3K-AKT pathway and 
stabilizing FOXO3A. However, it can be argued that CCN5 also might play a role in relieving 
epigenetic repression of ER-α (ESR1) gene through mechanisms that are yet to be discovered. It 
has been indicated in a previous study that CCN5 might localize into the cell nucleus and directly 
interact with HDAC1 (Histone Deacetylase 1) (Sabbah et al., 2011).  Recruitment of the 
transcriptional coactivators like p300/CBP by FOXO3A (F. Wang et al., 2009) can also lead to 
epigenetic activation of ESR1 gene promoter.  Investigations into these possibilities might 
provide further insights into CCN5 mediated induction of ER-α expression. 
Loss of ER-α expression has been one of the critical reasons behind endocrine resistance of the 
breast cancer cells. Our studies indicate that ability to induce CCN5 expression in the tumor cells 
might restore ER-α expression in the resistant cancer cells and might provide the clinicians with 
a strategy to overcome the problem of endocrine resistance. Interestingly, it has been shown in 
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other studies that activated PI3K-AKT pathway can lead to endocrine resistance of ER-α 
expressing breast cancer cells. Phosphorylation of ER-α at the Ser167 residue, which is a direct 
substrate of AKT, has been shown to be critical for ligand-independent activation of ER-α 
leading to inhibition of tamoxifen-induced apoptosis (Campbell et al., 2001). Thus, the inhibitory 
effect of CCN5 on the PI3K-AKT pathway might also help overcome the endocrine resistance of 
ER-α expressing cells. 
In the last section of the dissertation (Chapter IV), our observations from transgenic Neu (HER2) 
mouse model studies indicate that CCN5 expression in Neu overexpressing mammary epithelial 
cells lead to transcriptional upregulation of key Cyclin-Dependent Kinase inhibitors (P16INK4A 
and P21CIP1). We propose that this effect of CCN5 expression leads to a cell cycle arrest of the 
Neu-overexpressing cells resulting in slower tumor progression. Whether CCN5 induced 
inhibition of PI3K-AKT pathway should play any role in this model is still an unanswered 
question.  Further studies into the phosphorylation levels of the FOXO3A and P27KIP1 proteins, 
(along with other AKT substrates) in the tumor tissues harvested from the mice, will help us to 
address this query.  
Thus, after evaluating the results from all our studies collectively, we propose that – (a) therapy 
strategies leading to induction of CCN5 expression might have significant potential in breast 
cancer treatment and (b) CCN5 expression status in breast tumor tissues might have high 
prognostic value and help in prediction of resistance and recurrence of breast tumors. The next 
rational direction of CCN5 research would be the identification of ways, to induce 
overexpression of CCN5 protein or to deliver recombinant CCN5 protein specifically into the 
breast tumor tissue. CCN5 is a secreted protein, and most of the actions of CCN5 which have 
been elucidated are integrin receptor-mediated. We anticipate that ability to induce expression of 
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CCN5 in only a subset of tumor cells might also be beneficial, as the CCN5 protein secreted 
from the cells will be able to exert its role in an autocrine and paracrine fashion.  
Our studies, as described in this dissertation discovers novel roles of CCN5 protein, which 
further establishes the capability of CCN5 to negatively regulate progression of breast tumors by 
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